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ABSTRACT OF THE DISSERTATION 
Histones at the Nexus of Eukaryotic Evolution and Biology 
by 
Narsis Attar 
Doctor of Philosophy in Molecular Biology 
University of California, Los Angeles, 2017 
Professor Siavash K. Kurdistani, Chair
Histones have long been known for their functions in packaging the eukaryotic genome and 
in regulating DNA-based processes. These functions are dependent on physical and chemical 
properties of histones constructing the nucleosome, the basic structural unit for packaging DNA. 
The packaging of DNA into chromatin limits DNA accessibility for processes such as transcription 
and DNA replication, putting the nucleosome in a position to govern and fine-tune these processes. 
The influence on DNA metabolic processes can be mediated through alterations in nucleosome 
composition and positioning as well as covalent modification of histones. Variations in nucleosome 
structure and stability achieved by the use of non-canonical histone variants can lead to changes in 
DNA wrapping and accessibility. Similarly, covalent modifications of histone N-terminal or core 
domains can lead to structural changes for the nucleosome and the chromatin fiber. Covalent 
modification of histone tails also contributes to recruitment and anchoring of protein complexes 
required for transcription, DNA repair and replication. Changes in histone modifications and 
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mutations in the enzymes adding and removing them are implicated in a wide-range of pathologies 
including cancer (discussed in chapters II, III and IV). Histone modifications are dynamically 
regulated, which makes them suitable for integration of environmental and cellular cues with 
gene expression. While histone modifications locally participate in orchestrating transcription, 
global changes in histone modifications can have profound effects on cellular physiology and 
metabolism. In fact, alterations in cellular levels of histone modifications are observed in diseases 
such as cancer and can be responsive to changes in physiologic state of the cell like intracellular pH. 
In addition to the well-recognized structural elements of histones, a less well-known feature of these 
ancient proteins is their potential metal binding capabilities. Since metals such as copper and iron 
are required for a variety of important functions, a potential ability of histones to affect cellular 
metal homeostasis would greatly increase their influence on cellular functions. Indeed we have 
recently discovered the function of one such metal binding site at the nucleosome core within 
the H3 dimerization interface in regulating copper homeostasis. Investigating the role of this 
region of the nucleosome in metal biology revealed an unprecedented molecular function of the 
nucleosome as an oxidoreductase enzyme, capable of catalyzing the reduction of Cu2+ to its 
biousable form Cu1+. This remarkable enzymatic activity significantly affects copper-
dependent activities including mitochondrial respiration and Sod1 function, with a 
profound impact on the molecular biology of eukaryotes and potentially their evolutionary 
origin. The importance of copper for various physiological and pathological states in humans further 
underscores the broad implications of copper reductase activity of the nucleosome. These 
discoveries mark a new frontier into chromatin biology and a function of histones which may have 
deemed these proteins suitable participants in the emergence of eukaryotes on Earth (discussed in 
chapters V and VI). 
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Chapter I 
INTRODUCTION 
Histones were discovered as structural components of the eukaryotic genome functioning to 
package he genetic material. In the late 1980s, a series of seminal work provided evidence for the 
function of histones in regulating transcription and DNA replication, altering the view of the 
histones as inert DNA binding proteins to dynamic constituents of chromatin1–3. The first level of 
DNA packaging hierarchy in eukaryotes is the nucleosome consisting of ~147 bp of DNA wrapped 
around an octameric histone complex composed of two molecules of each 4 core histones (H3, H4, 
H2A and H2B)4. Array of nucleosomes are then folded into higher ordered fibers of 30 nm, which 
in turn compact progressively to form larger chromatin domains5. 
The four core histones exhibit substantial sequence and structural conservation across 
eukaryotic species. They share the common structure of a histone fold domain (HFD) and a highly 
basic N-terminal tail. The histone fold is an ancient structural motif consisting of 3 alpha helices 
connected by 2 loops and is thought to have originated in archaea with ubiquitous presence in 
eukaryotes6. This motif is often utilized in protein dimerization as is the case with histone proteins 
that form heterodimeric structures pairing H3 with H4 and H2A with H2B via a “handshake motif”. 
These dimeric structures are used to form the nucleosome as a heterotypic tetramer (H3–H4)2 
associated with two H2A-H2B dimers. 
Histones through the formation of the nucleosome are inherently involved in DNA-based 
processes to varying capacitates. Transcription through eukaryotic chromatin is a well-orchestrated 
molecular process that must be coordinated with nucleosome status. As early as 1980 it was 
observed that nucleosomes can prevent transcription initiation and pose an obstacle to this process 
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when present at high density7. Likewise, replication and repair of DNA need to be coordinated with 
nucleosome assembly/disassembly and repositioning8. Facilitation of such DNA-based processes on 
chromatin can be mediated by functions of nucleosome remodeling complexes, the use of non-
canonical histone variants as well as post-translation modifications of histone N-terminal tails. 
In this introductory chapter, I will briefly review the evolution and properties of the 
eukaryotic nucleosome. The extensive links between chromatin and both DNA-associated functions 
and other essential cellular processes will be discussed. 
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I. The Rise of Eukaryotes
The evolutionary events leading to the rise of eukaryotes has fascinated biologists for 
decades. The representation of Eukarya as the third domain in the tree of life may seem like a simple 
branching from the archaeal lineage. What is masked in this simple diagram representation is the 
series of complex events that took place to give rise to the last eukaryotic common ancestor 
(LECA)9. Eukaryotes harbor a number of unique features not found in the prokaryotic domains 
including the nucleus, the mitochondrion, endomembrane system, sterol synthesis, unique 
cytokinesis, phagocytic machinery, linear chromosomes with unique features (e.g. telomeres)9. The 
order of events and acquisition of these features leading to the LECA is unclear and a matter of 
debate. Which of these features were crucial and served as the impetus for eukaryogenesis is also not 
known. Simultaneous acquisition of these features in a primitive eukaryote seems doubtful because 
of its exceeding low likelihood. It is more likely that species with some eukaryotic features coexisted 
and a key event, the presence of a feature or the appropriate combination of features at some point 
in time led to the triumph of one and the demise of all other lineages10. Although no single feature 
may have been the determining factor for eukaryogenesis, the acquisition of the mitochondrion is 
considered a critical step. The view that Eukarya arose from the association of an archaeal host, 
likely a species from the Crenarchaea linage, and a bacterium, the proto-mitochondrion, is now 
accepted due to extensive sequence analyses and more comprehensive phylogenetic modeling11. The 
integration of the bacterial symbiont into the host is a unique endosymbiotic phenomenon. Unlike 
other symbiotic scenarios, the mitochondria and the archaeal host evolved to replicate as a whole, 
which may be a reflection of an early interdependence between the two. It is difficult to know the 
nature and mechanism of this interdependency. However, for the symbiont to be functional in the 
confines of the host cell, it must have depended on the host for provision of at least some resources. 
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Among these, we believe transition metals to be major candidates. Specifically, we postulate that the 
symbiont must have needed copper and iron, metals required by essentially all organisms for many 
functions including those associated with the mitochondria12. 
Copper in the mitochondria is required for the function of cytochrome c oxidase, a member 
of the heme-copper oxidase family13. These enzymes are involved in respiration, the process of 
relaying electrons from organic materials to an inorganic molecule such as dioxygen and are found in 
all three domains of life14. Copper-heme cytochrome oxidases are ancient membrane-associated 
complexes that evolved before the divergence of archaea and bacteria and thus prior to oxygenation 
of Earth15. The presence of a primitive copper-containing cytochrome oxidase, whether oxygen-
reducing or not, in the symbiont bacterium for eukaryogenesis is clear. We propose that the 
prokaryotic archaeal host must have had evolved a system for the intracellular handling of metals 
(e.g. iron and copper) which was then used for provision to the acquired intracellular bacterium¾at 
minimum copper for the function of cytochrome c oxidase. It is important to note that most 
prokaryotes have limit copper use, which is mostly confined to the extracellular or periplasmic 
space16. This is in contrast to eukaryotes that require the use of copper not only by the mitochondria 
but other cellular processes inside the cell. 
Intriguingly, the emergence of eukaryotes coincided roughly with accumulation of molecular 
oxygen on Earth, which led to oxidation of transition metals including iron and copper17. The 
oxidized metals (Fe3+ and Cu2+) became less usable for biological systems that had evolved in a 
previously reducing environment18. In presence of oxygen these essential metals were also becoming 
more toxic due to their ability to generate oxygen radicals, posing yet another challenge to all 
organisms18. Eukaryogenesis was taking place in the face of these major challenges begging the 
question, “What inventions or features of the emerging eukaryote gave the organism the ability to 
prevail in these conditions?” Perhaps a unique challenge was faced by the early emerging eukaryote. 
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This species may have needed a system to be able to maintain copper in its biousable cuprous form 
(Cu1+) intracellularly to supply the symbiont bacterium (i.e. proto-mitochondrion). Recent work by 
our group has identified a novel copper reductase activity of the eukaryotic histone tetramer and 
nucleosome (Attar, 2017. Submitted). In light of these findings, the presence of ancestral histones in 
the archaeal host for eukaryogenesis (see below) may have provided early eukaryotes with a tool to 
meet the challenges of utilizing copper intracellularly in an oxidizing environment. This idea will be 
further discussed in chapter V. 
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II. The Evolution of Eukaryotic Histones
The origin of eukaryotic histones can be traced back to archaea, which are prokaryotes with 
diverse biology. Histone-like proteins have been discovered in both major branches of archaea, 
Euryarchaea and Crenarchaea, suggesting their early evolution after the divergence of bacteria and 
archaea and long before eukaryotic emergence19. Archaeal histones found to date have sequence 
similarity to histones H3 and H4, and most strikingly, form structures homologous to the eukaryotic 
H3-H4 tetramer. Specifically, two histone proteins from Methanothermus fervidus, HMfA and HMfB 
and the histone protein HMk from Methanopyrus kandleri form homo or heterodimers and intra-
protein dimers using two histone fold domains, respectively20,21. In all cases, the dimeric structures 
are constituted into tetramers capable of binding ~60 bp of DNA forming a tetrasome. These 
tetrameric structures can form arrays on archaeal DNA resembling the eukaryotic chromatin22. 
Although the identity of the archaeal host for the eukaryotic endosymbiosis is still a matter of 
debate, the presence of primitive histones proteins in the host is certain. 
Archaeal histones as the ancestors of eukaryotic histones can provide insight into the 
functional evolution of the nucleosome. It is thought that an early histone gene duplication event to 
allow dimer and tetramer formation, and the evolution of histone gene doublets (i.e. end-to-end 
histone folds) in archaea, were important for the eventual transition to the four eukaryotic histone 
proteins19. In the evolutionary timeline of histones, H3 and H4 predate H2A and H2B given the 
presence of tetramers in archaea and the eventual evolution of an octameric structure in 
eukaryotes20. This suggests that the H3-H4 tetramer-like structure may have been the minimal 
required functional unit for the earliest emerging eukaryote.  
What are the functions of histones in archaea? Were those functions important for 
eukaryotic evolution? Archaeal histones contain a core histone fold, but unlike eukaryotic histones 
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are devoid of extended N-terminal tails. Thus, they lack N-terminal tail post-translational 
modifications that regulate eukaryotic chromatin structure and DNA processes. Although a function 
of archaeal histones in DNA compaction has been suggested in some archaeal22,23, histone DNA 
binding in archaea is not universal. Lack of genome-wide binding of archaeal histones in some cases 
is observed despite conservation of residues important for the function of eukaryotic histones24.
That archaeal genomes are small and do not need to be packaged into a nucleus, questions whether 
histone-mediated DNA compaction was the early functions of histones. Evidence has also been 
provided for a potential role of archaeal histones in regulating gene expression25,26. However, it is 
important to emphasize that the manner by which tail-less archaeal histones mediate such a function 
differs from that of eukaryotes that employ histone N-terminal tail modifications. These findings 
challenge the idea that DNA compaction or gene regulation were the fundamental functions of 
histones in archaea. Dinoflagellates, a large and diverse group of eukaryotes, lack histones despite 
having in some cases up to 80 fold larger genomes than histone-containing eukaryotes27,28. This 
further brings into question the notion that genome packaging was the driving force for the 
evolution of histones and chromatin structure in eukaryotes. However, it is possible that once 
histones had evolved and were present in the early eukaryote, additional features such as extended 
N-terminal tails and post-translational modifications aided in genome packaging and DNA-mediated
processes throughout the expansion of eukaryotes. 
To achieve the chromatin structure present in almost all eukaryotes today, the primordial 
tetrasome (i.e. histone tetramer associated with DNA) evolved to contain features required for 
eukaryotic biology. The transition from a tetramer to an octamer containing histone H2A and H2B 
is by far the most substantial alteration to the histone-containing globular structure19,20. It is 
suggested that the transition to an octamer was needed to achieve a greater degree of DNA 
compaction in eukaryotes; however, this cannot be fully reconciled when considering the small 
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genome of primitive eukaryotes and the larger genome size of certain archaeal species. Nevertheless, 
an octameric structure can be more feasible for compacting larger genomes. Additionally, 
incorporation of H2A-H2B dimer can modulate the structural flexibility of the tetrasome providing 
a layer of structural regulation29. 
While maintaining a high degree of structural conservation, the complexity of the 
nucleosome has expanded throughout eukaryotic evolution. Numerous variants of canonical 
histones have been appropriated that play roles in mediating chromosome dynamics and 
transcription30. Functional specialization of nucleosome is further achieved through the acquisition 
of highly modifiable extended N-terminal tails in all four core eukaryotic histones. These specialized 
features of the nucleosomes will be briefly discussed in the following sections. 
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III. The Properties and Functions of Histones
i. Histone Variants
Most eukaryotes possess multiple copies of each canonical histone gene usually arranged in 
clusters. The expression of canonical histones is tightly coupled to the S phase of the cell cycle; 
therefore, these constitute the majority of histones incorporated in nucleosomes genome-wide.31 
Genes encoding non-canonical histone variants are usually found singly and are expressed 
throughout the cell cycle. Variants are the major source of histones outside of S phase and in non-
dividing cells32. Multiple variants for histones H3, H2A and H2B have been identified in most 
lineages of eukaryotes, with limited presence in some lower eukaryotic species such as Saccharomyces 
Cerevisiae. Specific molecular functions have been ascribed to certain histone variants ranging from 
gene activation/repression to DNA-repair and X chromosome inactivation30. 
a. Histone H3 variants with varied levels of divergence
The deviation from canonical histones is in most cases minimal and restricted to a few 
residues, but more divergent variants are also present. An examples of highly divergent histone 
variants present in nearly all eukaryotes is the centromeric histone H3 having only ~50% similarity 
to the histone fold of canonical H3 and minimal conservation of the N-terminal tail31. Nucleosomes 
at the eukaryotic centromeres are highly enriched for the centromeric H3 variant as this variant is 
required, but not sufficient, for the special centromeric chromatin architecture, kinetochore 
formation and proper chromosome segregation33. In fact, the rapid evolution of centromeric H3 
across eukaryotes and its divergence from H3 may be due to the requirement for binding to and 
anchoring various components of the kinetochore and mitotic machinery20. 
Histone H3 variants with significantly higher conservation include the replication-
independent H3.3, differing for example at only five amino acid residues from replicative H3 (H3.1 
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and H3.2) in mammals34. With the exception of Acetomyces including Saccharomyces Cerevisiae that 
contains a sole histone H3 resembling H3.3, when present as a non-replicative variant, H3.3 is 
associated with transcriptionally-active chromatin replacing canonical H3 during gene activation35. 
Highlighting the function of H3.3 in gene activation, this variant harbors post-translational 
modifications associated with gene activity in humans, flies and plants36. 
Unique to mammals is the presence of an additional replication-dependent histone H3 
(H3.1), differing at one amino acid position from H3.234. This corresponds to cysteine and serine 96 
in H3.1 and H3.2, respectively. Although the significance of this subtle specification is not yet clear, 
the nature of this amino acid in H3.1 is intriguing, as cysteine residues can participate in oxidation 
and reduction cycles. How or whether C96 is linked to the redox state of the cell and what this could 
mean requires further investigation. 
b. Histone H2A variants and nucleosome stability
Similar to histone H3, histone H2A has several variants with varying levels of divergence 
from canonical H2A. Of these, histone H2A.Z and H2A.X are conserved through most eukaryotic 
lineages and have specialized functions in gene activation and DNA repair, respectively30. Histone 
H2A variants differ mostly in the sequence and length of the C-terminal tail37. This is interesting 
given the interactions between this region of histone H2A and the H3-H4 dimer and can affect the 
stability and flexibility of the H3-H4 tetramer38. In fact, nucleosomes containing H2A.Z show 
destabilization of the interaction between H2A.Z-H2B and the H3-H4 dimers leading to a looser 
packaging of the DNA protecting only ~120 bp39. It is also possible that the rate of histone H2A.Z-
H2B turnover and exchange is higher than that of H2A-H2B dimers. Therefore, H2A.Z-containing 
nucleosomes can be more dynamic in transitioning between the tetrasome and nucleosome states. 
The association of H2A.Z with transcriptional activation can provide a justification for this 
property. However, more recent studies have described enrichment of H2A.Z with heterochromatin 
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(i.e. inactive chromatin) and a function of this variant in suppression of antisense transcription40,41. 
Although, it is possible that the functions of H2A.Z are context-dependent, the instability of H2A.Z 
vs. canonical nucleosomes may be involved in regulating a function(s) of nucleosome other than 
transcription. 
c. Principles and functions of histone variants
How are the functions of histone variants mediated? One regulatory step is the timing of 
histone variant expression. In regards to more divergent variants, major amino acid changes, 
especially of exposed residues, can modulate interactions with histone modifying enzymes, 
transcriptional or DNA-repair machinery mediating specialized functions. Structural deviations from 
canonical nucleosomes have also been noted for such divergent variants, such as centromeric H3, 
MacroH2A and H2A.Z42,43. However, despite the striking sequence conservation between some 
canonical histones and their variants, the variant histone is required for specific functions on a 
cellular or even organismal level. For instance, in some multi-cellular organisms, the abundance of 
histone H3 variants can vary from tissue to tissue44. The only tissue-specific histone H3 variant that 
is well established is the testis-specific H3.1, which is essential for spermatogenesis45. Whether 
maintaining a specific histone variant composition in somatic cell types is required for cellular 
identity or certain functional demands of such cells is unclear. 
The presence of histone variants results in spatial and temporal nucleosome structural 
heterogeneity across the genome. It is clear that locally histone variants can impart structural and 
functional changes on chromatin. An intriguing question is whether this heterogeneity is dynamic 
genome-wide and functionally meaningful on a global level for certain cellular functions. For 
example, what roles, if any, do histone variants play in the regulation of the copper reductase activity 
of the nucleosome or the tetrasome? Differences in structural flexibility can result in confirmation 
changes or lack-there-of that may be required for or modulate the catalytic activity. Conceivably, 
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protein-protein interactions facilitated by the histone variant surface-exposed residues can recruit 
components of the reaction such as chaperons for copper delivery to or liberation from the 
nucleosome. Investigating these ideas by integrating our current knowledge of histone variants and 
the novel enzymatic activity of nucleosomes is imperative to understanding the full spectrum of 
chromatin function. 
ii. Histone N-Terminal Tails and Core Post-Translational Modifications
a. The contributions of N-terminal tails and their modifications to nucleosome structure
The N-terminal tails of core histones are targets for a multitude of covalent post-
translational modifications (PTMs) including acetylation, methylation and phosphorylation46. 
Histone modifications are heavily studied for their functions in changing the local chromatin 
landscape. Combinatorial presence of tail modifications, which has been well-appreciated in the last 
decade, index the genome and provide highly specific regulation of the chromatin state47,48.  This is 
partly achieved through recruitment and anchoring of various protein complexes at specific loci to 
mediate DNA-based processes. Tail modifications function as docking sites for chromatin readers, 
proteins harboring domains that specifically recognize these modifications, and include components 
of the transcription, DNA replication and chromatin remodeling machinery49. Recent studies have 
now provided a greater appreciation for the role of such PTMs in altering nucleosome structure and 
dynamics. 
Acetylation of lysine residues is one of the earliest histone modifications identified and was 
recognized as a means to neutralize the positive charge of numerous lysines in the N-terminal tails. 
Acetylation is thought to relax the electrostatic interactions between these basic residues and DNA 
and contributes to enhanced accessibility. Methylation of lysine and arginine residues involved in 
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histone-DNA interactions and to some extent serine phosphorylation can affect chromatin structure 
through diverse mechanisms such as recruitment of chromatin factors and introduction of a 
negative charge, respectively50. 
In the last two decades, multiple crystal structures of the nucleosome have provided insight 
into the effect of histone tails on chromatin structures51. These structures reveal histone N-terminal 
tails extend out from the face of the nucleosome and lack organized domains52. However, several 
contact sites between distal, less heavily modified regions of histone tails, specifically for histone H3 
and H2B, and the octamer-wrapped DNA are present52. The distal domain of the N-terminal tail for 
all four histones have also been shown to contribute to DNA wrapping around the nucleosome53. In 
addition, histone tails interact with linker DNA and the neighboring nucleosomes, which regulates 
higher-order chromatin fiber structure54. 
Structural analysis of nucleosomes reconstituted with one of the four histones lacking the N-
terminal tail, have determined the contribution of histone tails. Although these findings can be 
extended to predict the effect of chemical alterations of the tail via specific PTMs, more direct 
evidence is needed to precisely define the role of specific post-translational modifications. Mutations 
of lysine residues mimicking acetylated (glutamine) or non-acetylated (arginine) states have provided 
enormous insight into the function of these modifiable sites. Such studies have pinpointed specific 
contributions of lysine residues, for example, the link between H4 K5/K12 diacetylation and 
nucleosome assembly and the role of H4 K16 acetylation in heterochromatin formation among 
others47. It is important to note that acetylation-mimicking mutations, which address the presence or 
absence of the charge associated with lysine, are not perfect since they do not possess the structural 
property of an acetyl-lysine. Biochemical studies using acetylated histones have revealed the 
particular effect of this PTM on nucleosome dynamics. Interestingly, the effect of histone 
acetylation or deletion of histone tail was shown to be minimal for the nucleosome but producing 
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significant alteration of the H3-H4 tetrasome structure55. Hyperacetylated H3-H4 tetrasomes but not 
nucleosomes undergo structural changes adopting a relaxed conformation and altered DNA 
supercoiling55. These findings strongly suggest the effect of tail hyperacetylation may be mediated 
through transiently formed flexible H3-H4 tetramers in vivo. 
The prevalence and significance of tetrasomes in vivo is unclear. Transient formation of 
intermediate nucleosome states including tetrasome occurs during nucleosome 
assembly/disassembly but this is not shown to depend on histone tail hyperacetylation56,57. 
Transcription by RNA polymerase II on highly acetylated active chromatin may specifically rely on 
transient formation of flexible tetrasomes58. It is also possible that tetrasome formation in vivo is 
more prevalent that previously assumed through the combined functions of enhanced H2A-H2B 
dimer exchange and histone tail acetylation. This notion can broadly impact our understanding of 
the many functions associated with the nucleosome. One such a function is the copper reductase 
activity observed for nucleosomes, which is not limited to the octameric complex as is observed 
with H3-H4 tetramers in vitro. A major question for future investigations is whether in vivo the 
enzymatic activity is associated with just the nucleosome, the tetrasome or both. Dynamic 
nucleosome-tetrasome transition, potentially through histone acetylation, may regulate this function 
of histones. In the same scope of ideas, the role of histone tail acetylation either via provoking other 
structural changes or serving as docking sites for protein recruitment can impact the kinetics of 
copper reductase activity. 
b. Post-translational modifications of histone core domains
For decades studies on covalent histone modifications focused largely on those occurring at 
the N-terminal tail. Modifications of the core domain, depending on the position, can have diverse 
effects at the level of the nucleosome as well as chromatin architecture. Core PTMs can be divided 
into those at protein-protein or protein-DNA interfaces and at the nucleosome surface, greatly 
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impacting nucleosome structure and participating in recruitment of other proteins to chromatin, 
respectively59. Among solvent-accessible surface PTMs is histone H3K79 methylation that has been 
extensively studied for its influence on heterochromatin gene silencing60. Interestingly, it is thought 
that this function is indirect as this modification is more abundant on euchromatin. Based on studies 
in yeast it was proposed that H3K79 methylation functions to prevent the association of 
components of silent chromatin with the nucleosome ensuring the availability of these factors for 
assembly of silent chromatin elsewhere61. 
The widespread application of mass spectrometry for detecting protein modifications, has 
led to the discovery of numerous PTMs on histone core domains. Although most have not been 
extensively studied, a large number of these modifications fall at the lateral surface of the 
nucleosome near the dyad. A number of these residues are contributed by the c-terminal region of 
histone H3 and by histone H4 and include H3T118, H3K115, H3K122 and H4S4760.  This region is 
of interest since it contains many histone-DNA interaction sites. Modifications of these residues that 
for the most part are highly conserved can regulate the kinetics of octameric DNA unwrapping60. 
Given that the H3 residues mentioned above are within the 4 helix bundle that holds the H3-H4 
tetramer together, their modifications can also potentially affect protein-protein interactions52. 
Therefore, PTMs at these sites can affect nucleosome dynamics, DNA accessibility and nucleosome 
mobility. 
More recently, amino acid modifications with larger chemical moieties such as ubiquitin and 
glutathione have been identified in the core domains of histones. Mono-ubiquitination of lysine 119 
in H2A and lysine 120 in H2B in mammals with equivalent residues found in yeast and plant H2B 
are among the most well-recognized of these modifications. These are associated with gene silencing 
and transcription initiation, respectively62. The conserved lysine 122 in histone H3 has also been 
shown to be ubiquitinated and can impact nucleosome dynamics and assembly given its position as 
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previously highlighted63. Ubiquitin is a large molecule and would be expected to induce physical 
changes in the nucleosome conformation. Further investigations of the specific structural 
consequences of core lysine ubiquitination are needed. 
A less bulky, yet relatively large, protein adduct is glutathione (γ-L-Glutamyl-L-
cysteinylglycine). Glutathione is known for its function in maintaining the redox equilibrium of the 
cell but its reactivity with thiolate anions of cysteine residues in target proteins can regulate many 
protein functions64. Evidence for S-glutathionylation of a well-conserved cysteine residue (C110) of 
histone H3 has been found in mammals65. This cysteine residue lies at the core of the nucleosome at 
the interface of the two histone H3 molecules, and its modification by glutathione destabilizes the 
nucleosome in vitro65. Alterations of C110 through S-glutathionylation is correlated with proliferation 
in mammalian cells and is associated with young age in mice65. Oxidation and disulfide bridge 
formation between the two C110 residues, one from each H3 molecule, were reported as early as 
197766. The potential presence of a disulfide bridge at this site in vivo is likely biologically meaningful; 
however, further investigation is needed to address this. Although a disulfide bridge would be 
structurally and chemically different from glutathionylation of cysteines, the ability of this cysteine to 
undergo redox reactions with glutathione or with the opposing cysteine hints at an interesting but 
unknown function of this residue. 
c. Histone modifying enzymes and the link between chromatin and cellular metabolism
Covalent modification of histone tail and core residues is mediated by a diverse group of 
histone-modifying enzymes (HMFs). The enzymatic activity is in most cases contained in large 
multi-protein complexes that can also harbor histone chaperon, nucleosome remodeling, PTM 
recognition or DNA-binding activities67. The varied nature of these complexes allows for coupling 
of chemical modification of histone with physical alterations such as assembly and remodeling. 
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The reversibility of almost all histone modifications in an enzyme-dependent manner allows 
for dynamic regulation of the nucleosome and functions linked to PTMs. The rate of turnover for 
various modifications is set by the action of enzymes writing and removing the modification, with 
lysine acetylation having the highest rate of turnover68. This is an important concept for 
understanding the fluidity of chromatin states and the integration of cellular cues with chromatin. 
An emerging body of work has revealed links between histone modifications and metabolic 
networks facilitated in part by histone-modifying enzymes. Cellular metabolites can serve as 
regulatory co-factors such is the case with NAD-dependent Sir2 family of deacetylases or as the 
source of the chemical moiety (i.e. acetyl-CoA for acetylation reactions)69. Primary metabolism and 
the secondary metabolites derived from metabolic pathways can be theoretically linked to almost all 
functions of chromatin. Evidence for the converse relationship namely chromatin state altering the 
metabolome, has been put forth. The most recognized mode of mediating this is through regulation 
of expression of metabolic genes in response to sensing a relevant secondary metabolite by 
chromatin modifiers.70 More direct crosstalk can involve consumption or generation of a certain 
metabolic factor through establishing or removing certain histone modifications, respectively, either 
locally or genome-wide. For example, generation of acetate anions upon histone deacetylation can 
represent a substantial source of carbon and impact metabolism71. Although more investigation is 
required to understand such effects of chromatin on cellular metabolism, it is easy to imagine many 
instances of this type of crosstalk. 
Considering the evolutionary origin of the nucleosome, one might postulate the inheritance 
of the repertoire of histone-modifying enzymes from ancient archaea. Surprisingly, evidence 
suggests a proteobacterial origin of primitive histone modifying enzymes in eukaryotes72. Sequencing 
of a great number of bacterial genomes has identified genes with similarity to chromatin modifying 
enzymes of eukaryotes73. Conversely, archaea lack histone modifications and therefore do not have 
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the repertoire of modifier enzymes. The bacterial homologues of eukaryotic chromatin modifiers 
enrich for functions in secondary metabolism and bacterial defense system, which in some cases rely 
on modifying peptides, DNA and small molecules of the competing organisms72. Diversification of 
these enzymes is speculated to have occurred in bacteria partly due to the expansion of secondary 
metabolism as a result of the Great Oxygenation Event72. Interestingly, this includes the invention of 
oxygen-utilizing enzymes that are homologous to oxygen-dependent histone demethylases such as 
LSD1 present in eukaryotes73. Although the adaptation and advantage of these bacterial inventions 
are apparent in modern eukaryotes, that may not have been the case for the archaea host for 
eukaryogenesis. It has been proposed that active manipulation of the host’s DNA and protein by the 
bacteria endosymbiont may have in fact driven the emergence of the nucleus, a protective barrier to 
foreign modifications. 
iii. Histones and Transition Metals
As early as 1980s it was postulated that metal ions may play a role in chromatin structure and 
organization74. This postulate came after a series of investigations revealed potential metal binding 
motifs for numerous DNA-binding transcription factors. Zinc binding was demonstrated for some 
of those proteins and was shown to mediate their stabilization and association with DNA75. The idea 
that an analogous binding site was present in the nucleosome and could mediate interactions 
between histones and transcription regulators was entertained. The structure of the nucleosome core 
particle had in fact revealed the presence of a similar metal binding motif. This comprised of 
residues 110-113 in the C-terminal region of histone H3 generating a potential metal binding pocket 
upon H3 dimerization74. Decades later the ability of this region of the H3-H3’ dimerization interface 
to bind various metal ions was demonstrated in vitro76. Whether metal binding occurs in vivo, and the 
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biological significance of such binding had not been investigated. Our recent work (see chapter V) 
reveals a novel function of this region of the nucleosome in transition metal, specifically copper, 
homeostasis. The function of the nucleosome to support copper-dependent processes through the 
enzymatic reduction of copper ion, is affected by mutation of His113 to an asparagine in this region 
of histone H3. Interestingly, mutating the cysteine residue (C110), which together with histidine 113 
form the metal binding motif, to an alanine, almost abolishes the copper reductase activity of the 
H3-H4 tetramer in vitro. Altogether suggesting a role of this metal binding motif potentially as a site 
for copper coordination during catalytic reduction. More investigation into the mechanistic 
contribution of this metal binding domain to copper reductase activity as well as its link to other 
properties of the nucleosome is needed. 
In addition to the H3-H3’ dimerization interface, a metal binding site on the surface of the 
nucleosome was revealed in one of the early high resolution structures of the nucleosome core 
particle containing the histone variant H2A.Z38. Two well-conserved histidine residues, His112 and 
His114, in the H2A.Z docking domain mediate coordination of a manganese ion in the structure38,77.  
The identity of a potential metal at this site in vivo is not clear, but copper or zinc are plausible given 
the coordination chemistry. These histidine residues are not found in canonical H2A and are absent 
from Saccharomyces Cerevisiae H2A.Z77 suggesting a specialized function in some eukaryotes. The 
function of this metal binding site has not been examined thoroughly but a role for the two histidine 
residues in Xenopus laevis development has been shown. Specifically, a defect in mesoderm formation 
is observed in embryos with H2A.Z containing histidine mutations78. Of note, mutations of the 
copper transporter (Ctr1) in Xenopus laevis has been shown to result in a mesoderm induction 
defect79. Does this hint at the identity of the metal coordinated by H2A.Z in vivo?  More work needs 
to be conducted to answer such questions and to further understand whether H2A.Z putative metal 
binding affects cellular copper metabolism. Lastly, this property of histone H2A.Z may be linked to 
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the copper reductase function of the nucleosome. The docking site of H2A.Z which contains the 
metal binding pocket is in close proximity to the N-terminal region of histone H338. It is possible 
that copper binding by H2A.Z can participate in transfer of copper to/from the enzyme catalytic 
site, which is postulated to be at H3-H3’ dimerization interface. However, these two regions in a 
fully formed nucleosome are far apart and such direct interaction is improbable. However, the 
dynamic exchange of H2A-H2B dimers and structural transitions of the nucleosome may transiently 
mediate such an interaction. The co-localization of H2A.Z and histone H3.3 observed in the same 
genomic regions or nucleosome for transcriptional activation may hint at a specific interaction, 
physical or functional, between these variants in regards to copper reduction by the nucleosome. 
Extending this idea one can imagine differences in the copper reductase activity at various regions of 
chromatin. Changes in enzymatic activity can be associated with changes in histone variants or 
histone modifications, and even more broadly, with heterochromatic or euchromatic states.  
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Chapter II 
Layered regulation of the epigenome and its links to cellular metabolism 
and physiology 
This chapter was published in 2014 titled “Layered regulation of the epigenome and its links to 
cellular metabolism and physiology”. It appears as a chapter in the American Association of Cancer 
Research education book for the AACR annual meeting in 2014. Briefly, this chapter reviews the 
literature concerning the role of epigenetic changes including DNA methylation and histone 
modifications with special attention given to global histone acetylation, in cellular metabolism and 
cancer progression. The connection of epigenetic changes to clinical outcome in cancer is also 
discussed.  
I authored this chapter and was responsible for the literature review, writing the manuscript and the 
analysis of the primary data included.   
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Layered regulation of the
epigenome and its links to cellular
metabolism and physiology
Narsis Attar1,2 and Siavash K. Kurdistani1,2,3,4
Background
Epigenetics is the study of heritable changes in patterns of gene expression mediated by mechanisms other than 
alterations in primary DNA sequence. The main determinants of the gene expression state are sequences-speciﬁc 
DNA binding transcription factors; but methyl-ation of DNA, covalent modiﬁcations of the histones, 
nucleosome composition and posi-tioning as well as large and small noncoding RNAs are thought to inﬂuence 
the epigenetic information (1). Aberrations in the epigenome occur frequently in essentially all cancers and may 
contribute to cancer initiation or progression (1). Epigenetic abnormalities in cancer, especially patterns of 
histone modiﬁcations, occur at single gene level but also globally, at the cellular level. Global changes in the levels 
of histone modiﬁcations have proved to be surprisingly common prognosticators of clinical outcome in a variety 
of cancers types regardless of the tissue of origin (2). The aberrations in histone modiﬁcations are studied 
primarily for their deregulatory effects on DNA-based processes such as transcription and DNA repair but 
recent evidence suggest that histone modiﬁcations may also have unanticipated links to cellular metabolism and 
physiology. These novel links have important and practical implications for the use of epigenetic therapeutics in 
cancer.
Discussion
DNA methylation
One of the early epigenetic alterations observed in malignancies involves global loss of 5-methylcytosine (5mC) 
on CpG dinucleotides (3). This global DNA hypomethylation preferentially affects repetitive sequences 
including heterochromatic repeats and endogenous retroviral elements, potentially leading to genomic instability 
and transcription of regions that are otherwise silent in normal cells (3). The exact contribution of DNA 
hypomethylation to cancer initiation or progression is still unclear but studies of mice deﬁcient in DNA 
methylation suggest a causal role of DNA hypomethylation in cancer predisposition and tumorigenesis, in 
particular in the development of lymphomas (4). Recurrent inactivating mutations in the de novo 
methyltransferase DNMT3A is also seen in some leukemias and is associated with DNA hypomethylation and 
poor prognosis (5).
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Cancer genomes are also characterized by localized hypermethylation of CpG islands, which
are often associated with gene promoters (3). Many promoters containing CpG islands are
hypermethylated, leading to epigenetic silencing of genes whose expression may adversely affect
tumor growth (3). In fact, methylation status of certain gene promoters have been used as
molecular biomarkers of cancer prognosis (6). Notably, a signiﬁcant proportion of DNA
methylation changes occur in regions ﬂanking CpG islands designated as "shores" which are
normally differentially methylated in a tissue-type speciﬁc manner (7, 8). These shore regions
exhibit striking DNA methylation hyper-variability among tumors of the same cancer type,
raising the possibility that epigenetic plasticity at sites governing normal tissue differentiation
may confer an adaptive advantage to cancer cells.
Histone modifications
Alterations of histone modiﬁcations can occur locally, at speciﬁc genomic loci via
inappropriate activity or recruitment of histone modifying enzymes. When found in
gene-regulatory regions such as promoters or enhancers, these alterations are linked to
mis-regulation of downstream genes which may contribute to cancer development or
progression. For instance, EZH2-mediated H3K27 trimethylation at gene promoters is
associated with silencing of a number of tumor suppressor genes (9). Redistribution of
H3K4me1, a histone modiﬁcation found preferentially at enhancer elements, in colon cancer
is associated with improper usage of enhancer elements to promote a carcinogenic gene
expression program (10).
Histone modiﬁcation levels can also be regulated globally at the cellular level. Individual cells
or tissues display dramatic differences in the total levels of histone modiﬁcations contained
within chromatin, quantitatively demonstrated by immunohistochemistry orWestern blotting.
For example, cells of skeletal muscle, heart and stomach contain much lower levels of histone
acetylation compared to other tissues such as lung or colon (11). Cancer cells in primary
patients' tumors also exhibit marked differences in their global levels of histone acetylation and
methylation (12). Unlike alterations of histone modiﬁcations at speciﬁc genomic loci,
differences in the global levels of histone modiﬁcations are prognostic of clinical outcome
in many types of cancers (2, 14–17) (Table 1). In general, lower global levels of histone
acetylation and/or methylation, regardless of their general correlations with gene expression or
repression, are associated with more aggressive cancers and poor clinical outcome (13–16). The
ability of global histonemodiﬁcation levels to categorize different types of cancers into clinically
cohesive groups, presumably independent of gene expression states or mutational proﬁles, has
been a surprisingly common feature of all cancers examined to date. In most cases, the
prognostic of global histone modiﬁcations has been independent of key clinical or pathological
variables patterns, informing on an aspect of cancer pathobiology that is not reﬂected by other
clinic-pathological variables.
At the genomic level, extensive loss ofH4K16 acetylation andH4K20 trimethylation atDNA
repetitive elements is observed in many cancer types and correlates with tumor progression in
mouse models of multistage tumorigenesis (17). But very little is known about what functions
the changes in global levels of histone modiﬁcations serve for the cell or how the global
regulation of histone modiﬁcations is linked to more aggressive cancers.
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In the case of global acetylation, recent work from our lab has revealed an unanticipated
function in the context of cellular physiologic homeostasis, speciﬁcally intracellular pH (pHi)
(18).We found that global histone acetylation and deacetylation is in ﬂux with the extracellular
acetate through monocarboxylate transporters (MCTs) which are obligate proton symporters.
In acidic environments, histones become globally deacetylated and the liberated acetate
molecules are co-transported along with protons out of the cell through the MCTs, decreasing
the intracellular proton load. This cellular response to acidity is an active process marked by
increased histone deacetylation, resulting in the continuous generation of free acetate molecules
to be used for proton export. Conversely, histones are globally acetylated as pHi becomes more
alkaline in order to prevent undesired increases in pHi. Inhibitions of histone deacetylases
(HDACs) or MCTs, which respectively prevent the release of acetate from chromatin or its
efﬂux from the cell, compromise cellular pH maintenance. These ﬁndings suggest that
acetylation of chromatin acts as a rheostat for pHi control. Since cancer tissues commonly
exhibit low pH in vivo (19), cancer cells with lower levels of histone acetylationmay be using this
mechanism as a means to maintain a viable pHi in acidic microenvironments. Such acidic
conditions can select for resilient cells that are resistant to chemotherapy and/or radiation (19),
potentially explaining the association of low histone acetylation with aggressive cancers. At the
molecular level, the global regulation of acetylation is tied to coordinate control of thousands of
individual acetylation peaks throughout the genome (18) (Fig. 1). This indicates that histone
acetyltransferases (HATs) and HDACs must integrate the processes of pHi control with gene
expression by dynamically shaping the abundance and distribution of genome-wide acetylation
on histones.
Table 1. Changes in global levels histone modifications are prognostic of clinical outcome in various types of
cancers
Cancer type Modiﬁcation Clinical correlates
Renal cell carcinoma #H3K18ac Increased recurrence
#H3K9me2 Reduced cancer-related survival
#H3K4me1, 2, 3 Increased recurrence/reduced survival
Lung adenocarcinoma #H3K4me2, H3K18ac Reduced cancer-related survival
#H3K9ac, H3K9me3, H4K16ac Increased recurrence
Prostate cancer #H3K18ac, H3K4me2 Increased recurrence
#H3K9me2 Increased recurrence
#H3K4me1 Increased recurrence
Pancreatic cancer #H3K27me3 Reduced cancer-related survival
#H3K18ac, H3K4me2, H3K9me2 Reduced disease-free survival
Ovarian cancer #H3K27me3 Reduced cancer-related survival
Breast cancer #H3K27me3 Reduced cancer-related survival
#H3K18ac, H3K9ac, H3K4me2 Reduced disease-free survival
#H4K12ac, H3K4me2, H4K20me3,
H4R3me2, H4K16ac
Poor prognosis subtype
Hepatocellular carcinoma "H3K27me3 Reduced survival
"H3K4me3 Poor prognosis
Gastric carcinoma "H3K9me3 Reduced survival
AACR Education Book * http://educationbook.aacrjournals.org
Epigenetics in basic and clinical cancer biology
30
25_8200_Kurdistani; 10/3/2014; 11:29:9
Disruption of pHi maintenance by HDAC inhibitors (HDACi's) suggests a novel mech-
anism of action for these drugs. By compromising cellular pH buffering capacity, HDACi's may
render their companion drugs essentially ineffective because most drugs are developed for
function at neutral to slightly alkaline pH. These considerations could lead to more informed
use of HDACi's in oncology.
Themechanisms by which histone modiﬁcations levels are regulated globally are not very well
understood. For example, it is unclear how the balance of histone acetylation and deacetylation
is favored toward the latter in acidic conditions. One possible mechanism may be through
modulation of activities of epigenetic enzymes by co-factor availability or small molecule
allosteric regulators that link metabolic or physiologic states to epigenetic maintenance. Such
possibility has been highlighted by the discovery of mutations in isocitrate dehydrogenase
(IDH)1 and 2 in a subset of oligodendroglioma and leukemias that result in production of 2-
hydroxyglutarate (2HG) instead of 2-oxoglutarate. 2HG functions as a competitive inhibitor of
a-ketoglutarate-dependent dioxygenases including the jumonji family of histone demethylases,
leading to genomewide increases in various histone methylationmarks in cancer cells harboring
IDH mutations (5). Essentially all other histone modifying enzymes require and/or are
regulated by metabolic cofactors (20, 21), raising the possibility of additional links between
global regulation of histone modiﬁcations and speciﬁc physiological and metabolic processes
within the cell.
Normal
Acidic
pH
Fig. 1. Histones are globally and dynamically deacetylated in acidic conditions. Shown are genomic tracks
displaying levels of histone acetylation across a region of chromosome 1 in HeLa cells grown briefly in normal or low pH.
Most deacetylated regions regain acetylation in presence of HDACi’s suggesting that the deacetylation is favored over
acetylation, leading to the appearance of deacetylated histones. Dynamic acetylation and deacetylation of histones,
when favored toward the latter at low pH, generates free acetate molecules for proton export through the
monocarboxylate transporters and buffers intracellular pH.
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Future Directions
Understanding the distributions of histone modiﬁcations across the genome has led to
signiﬁcant investment in comprehensive mapping efforts (e.g., NIH Epigenome Roadmap).
These maps are used to infer the functions of histone modiﬁcations by comparing the location
of modiﬁed histones to genomic landmarks or nearby molecular processes such as gene
expression. Implicit in this approach is the assumption that histone modiﬁcations are regulated
locally and function mainly to regulate nearby DNA-based events. It is now clear that in
addition to the locus speciﬁc regulation of histone modiﬁcations, cells regulate levels of histone
modiﬁcations at a global scale in response to metabolic or physiologic cues. By changing the
fraction of total histones that are modiﬁed in a cell, global regulation of histone modiﬁcations
may affect numerous genomic loci at once (18), enabling coordinate regulation of cellular
metabolism/physiology and genomewide gene expression through large-scale epigenetic repro-
gramming. Whatever the case maybe, global levels of histone modiﬁcations in primary cancer
tissues have proved to be reliable molecular biomarkers for stratiﬁcation of tumors into more
clinically homogeneous subgroups that could be used to increase the speciﬁcity of cancer
therapies (22).
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p300 and CREB-binding protein (CBP), two homologous lysine acetyltransferases in meta-
zoans, have a myriad of cellular functions. They exert their influence mainly through their
roles as transcriptional regulators but also via nontranscriptional effects inside and outside of
the nucleus on processes such as DNA replication and metabolism. The versatility of p300/
CBPas molecular tools has led to their exploitation by viral oncogenes for cellular transfor-
mation and by cancer cells to achieve and maintain an oncogenic phenotype. How cancer
cells use p300/CBP in their favor varies depending on the cellular context and is evident by
the growing list of loss- and gain-of-function genetic alterations in p300 and CBP in solid
tumors and hematological malignancies. Here, we discuss the biological functions of p300/
CBP and how disruption of these functions by mutations and alterations in expression or
subcellular localization contributes to the cancer phenotype.
EP300 (hereafter referred to as p300) and itsclosely related paralog CREB-binding pro-
tein (CREBBP, hereafter CBP) are ubiquitously
expressed transcriptional coactivators and ma-
jor lysine acetyltransferases (KATs) in metazo-
ans. They regulate transcription by serving as
scaffolds that bridge sequence-specific DNA-
binding factors and the basal transcriptional
machinery (Chan and La Thangue 2001), and
facilitate transcription through acetylation of
histones, transcription factors, and autoacetyla-
tion (Sterner and Berger 2000; Black et al. 2006;
Pugh 2006; Das et al. 2014). p300 and CBP are
large proteins with multiple functional do-
mains accommodating diverse protein–protein
interactions. This has enabled a large number of
disparate transcription factors to use p300/CBP
as cofactors in regulating the expression of
thousands of genes in essentially all cell types
(Chan and La Thangue 2001). The large num-
ber of proteins that interact with p300 and CBP
underscore the widespread influence of these
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was shown to be critical for the G1 –S phase
transition in adenovirus-infected cells (Howe
et al. 1990). A number of other oncogenic viral
proteins (e.g., SV40/polyoma LT, HPV E7) were
subsequently shown to also target p300 or CBP
to promote cellular transformation (Eckner
et al. 1996; Zimmermann et al. 1999; Bernat
et al. 2003). The frequent exploitations of
p300/CBP as cofactors for viral oncoproteins
highlighted the fundamental role of these pro-
teins in regulating cellular proliferation, and
raised the possibility that alterations of p300/
CBP may also contribute to nonviral mecha-
nisms of tumorigenesis.
E1A was initially reported to inhibit p300/
CBP-mediated KAT activity and transcriptional
activation, which led to a hypothesis that p300
may normally function as a negative regulator of
S phase entry (Arany et al. 1995; Yang et al. 1996;
Chakravarti et al. 1999). However, many studies
have since revealed a major role for p300/CBP
in promoting growth and cell-cycle progression.
In fact, on adenoviral infection p300 is recruited
to genes with functions in cell cycle and prolif-
eration to promote their full activation and S
phase entry in otherwise nondividing cells (Fer-
rari et al. 2008, 2014).
The functions of p300 and CBP in regulat-
ing cell-cycle progression are partly mediated
through their influence on transcription by be-
ing recruited to gene regulatory regions, such as
enhancers and promoters, via sequence-specif-
ic DNA-binding transcription factors. Once
bound, they facilitate subsequent regulatory
events to ultimately direct RNA polymerase II
activation. p300 in particular contributes to the
formation of the transcription pre-initiation
complex, a large multiprotein complex required
for expression of genes. p300 does this partly
through dynamic association with and dis-
sociation from the transcriptional machinery,
which is facilitated by p300 auto-acetylation ac-
tivity (Black et al. 2006). The pervasive partici-
pation of p300 and CBP in transcriptional reg-
ulation is evident in their binding to .16,000
genes in human cells (Smith et al. 2004; Ramos
et al. 2010). Not all binding events lead to tran-
scriptional activation and a growing body of
evidence indicates a gene-repressive role for
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coactivators on essential cellular functions.
p300 and CBP regulate several fundamental bi-
ological processes including proliferation, cell
cycle, cell differentiation, and the DNA damage
response (Shi and Mello 1998; Goodman and
Smolik 2000; Grossman 2001; Polesskaya et al.
2001). But the versatility of these proteins has
also made it difficult to discern their specific
involvements in distinct biological processes
and pathophysiological states. Another imped-
iment to understanding the roles of p300 and
CBP is the overlapping contribution of these
proteins to the same molecular processes such
as gene regulation, hence, the commonly used
designation “p300/CBP.”
Although p300/CBP have been implicated
in cancer development, the specific contribu-
tions of each acetyltransferase to the cancer phe-
notype have been less precisely defined. This
is in part attributable to the participation of
p300/CBP in diverse and, at times, antagonistic
cellular pathways such as tumor-suppressive
and pro-oncogenic processes. The challenge is
even greater when attempting to understand
the consequences of mutations in p300 and
CBP, which have been identified in numerous
cancer genome studies. To fully understand
how genetic or epigenetic alterations of p300/
CBP contribute to the cancer phenotype, it is
important to determine which cellular path-
ways are specifically affected by mutations in
p300 or CBP. One important consideration is
that p300 and CBP, despite significant sequence
homology, also perform nonoverlapping cellu-
lar functions and can cooperate with distinct
binding partners. In this review, we discuss the
major functions of p300/CBP in the cell and
how cancer cells exploit these functions to their
advantage.
p300/CBP ORCHESTRATE THE CELL CYCLE 
AND REGULATE PROLIFERATION
p300 was initially identified through its physical
association with the adenovirus transforming
protein E1A and determined to be essential
for adenovirus-mediated oncogenic transfor-
mation (Whyte et al. 1989; Sawada et al.
1997). Soon after, the E1A–p300 interaction
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p300/CBP in certain contexts (Santoso and Ka-
donaga 2006; Sankar et al. 2008; Ferrari et al.
2014). p300 and CBP also regulate the cell cycle
through interactions with or acetylation of pro-
teins involved in cell-cycle progression, such as
the DNA replication machinery and histones
for the purpose of DNA replication through
chromatin.
Transcriptional Coactivation and the Cell 
Cycle
One of the earliest cell-based models showing
the role of p300/CBP in cell-cycle progression
involved depletion of p300 and CBP, through
microinjection of an antibody against both pro-
teins, which was found to limit S phase entry
(Ait-Si-Ali et al. 2000). This defect was reversed
by overexpression of exogenous CBP, indicating
a direct function of CBP in promoting cell-cycle
progression. p300 and CBP serve as transcrip-
tional coactivators for the E2F transcription fac-
tor family, which are central for expression of
genes required for G1/S transition (Trouche and 
Kouzarides 1996; Trouche et al. 1996; Wang
et al. 2007). In addition, p300/CBP acetylate
the E2F proteins themselves (e.g., E2F1), lead-
ing to enhanced DNA-binding and gene activa-
tion (Martı´nez-Balba´s et al. 2000; Marzio et al.
2000). The acetyltransferase activity of CBP is
regulated in a cell-cycle-dependent manner and
peaks at the G1/S boundary possibly as a con-
sequence of cyclin/Cdk-mediated phosphory-
lation of CBP before initiation of S phase
(Ait-Si-Ali et al. 1998). Cell-cycle-dependent
transcription of the major histone genes for
DNA replication is also dependent on p300/
CBP, which are recruited by NPAT, the general
histone expression regulator (He et al. 2011).
Therefore, the transcriptional coactivator func-
tions of p300/CBP mediate S phase entry
through proper expression of DNA replication
and cellular growth genes.
Nontranscriptional Effects of p300/CBP on 
Cell Cycle
p300/CBP may regulate DNA replication
through modifying the histones surrounding
the DNA replication origins. These two acetyl-
transferases are responsible for the bulk of his-
tone H3 lysine 18 acetylation (H3K18ac) and
H3K27ac, modifications associated with active
promoters and enhancers (Horwitz et al. 2008;
Jin et al. 2011). H3K18ac is also associated with
active DNA replication in certain cell types
(Li et al. 2014). p300/CBP may also direct-
ly regulate the DNA replication machinery by
acetylating two major endonucleases involved
in Okazaki fragment processing, FEN1 and
Dna2, inhibiting and stimulating their activi-
ties, respectively (Hasan et al. 2001; Bala-
krishnan et al. 2010). This differential regula-
tion is suggested to lead to increased accuracy
of DNA replication (Balakrishnan et al. 2010).
Complementing these results, pharmacological
inhibition of p300KATactivity prolongs S phase
because of reduced replication fork velocity and
defects in timing of replication origin firing and
synchronization (Prieur et al. 2011). Altogether,
p300/CBP regulate various aspects of the DNA
replication process, including the choice and
timing of origin firing and the assembly of the
newly synthesized DNA into chromatin.
p300/CBP function in other phases of the
cell cycle as well. Depletion of CBP leads to a
delay in mitosis and accumulation of cells in
G2/M because of the aberrant activity of the
anaphase-promoting complex (APC/C), an
E3 ubiquitin ligase required for progression
through mitosis (Turnell et al. 2005). Taken to-
gether with the above, these findings place p300
and CBP at multiple positions along the cell
cycle and emphasize the functions of these pro-
teins in promoting progression through the en-
tire cell cycle (Fig. 1).
Consistent with the critical roles of p300/
CBP in cell-cycle regulation, significant growth
defects are observed when these proteins are
depleted in cells or organisms. Mouse models
null for p300 or CBP are embryonic lethal and,
although p300-null cells obtained from these
embryos are viable, they show reduced prolifer-
ation (Yao et al. 1998). This also occurs when
p300 is transiently or stably depleted (Yuan et al.
1999; Iyer et al. 2007). Therefore, loss of p300/
CBP in most contexts leads to decreased prolif-
eration.
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p300 AND CBP IN CANCER
p300/CBP as Classic Tumor Suppressors
Early indicationsof tumor suppressionbyp300/
CBP came from findings in a rare congenital
developmental disorder, Rubinstein–Taybi syn-
drome (RTS). Germline heterozygous muta-
tions in CBP and less frequently in p300 are ob-
served in RTS and may play a role in the
pathogenesis of this disease. RTS patients have
an increased incidence of cancer with 5% di-
agnosed with childhood tumors of neural crest
origin (Miller and Rubinstein 1995). p300/CBP
mutations in RTS are variable and encompass
microdeletions, truncating mutations as well as
point mutations in different domains (Petrij
et al. 1995; Roelfsema and Peters 2007). A num-
ber of these genetic lesions reduce acetyltrans-
ferase and/or transcriptional activities of p300/
CBP implicating the reduction of these func-
tions in the etiology of RTS-associated malig-
nancies (Roelfsema and Peters 2007), a conten-
tion that is supported by studies inmice (Tanaka
et al. 1997; Rebel et al. 2002; Alarco´n et al. 2004).
Investigations of primary tumor samples
helped to strengthen the tumor-suppressive
functions of p300/CBP in humans. Work by
Gayther et al. identified the first cancer-associat-
ed inactivating genetic lesions in p300 in breast
and colorectal primary tumors and cell lines
(Gayther et al. 2000). The majority of cases har-
bored inactivation or deletion of the second al-
lele of p300. Studies of larger cohorts of solid
tumors including colorectal, gastric, ovarian,
and hepatocellular carcinomas also detected
loss of heterozygosity (LOH) at the p300 or
CBP loci at frequencies ranging from 1% to
50% (Bryan et al. 2002; Tillinghast et al. 2003;
Koshiishi et al. 2004; Dancy and Cole 2015). A
small fraction of p300/CBP LOH events in these
studies were accompanied by somatic mutations
in the second allele confirming earlier findings.
Tumors showing LOH indicate that haploinsuf-
ficiencyof p300/CBP may be afactor in the path-
ogenesis of cancer. This is consistent with the
idea that a limiting cellular pool of p300/CBP
may be a biological determinant of their effects
on the cell. In fact there is evidence that these
proteins are haploinsufficient because p300/
CBP heterozygote null embryos have reduced
survival (Yao et al. 1998). Therefore, different
molecular pathways have to compete for a limit-
ed pool of p300/CBP to regulate their target
genes (Kamei et al. 1996; Huang et al. 2007). So
P300/CBP serve as
coactivators for E2Fs  for
expression of G1 to S
transition genes
CBP regulates the
APC/C complex for
mitotic progression
P300/CBP acetylate proteins
in the DNA replication
machinery and chromatin
S
G 2
/M
G
1
Figure 1. p300/CREB-binding protein (CBP) regulate the cell cycle atmultiple points. The diagram summarizes
the known functions of p300/CBPat different points along the cell cycle. The E2F family of transcription factors
uses p300/CBP as transcriptional coactivators to facilitate expression of E2F target genes that orchestrate the
transition from G1 to S. p300 also facilitates S phase progression by acetylating the DNA replication machinery
(e.g., FEN1 and Dna2) and the histones surrounding the replication origins (e.g., H3K18). CBP promotes
progression throughmitosis by regulating the function of the anaphase-promoting complex (APC)/C complex.
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the reduced availability of p300/CBP through
LOH may contribute to cancer development or
progression by altering the equilibrium between
the various p300/CBP-dependent pathways.
Additional evidence suggesting a tumor-sup-
pressive function for p300/CBP came from
oral and cervical carcinoma cell lines. These
cell lines, which harbor either a homozygous
mutation in p300 or a heterozygous truncation
of p300 with inactivation of the normal allele,
show reduced proliferation on introduction of
a normal copy of p300 (Suganuma et al. 2002).
p300/CBP may exert tumor-suppressive ef-
fects through promoting the functions of other
bona fide tumor suppressors, such as p53, RB1,
BRCA1, or through inducing transforming
growth factor b (TGF-b)-responsive genes
(Nishihara et al. 1998; Pao et al. 2000; Chan
et al. 2001; Grossman 2001). The involvement
of p300/CBP in p53-mediated functions is ex-
tensively studied and occurs at multiple levels.
In response to DNA damage, p300/CBP aug-
ment p53-dependent transcriptional activation
of genes required for cell-cycle arrest and DNA
repair (Grossman 2001). In addition, p300 pro-
motes the nuclear accumulation and stability of
p53 in response to genotoxic stress. Interesting-
ly, in unstressed conditions and during recovery
from DNA damage, p300 is thought to ensure
degradation of p53 for resumption of the cell
cycle after DNA repair (Grossman et al. 1998;
Grossman 2001; Kawai et al. 2001). BRCA1,
which is frequently mutated in familial breast
and ovarian cancers, plays a role in cell-cycle
checkpoint, DNA damage repair, and transcrip-
tional regulation (Monteiro et al. 1996; Wu et al.
2010). The latter role has linked BRCA1 to
p300/CBP, which enhance BRCA1-mediated
transcriptional activation (Pao et al. 2000; Mul-
lan et al. 2006). Similarly p300/CBP mediate
the effects of TGF-b signaling by serving as tran-
scriptional coactivators for Smad3, a down-
stream effector of this tumor-suppressive path-
way (Feng et al. 1998; Derynck et al. 2001).
p300/CBP as Drivers of Cancer Growth
Despite the tumor-suppressive roles of p300/
CBP, several lines of evidence suggest that these
KATs can also participate in promoting cancer.
Although inactivating mutations in p300/CBP
are found in certain cancers (Kalkhoven 2004;
Pasqualucci et al. 2011), some cancer-linked
point mutations are in fact gain-of-function
alterations in p300/CBP that could contribute
to cancer development (Ringel and Wolberger
2013). In addition to the acetyltransferase do-
mains, important structural features of p300/
CBP include three cysteine/histidine-rich zinc-
binding domains (CH1-3), a bromodomain,
and a recently identified RING (Really Interest-
ing New Gene) domain within the larger CH2
region. The RING domain contacts the active
site of the KAT domain blocking substrate bind-
ing and decreasing acetyltransferase activity in
vitro. Disruption of the RINGdomain enhances
p300 KATactivity (Delvecchio et al. 2013). Mu-
tations in the p300 RING domain are found in
malignancies including melanoma, endometri-
al and colorectal carcinoma (Forbes et al. 2015),
as well as in RTS, and may boost p300 KAT
activity in these settings (Delvecchio et al.
2013). How increased KAT activity of p300 or
CBP promotes malignancy is not clear. In addi-
tion to acetylation of H3K18 andH3K27, p300/
CBP also mediate the acetylation of histone H3
lysine 56, a modification associated with nucle-
osome assembly in yeast and DNA replication
and repair in mammals (Li et al. 2008; Yuan
et al. 2009; Vempati et al. 2010). Increased cel-
lular levels of histoneH3K56ac are observed in a
numberof epithelial tumors and relate to tumor
stage and an undifferentiated phenotype (Das
et al. 2009). Enhanced KAT activity of p300 or
CBP may lead to increased acetylation of
H3K56 in certain cancers.
Another mode of p300/CBP acetyltrans-
ferase gain-of-function involves translocation
events in hematological malignancies such as
myelodysplastic syndrome and acute myeloid
leukemia. These translocations occur between
p300 or CBP and monocytic leukemia zing-fin-
ger (MOZ), MOZ-related factor (MORF), or
myeloid/lymphoid or mixed-lineage leukemia
(MLL) (Kitabayashi et al. 2001; Panagopoulos
et al. 2001). The translocation eventsmore com-
monly generate a fusion protein containing the
carboxy-terminal region of CBP with or with-
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Y1467 for p300 and Y1450 and Y1503 for CBP)
that are known to reduce or abolish the KAT
activity when mutated are among the most fre-
quent mutations in cancer (Delvecchio et al.
2013; Forbes et al. 2015). It is unclear, however,
whether and how the other frequently mutated
residues in this domain are important for the
KAT activity. The top four and five most fre-
quent missense mutations in p300 and CBP,
respectively, are highlighted in Fig. 3B. These
mutations in p300 including those thought to
reduce KATactivity are clustered near the site of
acetyl-CoA binding (Fig. 3B) (Liu et al. 2008;
Maksimoska et al. 2014). The location of the
other uncharacterized mutations near this site
suggests these may also have an effect on the
KAT activity.
Tables 1 and 2 list the cancers with p300 and
CBP mutation frequencies, respectively, of 5%
or higher as reported in the COSMIC (Cata-
logue of Somatic Mutations in Cancer) database
(Forbes et al. 2015). Both p300 and CBP are
frequently mutated in skin squamous cell carci-
noma followed by certain types of lymphomas.
Alterations of p300/CBP may therefore be key
contributory milestones to the development or
progression of these cancers. Alternatively, these
specific cellular contexts may provide a more
permissive background for accumulation of ge-
netic lesions in p300/CBP with no selective
pressure to avoid them. Tables 3 and 4 include
lists of cancers with 1% frequency of p300 or
CBP mutations, respectively. Of interest in these
71%
CBP
17%
9%
3%
p300
72%
Missense Nonsense Deletions Insertions
13%
9%
6%
Figure 2. Frequency of the different types of mutations in p300 and CBP in cancer. The majority of genetic
lesions to p300 or CBP in cancer aremissense mutations followed by nonsense mutations, deletions, and a small
number of insertions.
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out its KAT domain. The MOZ/MORF-CBP as
well as MOZ-p300 fusion proteins maintain the
KAT domains from both parent proteins poten-
tially resulting in highly active lysine acetyl-
transferases (Yang and Ullah 2007). In essential-
ly all translocation events, the amino-terminal
region of CBP is excluded from the fusion pro-
tein. The novel functions that are gained by the
fusion protein can contribute to the oncogenic
nature of these translocations. Mutations in the
KAT-inhibitory RING domain of p300 are also
detected in myelodysplastic syndrome (Forbes
et al. 2015). This further suggests a key role for
increased p300/CBP KAT activity in the patho-
genesis of these hematological malignancies.
Mutations in p300/CBP Are Nonrandom
The widespread application of next generation
sequencing has revealed an abundance of so-
matic genetic mutations with frequencies of
up to 30% in p300 and CBP in various types
of cancer. Although earlier studies of p300/CBP
had uncovered gross or partial gene deletions,
only a relatively small fraction of all p300/CBP
genetic lesions in cancer are of this nature. The
majority of alterations are, in fact, missense
point mutations (Fig. 2) that occur essentially
throughout the p300 and CBP proteins with a
higher frequency in the KAT domains, suggest-
ing a selective pressure in cancers for alteration
of this activity (Fig. 3A). Certain residues in the
KAT domain of p300 and CBP (e.g., D1399 and
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groups are prostate and pancreas carcinomas,
which may be under selective pressure to pre-
serve the normal functions of p300/CBP for
growth or may alter the functions of p300 or
CBP through nongenetic means.
Beyond Genetic Alterations
In the absence of genetic defects, mechanisms
such as changes in expression or subcellular lo-
calization can alter p300/CBP-associated func-
tions in cancer. Analysis of The Cancer Genome
Atlas (TCGA) data indicates differences in ex-
pression levels of p300 and CBP in multiple
types of carcinomas and hematological malig-
nancies. The effects of these changes in mediat-
ing the neoplastic phenotype cannot be de-
scribed under one umbrella as both higher
and lower levels of p300/CBP are found. These
expression differences in some cases are accom-
panied by changes in gene copy number as a
result of gross gene amplifications or deletions.
Several studies of primary tumors of varying
origins have also revealed changes in p300/
CBP protein levels, which in either direction
are prognostic in many cases. A study of 95
prostate cancer lesions revealed that increased
p300 protein levels, as compared with adjacent
normal tissue, correlate with increased prolifer-
ation, tumor volume, and extraprostatic in-
volvement (Debes et al. 2003). A function of
p300 in the progression of prostate cancer has
also been proposed as it mediates androgen-de-
pendent as well as independent transactivation
of the androgen receptor (Debes et al. 2002).
Additionally, increased p300 expression corre-
lates with poor survival and aggressive pheno-
types in breast, hepatocellular, esophageal, and
cutaneous squamous cell carcinoma (Li et al.
2011a,b; Xiao et al. 2011; Chen et al. 2014).
Consistently, pharmacological inhibition of
p300/CBP KATactivities in a panel of primary
melanoma cell lines sensitizes cells to DNA-
damaging chemotherapeutic agents (Yan et al.
2013). Higher nuclear CBP protein levels have
also been detected in precancerous hyperplastic
and dysplastic laryngeal lesions, suggesting
overexpression of p300/CBP may contribute
to different steps of cancer development and
growth (Karamouzis et al. 2002). Conversely,
reduced levels of p300/CBP have been detected
in certain cancers. Pasqualucci et al. (2011) de-
tected loss of p300 and/or CBP expression in
8% of diffuse large B-cell lymphoma with no
genetic lesion in these genes. The significance
of these changes has been underscored by the
prognostic value of this information. A study of
Table 1. Cancer subtypes with higher frequency of
p300 mutations
Cancer subtype N
Samples
mutated (%)
Skin squamous cell
carcinoma
82 26.8
Marginal zone B-cell
lymphoma
15 13.3
Bladder carcinoma 425 9.4
Follicular lymphoma 68 8.8
Lung small-cell carcinoma 48 8.3
Endometrial carcinoma 387 7.2
Esophageal squamous cell
carcinoma
511 5.9
Cervical squamous cell
carcinoma
193 5.2
Breast carcinoma (estrogen-
receptor-positive)
80 5.0
Data were obtained from the publicly available COSMIC
database (cancer.sanger.ac.uk).
Table 2. Cancer subtypes with higher frequency of
CBP mutations
Cancer subtype N
Samples
mutated
(%)
Follicular lymphoma 66 33.3
Skin squamous cell carcinoma 77 28.6
Marginal zone B-cell
lymphoma
15 13.3
Diffuse large B-cell
lymphoma
242 12.0
Salivary gland carcinoma 63 9.5
Bladder carcinoma 438 8.9
Endometrial carcinoma 337 8.0
Lung small-cell carcinoma 52 7.7
Breast carcinoma (estrogen-
receptor-positive)
80 7.5
Data were obtained from the publicly available COSMIC
database (cancer.sanger.ac.uk).
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327 melanoma samples found that decreased
nuclear levels of p300 associated with disease
progression and poor overall survival (Rotte
et al. 2013).
Interestingly, an increase in cytoplasmic lev-
els of p300 was observed in melanoma and cor-
related significantly with tumor size and disease
progression in early stages (Rotte et al. 2013;
Bhandaru et al. 2014). These findings suggest
that a shift in the subcellular localization of
p300 may be involved in the progression of this
cancer and highlight the importance of p300/
CBP cytoplasmic functions. However, few in-
vestigations addressing cytoplasmic functions
of p300/CBP have been conducted. Among
these are studies that provide evidence for a
p53-directed E4 ligase activity associated with
cytoplasmic p300/CBP leading to polyubiq-
uitination and degradation of cytoplasmic
p53 (Grossman et al. 2007; Shi et al. 2009).
The compartmentalized regulation of p53 by
p300/CBP provides an explanation for previ-
ously reported opposing effects of these KATs
on p53, namely, destabilization of the protein
and promoting its nuclear functions. Hence,
the physical separation of p300/CBP’s nuclear
transcriptional function from the cytosolic
E3/E4 ligase activity is an important aspect
of p53 regulation by p300/CBP. Extranuclear
functions of p53 involve triggering apoptosis
through interactions with mitochondrial outer
membrane proteins, which contribute to its tu-
mor-suppressive effects (O’Brate and Gianna-
kakou 2003). Inappropriate accumulation of cy-
tosolic p300/CBP can, therefore, suppress p53-
mediated apoptosis in response to stress signals.
The Effects of p300/CBP on Chromatin
in Cancer
Deregulated chromatin targeting by p300/CBP
can have profound effects in cancer. For in-
stance, alterations of H3K27ac, a major in vivo
target of p300/CBPat enhancer loci, is observed
in numerous cancers indicating disrupted activ-
ities of p300/CBP at specific enhancer elements
(Akhtar-Zaidi et al. 2012). These “variant en-
hancer loci” (VELs) as they were termed, corre-
late with aberrant expression of their putative
target genes. The enhancers with inappropriate-
ly acquired H3K27ac associate frequently with
genes that have known contributions to many
phenotypic hallmarks of cancer (Hnisz et al.
2013). Thus, alterations in the distribution of
H3K27ac (and likely H3K18ac, the other major
target of p300/CBP) and, hence, enhancer
activity in cancer can promote tumorigenesis
through promoting an oncogenic gene expres-
sion program. Possible mechanisms of deregu-
lated chromatin targeting may involve mutant
or inappropriately expressed p300/CBP as well
as changes in transcription factors that recruit
these coactivators to gene regulatory elements.
For example, genetic lesions in the acetyllysine-
binding bromodomain of p300/CBP can lead
Table 3.Cancer subtypeswith low frequencyof p300
mutations
Cancer subtype N
Samples
mutated (%)
Acute lymphoblastic
leukemia
438 0.9
Clear cell renal cell
carcinoma
692 0.9
Hepatocellular carcinoma 628 0.8
Chronic lymphocytic
leukemia
798 0.5
Ovarian carcinoma 693 0.3
Prostate adenocarcinoma 755 0.3
Pancreatic carcinoma 593 0.2
Data were obtained from the publicly available COSMIC
database (cancer.sanger.ac.uk).
Table 4. Cancer subtypes with low frequency of CBP
mutations
Cancer subtype N
Samples
mutated (%)
Pancreatic carcinoma 593 1.0
Breast carcinoma (triple-
negative)
121 0.8
Clear cell renal cell
carcinoma
692 0.6
Chronic lymphocytic
leukemia
798 0.5
Prostate adenocarcinoma 762 0.4
Acute myeloid leukemia 785 0.4
Data were obtained from the publicly available COSMIC
database (cancer.sanger.ac.uk).
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HISTONE ACETYLATION BALANCE AND ITS
IMPLICATIONS FOR CANCER
In addition to targeted recruitment and acety-
lation of specific genomic loci, histone acetyl-
transferases function globally throughout the
genome in a seemingly nontargeted manner
by mechanisms that are not yet clear (Vogelauer
et al. 2000). When coupled to the global actions
of lysine deacetylases (KDACs), the opposing
but continual functions of KATs and KDACs
result in fast turnover of histone acetylation
(Waterborg 2001), which consumes acetyl co-
enzyme A and generates acetate anions. In pri-
mary tumor tissues, cancer cells show marked
differences in the global levels of histone mod-
ifications including acetylation, which are prog-
nostic of clinical outcome inmany types of solid
tumors (Kurdistani 2007). Specifically, lower
global level of H3K18ac is associated with can-
cer-related mortality and/ormorbidity in pros-
tate, kidney, lung, pancreatic, and breast cancers
(Seligson et al. 2005, 2009; Manuyakorn et al.
2010; Mosashvilli et al. 2010; Kurdistani 2011).
Cancer-associated genetic lesions in p300/CBP
resulting in reduced KAT activity can certainly
lead to the global loss of H3K18/27ac. However,
recent work from our laboratory has revealed an
unanticipated function for global histone acet-
ylation in regulating intracellular pH (McBrian
et al. 2013). We found that in multiple cancer or
normal cell lines, the balance of KATand KDAC
activities is shifted toward the latter in response
to acidic cellular environment, resulting in his-
tones that are globally and continuously deace-
tylated. This leads to liberated acetate anions
that are in turn used by the membrane-bound
monocarboxylate transporters to export pro-
tons out of the cell, thus buffering the intracel-
lular pH. Proliferating cells including cancer
cells need to maintain an alkaline intracellular
pH relative to the outside for cell growth and
division (Webb et al. 2011). Because cancer tis-
sues commonly show low pH in vivo, it is pos-
sible that enhanced global histone deacetylation
serves to maintain a viable intracellular pH in
these tumors, providing a growth advantage
(Parks et al. 2011). This chromatin response to
acidity is an active process resulting in the con-
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to alterations in specificity or strength of chro-
matin binding and to redistribution of H3K18/
27ac across the genome. Such a scenario could
also occur through gene amplifications or
translocations, giving rise to aberrant formation
of enhancer loci in some tumors (Hnisz et al.
2013).
Functions of p300/CBP on chromatin can
also be co-opted by viral oncogenes leading
to cellular transformation. Adenovirus small
E1A (e1a), a splice variant of E1A that is re-
sponsible for reprogramming the expression of
thousands of host genes, relies on interactions
with p300/CBP to coerce normal, primary
cell-cycle-arrested fibroblasts into S phase
(Howe et al. 1990). The e1a protein causes
the recruitment of p300/CBP to and increased
H3K18ac (but not H3K27ac) at promoter re-
gions of cell-cycle genes for full transcriptional
activation. In parallel, e1a also actively repress-
es cell-type-specific genes by opposing the
functions of p300/CBP at promoters and en-
hancers of these genes as evident by substantial
deacetylation of H3K18 and H3K27 at these
sites on e1a expression (Ferrari et al. 2010,
2014). Furthermore, e1a represses cellular de-
fense response genes by forming a trimeric
complex between e1a, RB1, and, surprisingly,
p300 itself, which acetylates RB1 to prevent
its normal inactivation by phosphorylation
(Ferrari et al. 2014). The repressive RB1-e1a-
p300 complex binds to the promoter and gene
body regions of defense response genes, and in
some cases fully coating entire gene loci and
preventing their activation by the host cell.
This repression is accompanied by condensa-
tion of the local chromatin environment (Fer-
rari et al. 2014). The overall effect of e1a in the
24 h after entry into a cell is to turn off cell
identity and the antiviral cellular defense
genes, and to turn on genes that are required
for entry into S phase and DNA replication.
The bulk of this oncogenic reprogramming de-
pends on interactions of e1a with p300/CBP
and RB1. These findings provide a blueprint
for understanding how nonviral oncogenesis
may also depend on precise exploitations of
p300/CBP to achieve similar cellular out-
comes.
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tinuous generation of free acetate molecules
through enhanced deacetylation and thus de-
pends on intact or even enhanced histone acet-
ylation. Therefore, the function of KATs in
maintaining global histone acetylation is im-
perative to this pH-regulatory function of chro-
matin. In this regard, loss of KAT function may
in fact reduce fitness in tumors exposed to an
acidic environment.
LINKING CELLULAR ENERGETICS AND THE 
EPIGENOME
p300 and CBP target a significant number of
nonhistone proteins for acetylation, including
cytosolic proteins involved in essential metabol-
ic processes. This can potentially coordinate cy-
toplasmic and chromatin-related functions of
p300/CBP. The involvement of p300 in regulat-
ing metabolism via targeting the M2 isoform of
pyruvate kinase, PKM2, is one such example
(Lv et al. 2013). A majority of cancers express
PKM2, which unlike the constitutively active
PKM1 isoform, shows lower activity and is al-
losterically activated by an upstream glycolytic
intermediate (Christofk et al. 2008; Wong et al.
2015). The slower enzymatic rate of PKM2 is
thought to essentially serve as a road blockage
that causes a logjam in upstream glycolytic re-
actions, forcing glycolysis intermediates into
branching pathways, the products of which,
such as nucleotide precursors, are required for
general cellular biosynthesis. p300 acetylates a
lysine residue (K433) unique to PKM2, which
abolishes allosteric activation and enhances nu-
clear localization of this PK isoform. The switch
between cytoplasmic metabolic function and
nuclear protein kinase activity of PKM2 regu-
lated by p300 occurs in response to mitogens
and oncogenic signals and may be involved in
tumorigenesis (Lv et al. 2013). In the nucleus
PKM2 phosphorylates histone H3 at threonine
11, a modification shown to be required for
cell-cycle progression and tumorigenesis (Yang
et al. 2012). These findings indicate a role of
p300 in mediating the proliferative program in
cancer cells through switching a metabolic en-
zyme to a nuclear kinase to create a chromatin
state conducive for cell replication. The regula-
tion of PKM2 localization and activity is just
one recent indication of the broader influence
of p300/CBP beyond their nuclear functions as
transcriptional coactivators.
FUTURE DIRECTIONS AND THERAPEUTIC
APPLICATIONS
The central roles of p300/CBP in regulating cell
proliferation have spurred efforts to develop
specific inhibitors of the enzymatic activities as
well as protein–protein interactions of p300/
CBP. KAT inhibitors with higher specificity to-
ward p300/CBP showantiproliferative effects in
preclinical studies of cancer (Santer et al. 2011;
Yang et al. 2013). Small molecules that inhibit
p300/CBP interactions with other proteins also
show promising clinical use. ICG-001, which
specifically inhibits CBP binding to b-catenin,
a component of the Wnt signaling pathway, re-
duces tumorigenic phenotypes and enhances
drug sensitivity in both acute lymphoblastic
leukemia (ALL) and nasopharyngeal carcinoma
(Emami et al. 2004; Gang et al. 2014; Chan et al.
2015). This approach is thought to take advan-
tage of differential co-activator usage by b-cat-
enin. b-catenin may mediate the opposing out-
comes ofWnt signaling by using CBPor p300 to
either stimulate proliferation or initiate differ-
entiation, respectively (Ma et al. 2005; Teo and
Kahn 2010). Interestingly, the effect of ICG-001
is independent of CBPmutational status in ALL
(Gang et al. 2014). Most CBPmutations in ALL
are found carboxy terminal to the b-catenin
binding site where ICG-001 binds (Mullighan
et al. 2011). These findings suggest that the pres-
ervation of CBP-b-catenin interaction and not
the mutations in other regions of CBP may un-
derlie progression of ALL.
CONCLUDING REMARKS
Themany functions of p300/CBP can be differ-
entially exploited in cancer depending on the
context, cellular identity, and perhaps environ-
mental cues to confer a growth advantage. The
paradigm of cancer as an evolutionary system
suggests the sequential acquisition of somatic
mutations in a fluctuating microenvironment
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to gain fitness. Considering such a system, the
order and nature of other oncogenic events can
dictate the selection for or against p300/CBP
alterations that are most advantageous for sur-
vival and growth, therefore branding these pro-
teins as tumor suppressors or oncogenes.
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Chapter IV 
Histone Deacetylase Inhibitors Provoke a Tumor Supportive Phenotype in 
Pancreatic Cancer Associated Fibroblasts 
This chapter is a reprint of work published in 2016 in Oncotarget. Briefly, this collaborative 
study investigates the efficacy of HDAC inhibitors (HDACi) in the treatment of pancreatic 
cancer. An effect of HDAC inhibition in induction of a tumor supportive response 
in cancer-associated fibroblasts is described. This can account for the low efficacy of this 
treatment in pancreatic cancer. The potential use of combinatorial therapy for improving HDACi 
treatment is discussed.  
I contributed intellectually and provided technical assistance as well as critical revision of the 
article. 
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ABSTRACT
Although histone deacetylase inhibitors (HDACi) are a promising class of anti-
cancer drugs, thus far, they have been unsuccessful in early phase clinical trials 
for pancreatic ductal adenocarcinoma (PDAC). One potential reason for their poor 
efficacy is the tumor stroma, where cancer-associated fibroblasts (CAFs) are 
a prominent cell type and a source of resistance to cancer therapies. Here, we 
demonstrate that stromal fibroblasts contribute to the poor efficacy of HDACi’s in 
PDAC. HDACi-treated fibroblasts show increased biological aggressiveness and are 
characterized by increased secretion of pro-inflammatory tumor-supportive cytokines 
and chemokines. We find that HDAC2 binds to the enhancer and promoter regions 
of pro-inflammatory genes specifically in CAFs and in silico analysis identified AP-1 
to be the most frequently associated transcription factor bound in these regions. 
Pharmacologic inhibition of pathways upstream of AP-1 suppresses the HDACi-induced 
inflammatory gene expression and tumor-supportive responses in fibroblasts. Our 
findings demonstrate that the combination of HDACi’s with chemical inhibitors of the 
AP-1 signaling pathway attenuate the inflammatory phenotype of fibroblasts and may 
improve the efficacy of HDACi in PDAC and, potentially, in other solid tumors rich in 
stroma.
INTRODUCTION
Pancreatic ductal adenocarcinoma (PDAC) is 
associated with poor overall prognosis and resistance to 
both conventional and emerging therapies. Gemcitabine 
is the most frequently used chemotherapy for PDAC, but 
at best, it increases survival by just a few weeks in both 
early- and advanced-stage patients [1]. Over the last 10 
years, there have only been three new drugs approved 
by the FDA for PDAC, each of which confers only 
modest survival improvement in advanced-stage patients. 
In 2005, erlotinib, an EGFR inhibitor, was approved 
after being shown to increase survival by an average 
of 10 days as compared to gemcitabine alone [2]. In 
2014, a nanoparticle coated with albumin and packaged 
with paclitaxel (nab-paclitaxel) was also approved 
after demonstrating 2 months additional survival over 
gemcitabine [3]. Recently, liposomal irinotecan combined 
with fluorouracil/leucovorin has been approved for 
advanced-stage disease, also adding a modest 2 months 
additional survival compared to fluorouracil alone. As 
PDAC is predicted to become the second leading cause of 
cancer-related deaths in the United States within the next 
10 years, there is an ever-pressing need to identify new 
therapies that are broadly effective against this particularly 
difficult to treat malignancy [4].
Research Paper
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Histone deacetylase inhibitors (HDACi’s) 
are a chemically diverse class of anti-cancer drugs 
that function by inhibiting lysine deacetylases, 
resulting in greater acetylation of histones by histone 
acetyltransferases (HATs) and transcriptional de-
repression of their target genes. In tumor cells (TC), 
HDAC inhibition predominantly induces G1-S cell cycle 
arrest by increasing CDKN1A/p21 expression [5, 6]. 
HDACi’s have shown greatest promise in the treatment 
of hematologic malignancies. FDA approval was granted 
for the pan-HDACi vorinostat (suberanilohydroxamic 
acid/SAHA) in 2006 [7], and class I selective HDACi 
romidepsin in 2009 for refractory cutaneous T-cell 
lymphoma [8] and in 2011 for other peripheral T-cell 
lymphomas [9]. In 2015, panobinostat, another pan-
HDACi, was approved for the treatment of multiple 
myeloma [10]. However, early phase clinical trials of 
HDACi’s, such as vorinostat/SAHA and panobinostat/
LBH-589, combined with standard-of-care cytotoxic 
chemotherapy for solid tumors, including PDAC, did 
not show any therapeutic benefit [11, 12]. Although 
HDACi’s appear to be effective against solid tumor 
cancer cell lines, including PDAC, in culture and in 
vivo, these preclinical results have not been reproduced 
in early phase clinical trials [13].
As compared to most hematologic malignancies, 
many solid organ tumors contain a diversity of cellular 
and non-cellular components in the peritumoral 
microenvironment, collectively referred to as the 
“tumor-associated stroma.” PDAC has the highest 
stromal volume that comprises approximately 80 percent 
of the tumor mass, including a cellular compartment 
comprised predominantly of cancer-associated 
fibroblasts (CAFs). In PDAC, CAFs contribute to 
treatment resistance by synthesizing extracellular matrix 
proteins that impede drug delivery, and also secrete 
cytokines and chemokines, which act on neighboring 
TCs via paracrine signaling. These secreted factors 
derived from PDAC CAFs increase TC proliferation, 
migration, invasion, and colony formation in cell culture 
and in vivo [14–16].
In this study, we hypothesized that PDAC CAFs 
contribute to the poor efficacy of HDACi’s in PDAC and 
therefore evaluated the effects of HDACi’s on PDAC 
CAFs in culture and in vivo. We found that PDAC 
CAFs treated with HDACi’s paradoxically become pro-
tumorigenic. SAHA transiently increased proliferation of 
PDAC TCs when co-cultured with CAFs, a phenotype 
mediated by a pro-inflammatory secretory response 
induced in CAFs by HDACi’s. ChIP-sequencing 
for HDAC2 revealed enrichment upstream of pro-
inflammatory genes that are also commonly regulated by 
the AP-1 transcription factors. Finally, blockade of this 
pro-inflammatory response with JNK inhibitors markedly 
attenuated the tumor-promoting HDACi-induced 
inflammatory response in these CAFs.
RESULTS
HDACi’s decrease PDAC tumor cell viability in 
isolation but not in the presence of CAFs
In a syngeneic, orthotopic KrasLSL.G12D/+; 
p53R172H/+; PdxCretg/+ (KPC) PDAC mouse model, 
systemic treatment with the pan-HDACi SAHA 
suppressed tumor growth as compared to untreated 
controls (Figure 1A, Supplementary Figure 1). Analysis 
of untreated or treated tumor explants on day 37 after 
implantation revealed that they were almost entirely 
comprised of TCs with homogeneous morphology 
(Supplementary Figure 1B) and without the typical 
dense fibrotic stroma typical of human PDAC histology 
(Supplementary Figue 2). Therefore, we hypothesized 
that SAHA was effective in this model because of the 
lack of the typical stroma which comprises up to 80% of 
human PDAC.
We observed that immortalized PDAC cells are 
sensitive to HDACi in culture. MIA PaCa-2 cells were 
highly sensitive to SAHA with an IC50 of 4 μM (Figure 
1B). PANC-1 cells were also sensitive after 96h, albeit 
with a higher IC50 (10 μM) (Figure 1B). In contrast to 
TCs, two patient-derived primary PDAC CAF lines 
were extremely resistant to SAHA across a wide range 
of doses (Figure 1C). The resistance was not unique to 
SAHA as CAFs were also resistant to either the Class I 
selective HDACi entinostat (MS-275) or the pan-HDACi 
panobinostat (LBH-589), both of which decreased MIA 
PaCa-2 viability (Supplementary Figure 3). Interestingly, 
hTERT immortalized PDAC CAFs were found to be 
highly sensitive to SAHA, which is similar to MIA PaCa-
2 cancer cells with an IC50 of 4 μM (Figure 1C). For this 
reason, in subsequent experiments, we utilized only early 
passage non-immortalized patient-derived primary PDAC 
CAFs.
We next asked if the presence of fibroblasts affected 
TC sensitivity to HDACi’s. Using a 3D TC:CAF co-
culture model on Matrigel, GFP-expressing PANC-1 
TCs formed 3D tumor-like spheres only when cultured 
in the presence of CAFs (Figure 1D) where CAFs are 
evenly distributed among TCs (Supplementary Figure 
4). PANC-1 cells cultured in the absence of fibroblasts 
formed only small clusters of cells rather than a larger 
sphere (Supplementary Figure 5). To quantify tumor cell 
proliferation while in TC:CAF co-culture, measurements 
of fluorescence from GFP expressing cancer cells 
was performed. Fluorescence measurements using 
a multimode microplate reader in this heterocellular 
model were validated with the Cell Titer Glo assay as an 
accurate measure of TC numbers (Supplementary Figure 
6). Additionally, GFP-expressing TCs were treated with 
SAHA and the Cell Titer Glo assay was performed and we 
observed the addition of SAHA did not affect the linear 
relationship between GFP fluorescence measurements 
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and cellular viability (Supplementary Figure 7). While 
PANC-1 cells cultured alone on plastic (Figure 1B) or 
Matrigel (Supplementary Figure 8) were sensitive to 
HDACi, both longer exposure and higher doses were 
required to suppress TC proliferation in the 3D TC:CAF 
co-culture model (Figure 1D). Intriguingly, PANC-1 cells 
in the TC:CAF model were more proliferative with SAHA 
treatment at early time points during continuous treatment 
compared to untreated controls (see days 1 and 2 in Figure 
1D). Taken together, these results suggest that the HDACi-
treated PDAC TCs benefit from the presence of tumor 
supportive CAFs.
HDACi-treated CAFs enhance aggressiveness 
of neighboring tumor cells via a paracrine 
mechanism
We next determined how HDACi-treated CAFs 
modulate various TC phenotypes through a series of cell 
culture and in vivo models. First, both MIA PaCa-2 and 
PANC-1 TCs were more proliferative when cultured in 
conditioned media (CM) from CAFs pre-treated with 
HDACi than CM from untreated controls as measured 
by plate fluorescence (Figure 2A–2B). Similarly, PANC-
1 TCs grew faster in the TC:CAF Matrigel model with 
Figure 1: Effect of HDAC inhibition on PDAC tumor cell viability in isolation and in 3D co-culture with CAFs. 
A. KPC-luc cells were implanted in the pancreata of C57BL/6 mice and mice were treated with oral gavage of SAHA 5 times weekly
beginning on Day 7. Luminescence measurements were measured on days 16, 23, and 30 in SAHA treated and control mice. Error bars
represent SEMs. *P < 0.05. B. MTT assay of PANC-1 and MIA PaCa-2 PDAC tumor cell viability at various doses of SAHA for 96h. C.
MTT assay of WR100 and WR105 primary PDAC fibroblasts and immortalized CAFs at various doses of SAHA for 96h. D. Images of
PANC-1-GFP/PDAC fibroblast co-culture under fluorescence and light microscopy (left) (4X; scale: 300 μm) and 5 day time course of
relative fluorescence of PANC-1-GFP/PDAC CAF co-cultures with treatment of SAHA. Fluorescence is normalized to untreated control
cell co-cultures.
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Figure 2: HDACi-treated ibroblasts enhance tumor cell malignant phenotypes. Fluorescence measurements of A. MIA PaCa-2-GFP and 
B. PANC-1-GFP cells cultured with conditioned media (without drug) from CAFs pre-treated with or without SAHA for 7 days. C. Fluorescence
measurements of PANC-1-GFP 3D co-cultured (without drug) for 7 days with CAFs pre-treated +/- SAHA. D. Schematic of in vivo experimental design
(above) and tumor volume (below) of subcutaneous flank MIA PaCa-2 tumors of 8 tumors per group injected thrice weekly with conditioned media from
cultured CAFs +/- SAHA. *P < 0.05, **P < 0.01. E. Light microscopy images (left) (10X; scale: 100 μm, 40X; scale 10 μm) and relative invasion (right) of
MIA PaCa-2 invasion with control or 10 μM SAHA pre-treated PDAC CAFs after 24h in a modified Boyden chamber. *P < 0.05, **P < 0.01, ***P <
0.001.
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CAFs that had been pre-treated with SAHA than untreated 
controls (Figure 2C). Finally, we also examined if HDACi-
treatment of the same patient-derived CAFs could also 
enhance tumor growth in vivo. MIA PaCa-2 cells were 
implanted in bilateral subcutaneous flanks of NOD/SCID/
IL2γ mice and tumors were supplemented thrice weekly 
with CM (without drug) from cultured CAFs pre-treated 
+/- SAHA (Figure 2D). Consistent with the cell culture 
results, tumor growth was accelerated, particularly at 
earlier time points, in mice injected with SAHA-treated 
CAF CM.
In addition to enhancing cell proliferation, 
pretreatment of CAFs with HDACi increased the invasion 
of co-cultured TCs. CAFs were included in this assay, 
as their presence has been shown to be important for the 
process of TC invasion [17]. We observed significantly 
greater invasion of MIA PaCa-2 cells when cultured in the 
presence CAFs that had been pre-treated with SAHA as 
compared to untreated control CAFs (Figure 2E). Taken 
together, these results suggest that HDACi treatment 
causes CAFs to become more supportive of tumor growth 
and aggressiveness in cell culture and in vivo through a 
paracrine mechanism.
SAHA treatment increases expression of 
tumor-supportive, pro-inflammatory 
mediators in CAFs
A key mechanism by which CAFs modify the 
behavior of neighboring TCs is via release of pro-
inflammatory factors into the tumor microenvironment 
[15, 16, 18, 19]. Given our findings with CM from 
HDACi-treated CAFs that indicated a paracrine 
mechanism of action, we explored whether pro-
inflammatory mediators were increased following 
HDACi-treatment of CAFs. We initially compared the 
composition of CM from PDAC CAFs treated with 
SAHA vs. untreated controls using a membrane-based 
antibody cytokine array and found HDACi treatment 
was associated with increased production of pro-
inflammatory mediators CXCL1 and IL-8 (Figure 3A), 
which are known to enhance TC malignant phenotypes 
[20]. These findings were further validated in a panel 
of pro-inflammatory genes by quantitative RT-PCR 
which demonstrated SAHA treatment caused a dose-
dependent increase in the expression of this panel of 
inflammatory genes linked to the tumor-supportive 
Figure 3: HDACi treatment increases secretion of tumor supportive pro-inflammatory mediators in PDAC CAFs. 
A. Secretion of pro-inflammatory cytokines was assessed after 24h in control and 10 μM SAHA treated CAFs by cytokine array (left) with
relative densitometry measurements (right). B. Gene expression of inflammatory mediators was determined by qRT-PCR in PDAC CAFs
treated for 24h with SAHA.
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senescence associated secretory phenotype (SASP) [16, 
21], including IL8, CXCL1, IL1A, SPP1, IL6, CCL2, 
and ICAM1 (Figure 3B). To determine if the enhanced 
expression of pro-inflammatory mediators was unique to 
the pan-HDACi SAHA, we next treated primary PDAC 
CAFs with class I selective HDACi entinostat/MS-275 
or the highly potent pan-HDACi panobinostat/LBH-589 
(Supplementary Figure 9), each of which also increased 
the expression of the same panel of genes.
HDACi effects on gene expression are 
cell-type specific
We next determined the mechanism by which 
HDACi’s increase the expression of pro-inflammatory 
genes in PDAC CAFs. Histone hyperacetylation through 
HDAC inhibition results in a permissive transcriptional 
landscape and the expression of HDAC-regulated genes 
[22]. In PDAC CAFs, we found that increasing doses of 
HDACi resulted in increased global histone acetylation 
(Figure 4A) with the threshold for histone hyperacetylation 
occurring in the range of 5–10 μM SAHA; therefore, 10 
μM HDACi was used for subsequent experiments.
To determine whether HDACs may directly 
suppress the expression of pro-inflammatory genes in 
CAFs, we performed ChIP-Seq for HDAC2 in primary 
PDAC CAFs and the PANC-1 TC line. HDAC2 is known 
to have a role in cell cycle dysregulation in cancer [23, 
24]; it is highly expressed in PDAC and associated with 
resistance to therapy and apoptosis [25, 26]. However, the 
role of HDAC2 in CAFs is not well defined. In CAFs, we 
found that HDAC2 binding is enriched in the regulatory 
regions primarily within 2 Kb of the transcription start site 
of a large group of pro-inflammatory genes, which was not 
present in PANC-1 cells (Figure 4B).
In contrast, using GREAT gene ontology analysis 
[27], HDAC2 binding in PANC-1 TCs occurs in genes 
predominantly involved in growth factor signaling and cell 
cycle regulation (Supplementary Figure 10). Induction of 
cell cycle-related CDKN1A/p21 expression by HDACi’s 
in TCs is believed to be a key mechanism for the resultant 
cell cycle arrest [5, 22, 28].
These distinct HDAC2 binding patterns in CAFs 
and TCs may explain differential effects HDACi’s have 
on these two cell types. We next used the HOMER Motif 
Analysis to identify the enrichment of transcription factor 
motifs in ChIP-Seq data [29], and found that HDAC2 
binds to motifs associated with the AP-1 transcription 
both PANC-1 TCs and in CAFs although AP-1 motifs 
were more frequent in CAFs (Figure 4C). These findings 
were similarly replicated in a search using the Cistrome 
SeqPos Motif Analysis [30], which identified the c-JUN/
AP-1 related binding motifs to be present in the vicinity 
of HDAC2 binding in CAFs (Supplementary Figure 11).
We further broadly queried common transcription 
factors that regulate a panel of pro-inflammatory genes 
upregulated after HDACi treatment in CAFs using the 
ENCODE ChIP-Seq Significance Tool [31]. This tool 
identifies transcription factors that commonly regulate sets 
of genes by searching publically available ChIP-Seq data 
sets from the ENCODE Project. We searched for DNA 
binding factors present within 5,000 base pairs upstream 
and downstream of the transcription start site of the seven 
SASP pro-inflammatory genes consistently increased 
with HDACi treatment in our studies: IL8, CXCL1, 
IL1A, SPP1, IL6, CCL2, and ICAM1 (Figure 4D). This 
tool identified STAT3, c-FOS (a component of AP-1), 
and GATA2 (q<0.05) to be in regulatory regions of these 
genes. As AP-1 is a well known regulator of inflammation 
[32] and our HDAC2 ChIP-Seq studies suggest the
greatest association of HDAC2 to AP-1 transcription factor
binding motifs, we chose to further investigate blockade
of the upstream pathways of AP-1 signaling to inhibit the
CAF-mediated inflammatory response to HDACi’s.
JNK1 inhibition potently suppresses pro-
inflammatory, tumor-supportive changes in 
HDACi-treated CAFs
A key step in forming the active AP-1 transcription 
factor includes the phosphorylation of c-JUN by Janus 
N-terminal Kinases (JNKs) to allow heterodimerization
of the c-Fos/c-JUN complex. JNK has been implicated as
a key regulator of a feed-forward loop of inflammatory
signaling, amplifying the production of pro-inflammatory
cytokines including IL-8 [33]. JNK inhibition has
additionally been shown to effectively inhibit PDAC
growth in culture and in vivo, using transgenic [34] and
human tumor xenograft models [35]. Our previous results
have also shown that inhibition of stress response kinases,
including JNK, attenuates the inflammatory response in
CAFs to DNA damaging chemotherapies [16]. Thus, taken
together with our in silico results with HDAC2 ChIP-Seq,
we focused the remainder of our studies on JNK inhibition
as a potentially effective co-therapy with HDACi.
The JNK family of kinases consists of three different 
isoforms (JNK 1, 2, or 3), which regulate a diverse set 
of pathways with variable activity based on cell-specific 
context [36]. We examined a panel of non-specific 
and isoform-specific JNK inhibitors. We found that 
SP600125 inhibited c-JUN activation (decreased p-c-JUN) 
(Figure 5A) and was markedly effective at suppressing 
inflammatory genes induced by HDACi treatment in 
a dose-dependent manner (Figure 5B). SP600125, the 
potent ATP competitive JNK specific inhibitor, is known 
to decrease expression of inflammatory mediators [37]. 
JNK-IN-8, which inhibits JNK1/2, suppressed c-JUN 
phosphorylation (p-c-JUN, Figure 5A) and silenced 
HDACi-induced inflammatory gene expression in a 
dose-dependent manner (Figure 5C). In contrast, JNK-
IN-9 (a JNK2/3 specific inhibitor) and SR3576 (a JNK3 
specific inhibitor) failed to block c-JUN phosphorylation 
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(Figure 5A) or suppress HDACi-induced gene expression 
changes in PDAC CAFs (Figure 5D-5E), indicating that 
JNK1 inhibitors specifically block c-JUN activation and 
expression of inflammatory mediators in response to 
HDACi in PDAC CAFs.
We next examined the functional impact of dual 
HDAC and JNK inhibition in two heterocellular PDAC 
culture models. First, to determine the effects of JNK 
inhibition specifically in SAHA-treated CAFs on TC 
behavior, CM was generated from CAFs pre-treated with 
Figure 4: HDAC inhibition causes histone hyperacetylation in CAFs. A. Near-infrared western blots of histone extracts of PDAC CAFs treated at 
various doses of SAHA for 24h. Quantitative near-infrared fluorescent western blots were performed using the LI-COR Odyssey Fc imaging system with 
densitometry measurements were performed relative to untreated control cell blots are reported. B. HDAC2 ChIP-Seq was performed in primary PDAC CAFs 
and PANC-1 TCs. Average profile Distribution of HDAC2 binding ± 10 Kb from the transcription start site (TSS) of pro-inflammatory genes (top) and heat 
map of HDAC2 distribution ± 2.5 Kb from the TSS (below) of individual pro-inflammatory genes using significant peaks (P = 104 over three 50 bp 
windows). C. Transcription factor binding motif analysis using HOMER (Hypergeometric Optimization of Motif EnRichment). The top motif identified with 
HDAC2 peaks in CAFs was found to be associated with AP-1 transcription factor as displayed (P = 1.0 x 10-2031). This motif was present in 22% of HDAC2 peak 
sequences in fibroblasts. D. Factors bound to chromatin common among 7 pro-inflammatory genes within 5,000 base pairs of the transcription start site of these 
genes were identified using the ENCODE ChIP-Seq Significance Tool (q < 0.05). STAT3, C-FOS (a component of the AP-1 heterodimer), and GATA2 were 
found to commonly bind in gene regulatory regions in the vicinity of the TSS of all 7 genes.
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Figure 5: Chemical inhibition of JNK suppresses tumor supportive effects of HDACi in CAFs. A. PDAC CAFs were treated with SAHA 
+/- various JNK inhibitors and western blots for P-c-JUN and GAPDH was performed of cell lysates with measurements of relative densitometry reported 
below blot signals. qRT-PCR was performed of PDAC CAFs treated with SAHA and various doses of B. SP600125, C. JNK-IN-8, D. JNK-IN-9, or E. 
SR3576. F. Fluorescence measurements of GFP-expressing MIA PaCa-2 (left) and PANC-1 (right) cells grown in conditioned media (without drug) from i) 
naïve CAFs or ii-iii) CAFs pretreated with 10 μM SAHA+/- 50 μM SP600125. T-tests were performed to compare 10 μM SAHA CM and 10 μM SAHA + 
50 μM SP600125 CM groups (**P < 0.01, ***P < 0.001). G. PANC-1-GFP / CAF 3D co-cultures were treated with SAHA +/- JNK inhibitors: 50 μM 
SP600125 or 10 μM JNK-IN-8 and fluorescence measurements were performed daily (4X; scale: 300 μm).
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SAHA +/- SP600125. Viability of both PANC-1 and MIA 
PaCa-2 cells were decreased when cultured in CM from 
SP600125/SAHA treated CAFs as compared with SAHA 
controls (Figure 5F). Next, to evaluate the phenotype 
of TCs in the presence of CAFs and dual SAHA/JNK 
inhibitor treatment, the 3D TC:CAF co-culture model 
was employed (Figure 5G). Here, addition of SP600125 
suppressed the SAHA-induced spike in CAF co-cultured 
PANC-1 TC proliferation on Days 1 and 2 (Figure 1D and 
5G). Taken together, these data show that JNK inhibition 
can overcome the SAHA-induced tumor-supportive 
inflammatory response from CAFs, thus potentially 
isolating the beneficial effects on TCs and overall efficacy 
of HDACi’s in this notoriously difficult to treat cancer and 
other solid tumors with a CAF laden stromal compartment.
DISCUSSION
HDAC inhibitors effectively kill PDAC TCs in 
culture and pre-clinical in vivo models but have been 
unsuccessful in early phase clinical trials. Here we 
show that the poor clinical efficacy of HDACi’s may 
be mediated partly by their effect on the PDAC stromal 
microenvironment.
As depicted in our proposed model (Figure 6), 
primary human PDAC CAFs treated with HDACi’s 
develop a counter-productive and paradoxical tumor-
supportive response, linked to the release of numerous 
pro-inflammatory SASP cytokines and chemokines. 
In part, regulation of these genes is dependent upon 
acetylation and deacetylation by HATs and HDACs, 
respectively. In CAFs, HDACs bind preferentially to 
enhancer and promoter regions upstream of these pro-
inflammatory genes, in contrast to TCs where they directly 
regulate CDKN1A/p21 expression [24] as suggested 
by our gene ontology findings in PANC-1 TCs which 
identified cell cycle regulation. Inhibition of HDACs may 
yield a permissive landscape for the transcription factors, 
which include AP-1 (c-JUN/c-FOS), to drive transcription 
of the pro-inflammatory SASP genes in CAFs. Inhibition 
of JNK signaling, upstream of AP-1, attenuated the tumor 
supportive inflammatory response to HDACi’s.
Our findings that HDAC inhibition unleashes a 
pro-inflammatory cytokine release rather than cell arrest 
or death in CAFs is consistent with previous reports.
[38]. Pazolli et al. demonstrated that chemical HDAC 
inhibition with trichostatin A induced the expression of 
pro-inflammatory osteopontin, IL-6, and IL-8 in CAFs; 
and an HDAC1 dominant-negative mutation that causes 
hyperactivation of its target genes caused a similar pro-
inflammatory phenotype [39]. Additionally, it has also 
been shown that HDAC inhibition exaggerated the pro-
inflammatory cellular response to toll-like receptor 
mediated ligation [40, 41], which is suggested to occur as 
a result of histone hyperacetylation, allowing deregulated 
transcription of pro-inflammatory genes.
In PDAC and other cancers characterized by a 
prominent desmoplastic stroma, pro-inflammatory stromal 
fibroblasts have been described to enhance TC survival and 
chemoresistance [15, 42, 43]. Our lab recently identified 
that this CAF phenotype can be accentuated by exposure 
to DNA damaging chemotherapies [16]. In the current 
study, we find that HDAC inhibition, which creates a 
permissive transcriptional landscape for pro-inflammatory 
gene expression, causes increased secretion of a variety of 
tumor supportive cytokines and chemokines from PDAC 
CAFs. We demonstrate that HDAC inhibition drives an 
inflammatory response in CAFs that is counterproductive 
and tumor supportive.
By identifying HDAC2 binding patterns in CAFs 
and querying ENCODE project data, we found that the 
transcription factor AP-1 may regulate the changes in gene 
expression enabled by HDACi’s. AP-1, which becomes 
active via phosphorylation of c-JUN by JNKs, is a crucial 
component involved in the expression of tumor-supportive 
cytokines and chemokines. JNKs occur in three isoforms 
(JNK 1, 2, or 3) [36] and have been shown to be activated 
in inflammatory diseases, including experimental models 
of pancreatitis [44, 45] and cancer [46]. We propose that 
specifically JNK1 inhibition may be additive or synergistic 
with HDACi’s in PDAC, as we demonstrated that both 
the non-specific JNK (1, 2, and 3) inhibitor SP600125 
or the JNK1/2 selective inhibitor JNK-IN-8 suppress 
the pro-inflammatory gene expression induced in PDAC 
CAFs by SAHA. We also find that these JNK inhibitors 
reduced the presence of phosphorylated c-JUN, thus 
decreasing the availability of the active AP-1 heterodimer, 
downregulating AP-1-dependent transcription, 
and arresting the production of tumor-supportive 
inflammation. While it has been previously suggested 
that JNK3 is a key isoform in the amplification, but not 
the initiation, of inflammation signaling [33], we found 
that JNK2/3 or specific JNK3 inhibition was ineffective 
in suppressing phosphorylation of c-JUN and did not alter 
HDACi-induced inflammatory gene expression in PDAC 
CAFs. In addition, SP600125 has been previously shown 
to enhance G1 arrest on PDAC TCs [34] which may also 
prove beneficial with HDACi’s that induce p21 expression 
and subsequent cell cycle arrest in TCs.
JNK inhibitors are a particularly attractive therapy 
for PDAC. In addition to our current work which 
illustrates their tumor suppressive effects on CAFs treated 
with HDACi’s, they have also been previously shown to 
also exert anti-tumor effects directly on PDAC tumor cells: 
inhibiting TC proliferation in culture [34] and decreasing 
primary human tumor xenograft growth in vivo [35].
In conclusion, traditional therapies for the treatment 
of PDAC target rapidly proliferating TCs with cytotoxic 
agents. However, this TC centric view of cancer therapy 
can result in unanticipated and paradoxically deleterious 
tumor-supportive effects in the adjacent CAFs [16]. 
Recently, there has been greater recognition of the 
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contribution of the tumor stroma to cancer progression and 
therapy resistance. We now provide further evidence the 
pan-HDACi SAHA dramatically increases the expression 
of tumor-supportive pro-inflammatory mediators in 
stromal fibroblasts. We identify the AP-1 transcription 
factor likely to be present at HDAC2 binding sites and in 
a focused chemical inhibitor screen, identify compounds 
that can suppress this counterproductive pro-inflammatory 
response. Finally, we provide experimental evidence 
that inflammation-suppressing JNK inhibition could 
Figure 6: A schematic of the effects of HDACi’s +/- JNK inhibition in PDAC CAFs. HDAC inhibition results in hyperacetylation of histones and 
allows permissive gene expression of AP-1 target genes. A. HATs and HDACs regulate DNA acetylation. B. HDAC inhibition creates a permissive 
transcriptional landscape for SASP pro-inflammatory gene expression, which is mediated by transcription factor AP-1. C. JNK1 inhibition prevents pro-
inflammatory gene expression despite HDAC inhibition.
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potentially be a rational addition to HDACi treatment 
in PDAC. This work provides important insights into a 
strategy to improve treatment outcomes in stroma-rich 
solid organ malignancies with HDAC inhibitors.
MATERIALS AND METHODS
Cell lines
PANC-1 and MIA PaCa-2 pancreatic cancer 
cells were purchased from the American Type Culture 
Collection (ATCC). Short tandem repeat analysis was 
performed by ATCC. PANC-1 GFP pancreatic cancer cells 
were a gift from Dr. Huan Meng (UCLA, Los Angeles, 
CA) and MIA PaCa-2 GFP pancreatic cancer cells were 
a gift from Dr. David Dawson (UCLA, Los Angeles, 
CA). hTERT immortalized pancreatic cancer associated 
fibroblasts were gifts from the laboratory of Dr. Rosa 
Hwang (MD Anderson, Houston, TX). KPC-luc cells were 
a gift from Dr. Caius Radu (UCLA, Los Angeles, CA). 
KrasLSL.G12D/+; p53R172H/+; PdxCretg/+ (KPC) cells 
were a gift from Dr. Guido Eibl (UCLA, Los Angeles, 
CA). All cell lines were maintained in DMEM/F12 
containing 10% FBS, 1% GlutaMax, and 1% penicillin/
streptomycin and were routinely tested for Mycoplasma.
Human primary pancreatic fibroblast isolation
Fresh pancreatic tissue was obtained from the 
Translational Pathology Core Laboratory from patients 
undergoing pancreatic resection at the Ronald Reagan 
UCLA Medical Center . All samples were obtained 
from consenting patients in accordance with policies 
and practices of the Institutional Review Board and 
the Office of the Human Research Protection Program 
at UCLA. Tumor samples underwent mechanical and 
enzymatic digestion and then digested tissues were 
cultured in DMEM/F12 (Corning) containing 10% fetal 
bovine serum (FBS) (Omega Scientific), 1% GlutaMax, 
and 1% penicillin/streptomycin (both Life Technologies). 
Newly establish primary fibroblast cultures were treated 
with 25 μg/ml Plasmocin (Invivogen) for two weeks 
and then maintained at 2.5 μg/ml. Because these are a 
finite resource, it was not feasible to use the same line 
in all cases. Primary pancreatic fibroblasts were used 
between passage numbers 3 to 6. Primary fibroblasts were 
characterized by wild-type KRAS status and α-smooth 
muscle actin positivity as previously described [47].
Chemical inhibitors
The following chemical inhibitors were dissolved 
in DMSO (Sigma) (unless stated otherwise) as stock 
solutions and then subsequently diluted in culture 
media: Vorinostat/SAHA (Biotang), LBH-589 (Biotang), 
MS-275 (Biotang), SP600125 (LC Lab), JNK-IN-8 
(Selleck Chem), JNK-IN-9 (Selleck Chem), and SR3576 
(ApexBio).
Conditioned media generation
Primary pancreatic fibroblasts were grown to 90% 
confluence. Fibroblasts were treated with HDACi, HDACi 
combined with a chemical inhibitor, or DMSO control 
for 24 hours. Plates were then washed and cells were 
incubated with phenol red free, serum-free DMEM/F12 
containing 1% GlutaMax and 1% penicillin/streptomycin. 
After 24 hours incubation, conditioned media was 
harvested, 0.22 μm filtered, and then stored in aliquots at 
-20°C.
In vitro cell viability
Cells were seeded in 96-well plates with doses 
of HDACiʼs diluted in media in a total volume of 100 
μl per well. At indicated time points, 10 μl of 5 mg/ml 
MTT (Life Technologies) in PBS was added to each well 
and incubated for 4 hours at 37°C and 5% CO2. Cells 
were then lysed with 100 μl 10% SDS (Sigma), 0.01M 
HCl (Sigma) and incubated overnight at 37°C and 5% 
CO2. Absorbance readings were measured at 560 nm 
wavelength using a Modulus II Microplate Multimode 
Reader (Turner BioSystems). Alternatively, cell viability 
was measured using the CellTiter-Glo Luminescent Cell 
Viability Assay (Promega) according to the manufacturer’s 
recommendations. Experiments were performed in 
triplicate wells and repeated at least twice.
In vitro tumor cell-fibroblast 3D co-culture
40 μl of Matrigel (Corning) was plated in black 
walled, flat bottom 96 well plates (Corning) and allowed 
to polymerize for 30 minutes at 37°C and 5% CO2. 5 x 
103 PANC-1 GFP cells and 1 x 104 primary pancreatic 
fibroblasts were seeded together with HDACiʼs with or 
without other chemical inhibitors in 100 μl DMEM/F12 
containing 10% FBS, 1% GlutaMax, and 1% penicillin/
streptomycin and 2% Matrigel. In experiments with 
PANC-1 cells were cultured alone, 5 x 103 PANC-1 GFP 
were used. Fluorescence readings were measured using 
a blue optical kit (Ex 490 nm/Em 510-570 nm) on a 
Modulus II Microplate Multimode Reader. Images were 
taken using a CX41 Inverted Microscope with a DP26 
Digital Camera (Olympus). Experiments were performed 
in triplicate wells and repeated at least twice.
In vitro tumor cell proliferation
PANC-1 GFP and MIA PaCa-2 GFP cells were 
plated in black walled, flat bottom 96 well plates at 
3 x 103 cells per well in fibroblast conditioned media 
containing 1% FBS. Fluorescence readings were 
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measured daily using a blue optical kit (Ex 490 nm/Em 
510-570 nm) on a Modulus II Microplate Multimode
Reader. Experiments were performed in triplicate wells
and repeated at least twice.
In vivo xenograft tumor growth
All mouse experiments were conducted in 
accordance with protocols approved by the Institutional 
Animal Care and Use Committee at the University of 
California, Los Angeles. 5 x 105 PDAC tumor cells 
were resuspended in 1:1 diluted Matrigel in DMEM/
F12 1% GlutaMax and 1% penicillin/streptomycin and 
then injected in 100 μl volumes in the subcutaneous 
flank five 6-8 week old sex-matched NOD/SCID/
IL2γ mice. Alternatively, in our orthotopic KrasLSL.
G12D/+; p53R172H/+; PdxCretg/+ (KPC) PDAC mouse 
model, KPC tumor cells in 40 μl suspensions were 
implanted in the pancreata of 6-8 week old sex-matched 
C57BL/6 mice. For conditioned media supplementation 
experiments, beginning at day 7, tumors were 
supplemented thrice weekly with 50 μl peri-tumoral 
injections of conditioned media. For SAHA treatment 
experiments, mice were treated 5 times weekly with 
40 mg/kg SAHA in PBS by oral gavage. Subcutaneous 
tumors were measured weekly by dial caliper or in vivo 
bioluminescence and mice were sacrificed when tumor 
diameters approached 15 mm.
In vitro tumor cell-fibroblast invasion assay
MIA PaCa-2 and primary pancreatic fibroblasts 
were each seeded at 5 x 104 cells per Matrigel-coated 8 μm 
pore PET membrane 24-well cell culture inserts (Corning) 
in conditioned media supplemented with 0.1% FBS. 10% 
FBS conditioned media was placed in the bottom wells 
and cells were allowed to invade for 24 hours. After 
completion of invasion, cells on the lower surface of 
the membrane were fixed and stained with hematoxylin. 
Images were taken using a CX41 Inverted Microscope 
with a DP26 Digital Camera. Invaded tumor cells were 
quantified in five 20X microscope visual fields based 
on distinct differences in morphology between primary 
pancreatic fibroblasts and MIA PaCa-2 cells. Experiments 
were performed in triplicate wells and repeated at least 
twice.
Chemiluminescent cytokine array
Primary pancreatic fibroblasts were treated for 
24 hours with HDACi or with DMSO alone and media 
was subsequently harvested. Media was assayed using 
the Human Cytokine Array Panel A (R&D Systems), 
according to manufacturer’s instructions. Membranes were 
developed using standard chemiluminescent techniques 
and images were captured using the Odyssey Fc Imaging 
System (LI-COR). Pixel density was calculated using 
Image Studio software (LI-COR).
Gene expression by quantitative real-time PCR
Total RNA was isolated from cells using the 
Quick-RNA MiniPrep kit (Zymo). Reverse transcription 
was performed using the High Capacity cDNA Reverse 
Transcription kit (Life Technologies). Quantitative 
PCR was performed using EvaGreen qPCR Master 
Mix (Lamda Biotech). RNA expression values were 
normalized to 36B4 control gene and then calculated as 
relative expression to control. Primers used are reported 
in Supplmentary Table 1.
ChIP-Seq
Chromatin Immunoprecipitation (ChIP) was 
performed as described previously [48] using αHDAC2 
antibody from Bethyl laboratories (Cat#A300-705/Lot#1). 
Sequencing libraries were constructed from 0.2ng of input 
and immunoprecipitated DNA using the KAPA DNA 
Library Preparation Kit (KapaBiosystems). Sequencing 
on an Illumina HiSeq 2000 sequencer yielded between 
13 and 30 million reads. Analysis of sequence data was 
as previously described [49], except that the genome was 
tiled into 50 bp windows.
Western blots
Western blots were performed using the LI-COR 
Odyssey infrared blot system, according to manufacturer’s 
instructions. Blots were performed on acid-extracted 
histones or whole cell lysates. The following antibodies 
were used: p-c-JUN (Ser63) Lot #6 (Cell Signaling), 
GAPDH Lot #PJ20538 (ThermoFisher), acetyl-
Histone-H3 Lot #2370129 (Millipore), acetyl-Histone-H4 
Lot #2302181 (Millepore), H3K18ac Lot #30508004 
(Active Motif), H3K27ac Lot #GR167613-1 (Abcam). 
LI-COR IRDye 700 and 800 nm channel secondary
antibodies were used. Western blots were imaged using the
Odyssey Fc Imaging System in 700 and 800 nm channels
and densitometry analysis was performed using the LI-
COR Image Studio software.
Statistical analyses
Data are presented as the mean ± standard error of 
the mean unless otherwise stated. Statistical significance 
was calculated via the Student’s t-test. Values of ≤0.05 
were considered statistically significant. Statistical 
analyses were performed using Prism 6 Software 
(GraphPad). Transcription binding significance of 
the ENCODE ChIP-Seq Significance Tool results are 
calculated by a hypergeometric test with a multiple 
hypothesis correction [31].
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Abbreviations
HDAC - histone deacetylase, HDACi – histone 
deacetylase inhibitor, PDAC – pancreatic ductal 
adenocarcinoma, CAF – cancer-associated fibroblast, HAT 
– histone acetyltransferase, SAHA - suberanilohydroxamic
acid, ChIP - chromatin immunoprecipitation, KPC -
KrasLSL.G12D/+; p53R172H/+; PdxCretg/+, TC – tumor
cell, CM – conditioned media, JNK - janus N-terminal
kinase.
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Chapter V 
The Histone H3-H4 Tetramer is a Copper Reductase Enzyme 
This chapter is unpublished and under peer review. It describes a novel function of the 
eukaryotic chromatin. Briefly, this work reveals that the eukaryotic nucleosome functions 
as a major nucleocytoplasmic oxidoreductase catalyzing the reduction of Cu2+ to Cu1+, that 
provides cuprous ions for cellular and mitochondrial biology. The significance of this function 
for understanding eukaryotic evolution and cellular physiology is discussed.  
I co-authored this manuscript and contributed to the conception and design of the 
experiments and the preparation of the initial draft for submission. I conducted growth assays, 
inductively-coupled plasma mass spectrometry and mRNA-sequencing independently as well as in 
collaboration with Oscar Campos and Dr. Maria Vogelauer.
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Summary 
The histone H3-H4 tetramer forms a putative metal-binding region of unknown function at the 
interface of the two apposing H3 proteins. We report that mutating a highly conserved histidine 
residue in the H3-H3’ interface impairs cellular activities such as mitochondrial respiration and 
Sod1 function that depend on availability of reduced copper. The impairment of copper 
homeostasis is not due to altered gene expression or total copper abundance but is consistent 
with decreased levels of cuprous ions, suggesting histones may directly affect copper’s oxidation 
state. Indeed, the intact nucleosome or the H3-H4 tetramer assembled in vitro from recombinant 
histones exhibits robust copper reductase activity, catalyzing Cu2+ to Cu1+. We propose that 
eukaryotic chromatin is an oxidoreductase enzyme, which provides biousable copper for cellular 
and mitochondrial chemistry. As the emergence of eukaryotes coincided with increased oxidation 
and therefore decreased biousability of essential metals, the enzymatic function of histones could 
have facilitated eukaryogenesis.
Keywords 
Histones, Nucleosome, Copper, Mitochondria, Respiration, SOD1, Oxidoreductase, Enzyme, 
Eukaryogenesis
68
Introduction 
Eukaryotic genomes are nearly universally packaged in the form of chromatin, a 
nucleoprotein structure that protects the DNA and facilitates its compaction while also regulating 
DNA-based processes. The core histones H2A, H2B, H3 and H4—the main protein components 
of chromatin—evolved from histone-like proteins in archaea such as the HMf-1 and HMf-2 
proteins of Methanothermus fervidus (Sandman et al., 1990). The H3-H4 tetramer bound to DNA, 
also known as a tetrasome, docks with two H2A-H2B dimers to form the canonical 146 bp 
eukaryotic nucleosome. However, archaeal histones wrap only ~60 bp of DNA to form structures 
similar to the H3-H4 tetrasome (Pereira et al., 1997). Unlike eukaryotic chromatin, archaeal 
histones lack extended N-terminal tails and are typically devoid of post-translational modifications 
(Forbes et al., 2004); and thus could not contribute to gene regulation in the way that eukaryotes 
employ histone modifications. Although the archaeal nucleosomes could provide basic forms of 
regulation by restricting access of proteins to the DNA  (Soares et al., 1998), the rationale for 
evolution of histones in certain archaeal species, with typically small genomes ranging from 1-3 
Mbp, has been unclear. Histones may have evolved in archaea to maintain the integrity of the 
genome in the harsh environments in which they thrive (Li et al., 1998). But not all archaea that 
live in extreme environments contain nucleosome-like structures (Brochier-Armanet et al., 2011). 
Here we reveal a novel function of histones in copper homeostasis that could provide a basis for 
their evolutionary origin.
Eukaryotes derive from the merger of a histone-containing archaeon with a bacterium 
approximately 1.5-2 billion years ago (Koonin, 2015). A histone-based genome packaging system 
is thought to have been fortuitously present in the archaeal ancestor (Sandman and Reeve, 1998). 
In such a scenario, histones could only later have facilitated evolution of eukaryotic complexity in 
part by compacting an expanding genome size (Sandman and Reeve, 1998). It is possible, 
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however, that the presence of histones in our archaeal ancestor was not incidental, rather 
essential for the emergence of early eukaryotes. So far, no viable scenario has been put forth to 
account for a possible contribution of histones to the development of features in early eukaryotes 
including the endosymbiotic evolution of mitochondria.
The emergence of eukaryotes coincided roughly with accumulation of molecular oxygen 
(Anbar, 2008), which resulted in significant alterations in the abundance and oxidation states of 
transition metals. For instance, before the great oxidation event, iron (Fe) and copper (Cu) were 
present in their reduced and therefore biousable forms, with iron being much more prevalent than 
copper (Saito et al., 2003). The earliest eukaryotes appeared when iron and copper were being 
increasingly oxidized and less biousable yet more toxic in presence of oxygen (Saito et al., 2003). 
This presented a formidable challenge for acquisition or intracellular usage of these essential 
metals by organisms that had evolved in a previously reducing environment. Whether early 
eukaryotes relied partly on histones to meet this challenge has not been considered.
Copper is an essential element in eukaryotes and serves as a co-factor for numerous 
enzymes that function in key intra- and extra-cellular processes (Nevitt et al., 2012). Copper is 
required for mitochondrial respiration as a co-factor for cytochrome c oxidase, the last enzyme 
(complex IV) in the mitochondrial electron transport chain (ETC), and for Cu, Zn-superoxide 
dismutase 1 (Sod1), which catalyzes disproportionation of superoxide radicals to prevent 
oxidative damage (Nevitt et al., 2012). Copper is imported through dedicated transporters and 
distributed to its cellular destinations via protein chaperones. In Saccharomyces cerevisiae, CTR1 
(Copper Transport) encodes the main high-affinity copper transporter that mediate nearly all 
copper import in limited copper conditions (Dancis et al., 1994). Protein chaperones such as Ccs1 
(Copper Chaperone for SOD1) and Cox17 (Cytochrome c Oxidase) are then required for delivery 
of copper to Sod1 or cytochrome c oxidase, respectively (Culotta et al., 1997; Glerum et al., 1996). 
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As a co-factor, copper is utilized in its cupric (Cu2+) or cuprous  (Cu1+) forms but only the latter is 
bound by chaperones, indicating  that its oxidation state is important for proper intracellular 
trafficking (Pufahl et al., 1997). The intracellular ratio of oxidized vs. reduced copper and how this 
proportion is established are unknown, although evidence suggests that most, but not all, exists 
as Cu1+ bound to protein and non-protein ligands (Rae et al., 1999; Yang et al., 2005). Copper 
may also serve as a signaling element to regulate specific biochemical pathways such as lipolysis 
(Krishnamoorthy et al., 2016). The utility of copper, however, must be balanced against its toxicity 
caused by displacement of other metals in proteins or its redox activity (Macomber and Imlay, 
2009). Organisms have therefore evolved homeostatic mechanisms for careful provision of 
copper to meet specific demands. Several diseases in humans, including cancer, 
neurodegenerative diseases like Amyotrophic Lateral Sclerosis (ALS), Alzheimer’s, Wilson, 
Menkes and others, involve disruption of copper homeostasis (Bleackley and Macgillivray, 2011; 
Turski and Thiele, 2009).
As early as 1986, it was noted that the eukaryotic nucleosome has a potential metal-
binding structure comprising amino acid residues in the C-terminal regions of the two apposing 
histone H3 proteins. These residues include cysteine 110 (H3C110) and histidine 113 (H3H113) 
(Saavedra, 1986) (Figure 1A). Several hydrogen bonds involving residues in and around the H3-
H3’ interface, including those that constitute the putative metal-binding pocket, form a 4-helix 
bundle that is also required for the assembly of the H3-H4 tetramer (Luger et al., 1997). 
Interestingly, the evolutionary conservation of individual or pairs of amino acids in this region is 
not readily explained by their contributions to the thermodynamic stability of the nucleosome 
alone. This observation suggests that “a novel function” provided by the H3-H3’ interface is driving 
the surprising conservation (Ramachandran et al., 2011). The functional significance of a potential 
metal-binding structure in H3, and whether a metal-binding function could explain the evolutionary 
conservation, have not been investigated.
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Two lines of reasoning prompted us to investigate whether histone H3 may play a role in 
cellular copper homeostasis. First, the coincidence of eukaryotic emergence and geochemical 
alterations of transition metals raised the possibility of histones having a role in enhancing 
intracellular metal homeostasis. Second, a functioning complex IV in the ETC of the bacterial 
ancestor of mitochondria at the time of its merger may have depended on the intracellular 
provision of cuprous ions by the archaeal host—as it occurs today in eukaryotes. Here, we provide 
biochemical, molecular and genetic data that histone H3 is required for efficient use of copper 
inside cells. We show that recombinant Xenopus laevis H3-H4 tetramer, identical at the protein 
level to the human H3.2-H4 tetramer, catalyzes reduction of cupric to cuprous ions. Our data 
suggest that the catalytic site likely forms at the interface of the two histone H3 proteins as 
mutations in this region alter or abolish the in vitro enzymatic activity of the H3-H4 tetramer; and 
cause defects in mitochondrial respiration and Sod1 activity—both of which depend on the 
availability of intracellular cuprous ions—in S. cerevisiae. Alterations in gene expression, 
nucleosome assembly, or total cellular copper quota could not explain these phenotypes. Rather, 
the phenotypes are consistent with decreased levels of Cu+1 and can be recapitulated by 
decreasing intracellular reducing power. Our data reveal that in eukaryotes, DNA wraps around 
an enzyme that catalyzes reduction of copper for utilization by various cellular and mitochondrial 
proteins. This notion has a profound impact in the fields of evolution and the molecular biology of 
the eukaryotic cell and may be relevant to a range of human pathologies in which alterations of 
copper-dependent processes are implicated (Bleackley and Macgillivray, 2011; Turski and Thiele, 
2009)
Results 
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Mutation of histone H3 histidine 113 to asparagine (H3H113N) has little effect on global 
chromatin accessibility or gene expression. Since the H3-H3’ interface contributes to the 
stability of the H3-H4 tetramer, we first determined the impact of mutating H3H113, a highly-
conserved residue that is also found in archaeal histones (Figure 1B), on chromatin accessibility 
and global gene expression. Mutation of this residue to alanine (H3H113A) or glutamine 
(H3H113Q) is lethal in yeast for unknown reasons (Huang et al., 2009). However, we noticed that 
in the COSMIC (Forbes et al., 2015) and ExAC (Lek et al., 2016) databases H3H113 is mutated 
to asparagine (H3H113N) in certain individuals, suggesting that this mutation may be tolerated in 
yeast as well. We used CRISPR/Cas9 to generate a S. cerevisiae strain with H113N mutations in 
both copies of histone H3 genes (HHT1 and HHT2) in their chromosomal loci under their natural 
promoters without any other genetic disruption. This strain, H3H113N, is viable but exhibits a 2-fold 
increase in growth doubling time compared to wildtype (WT) in rich media (Figures 1C and 1D). 
Asf1 (Anti-Silencing Function) is a histone chaperone that binds to the H3-H4 dimer through 
interactions with H3H113 and other residues, and is required for nucleosome assembly and 
disassembly (Adkins et al., 2004; Agez et al., 2007). We also assessed the phenotype of an ASF1 
deletion strain (asf1∆) to exclude potential disruption to Asf1-H3/H4 dimer interactions and 
consequent alteration in chromatin structure as underlying factors for the phenotypes of the 
H3H113N strain. Deletion of ASF1 also increases doubling time (Figures 1C and 1D) but to a lesser 
extent than did the H3H113N mutation. Analysis of global chromatin structure by Micrococcal 
nuclease (MNase) revealed essentially similar digestion patterns for WT, H3H113N and asf1∆ 
strains, with the latter two being slightly less accessible at lower MNase concentrations (Figure 
1E). Global gene expression patterns were also essentially similar between WT and H3H113N 
grown in yeast extract peptone dextrose (YPD) or in synthetic complete (SC) medium with no 
gene having a statistically significant difference at a Benjamini-Hochberg false discovery rate 
(FDR) of <10% (Figure 1F). Thus, the H3H113N mutation has no significant effect on steady state 
genome-wide gene expression or chromatin accessibility.
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The H3H113 residue is required for efficient use of copper for mitochondrial respiration. 
We reasoned that if the putative metal binding pocket at the H3-H3’ interface is disrupted, the cell 
might suffer from aberrant metal ion homeostasis. To assess copper homeostasis, we examined 
the ability of H3H113N to grow on non-fermentable carbon sources and therefore rely on 
mitochondrial respiration for growth. Although H3H113N displays a growth defect compared to WT 
in YPD, it did not display a further defect under respiratory conditions where non-fermentable 
ethanol and glycerol were substituted for dextrose (YPEG) (Figure 2A). In rich media conditions, 
abundant copper uptake might mask an underlying deficiency in copper utilization. We therefore 
deleted CTR1, the main copper importer in yeast, to disrupt copper availability in the context of 
WT and H3H113N histones. The ctr1∆ mutant is unable to grow on YPEG with baseline copper 
abundance (Figure 2A, lower panel). Addition of 20 µM copper rescues the ctr1∆ respiratory 
growth defect but only in the background of WT histone H3 (Figure 2A). Four times more 
exogenous copper is required to rescue the growth defect of ctr1∆ in the presence of H3H113N 
mutant histones (Figure 2A). The rescue of asf1∆ctr1∆ is achieved at similar levels of copper as 
ctr1∆ alone, and therefore does not phenocopy H3H113Nctr1∆ (Figure 2A). Combination of 
H3H113N mutation with deletion of MAC1 (H3H113Nmac1∆), a copper-sensing transcription factor 
required for expression of copper transport genes including CTR1 (Graden and Winge, 1997), 
also increased the amount of exogenous copper required for growth on YPEG compared to 
mac1∆ alone (Figure 2B). Addition of iron, zinc, or manganese did not rescue the growth defects 
of strains with ctr1∆, confirming the specific copper deficiency (Figure S1A). The copper-mediated 
rescue of growth in these mutants is indeed dependent on mitochondrial respiration because 
deletion of Cox17, which functions downstream of Ctr1 for eventual delivery of copper to 
cytochrome c oxidase (Glerum et al., 1996), prevented rescue even if >100-fold more exogenous 
copper is provided compared to ctr1∆ strains (Figure S1B). In liquid YPEG culture, H3H113Nctr1∆ 
also lagged behind ctr1∆ in growth and oxygen (O2) consumption at several medium copper 
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concentrations (Figure 2C). These results indicate that the histone H3H113N mutation decreases 
copper availability for respiratory growth when copper is limiting.
The H3H113Nctr1∆ respiratory deficiency is not due to copper buffering capacity, intracellular 
levels of copper or gene expression differences. Cup1 is a metallothionein that binds and 
stores copper and thereby buffers the cytotoxic effects of high concentrations of copper (Jensen 
et al., 1996). CUP1 is amplified to varying copy numbers in laboratory strains of yeast (Karin et 
al., 1984). To exclude the possibility that an increased Cup1 capacity for sequestering copper 
accounts for the inability of H3H113Nctr1∆ to efficiently utilize copper for mitochondrial respiration, 
we introduced a stop codon (F8stop) in every copy of the CUP1 gene using CRISPR/Cas9. As 
expected, loss of Cup1 sensitizes cells to high concentrations of copper (data not shown) but the 
cup1F8stopH3H113Nctr1∆ strain still required more copper than did cup1F8stopctr1∆ to grow on YPEG 
(Figure S1C).
There were also no differences in intracellular levels of copper or iron between WT and 
H3H113N strains in the same stage of growth in YPD (Figure S1D) or YPEG (Figure 2D) as 
measured by inductively coupled plasma mass spectrometry (ICP-MS). Deletion of CTR1 lowered 
the intracellular levels of copper as expected and to the same extent with or without the H3H113N 
mutation (Figures 2D and S1D). Addition of excess copper to YPEG increased intracellular levels 
of copper to similar levels in both ctr1∆ and H3H113Nctr1∆ strains (Figure 2D), suggesting that the 
H3H113Nctr1∆ growth defect relative to ctr1∆ is not due to an inability to uptake copper through 
alternative routes (Hassett et al., 2000).
Analysis of gene expression by mRNA-seq revealed very similar global gene expression 
profiles in WT and H3H113N strains in YPEG (Figure S1E). The H3H113N strain showed comparable 
changes in gene expression as those observed in WT, including upregulation of genes that 
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function in the ETC and the TCA cycle as well as copper or iron regulons, all of which are required 
for growth on YPEG (Figures 2E and S1F). Thus, the H3H113N mutation does not interfere with 
either sensing of non-fermentable carbon sources or establishing the proper gene expression 
profiles for their metabolism. The inability of H3H113Nctr1∆ to utilize copper for growth in non-
fermentative media is therefore not caused by altered expression of genes important for 
respiratory growth.
Diminishing reducing power phenocopies the respiratory deficiency of H3H113Nctr1∆ 
mutant.  The increased copper requirement of H3H113Nctr1∆ for growth on YPEG despite having 
normal levels of intracellular copper raised the possibility that the levels of cuprous ions, which 
are required for cuproprotein assembly, is lower in H3H113Nctr1∆ compared to ctr1∆. However, 
there are difficulties associated with reliable determination of the oxidation state of intracellular 
copper in yeast. To indirectly address the effects of the copper oxidation state, we reasoned that 
decreasing cellular reducing power might phenocopy the respiratory deficiency of H3H113Nctr1∆ by 
limiting the availability of electrons for reduction of Cu2+. To disrupt the cellular redox state, we 
placed the expression of gamma glutamylcysteine synthetase (GSH1), which catalyzes the first 
step in glutathione (GSH) biosynthesis, under the control of the GAL1 promoter in ctr1∆ to 
generate the ctr1∆p(GAL1)-GSH1 strain. In media without galactose, the expression of GSH1 is 
turned off, leading to decreased glutathione levels, a major source of reducing equivalents in the 
cell. The ctr1∆p(GAL1)-GSH1 strain required more copper to grow on YPEG than ctr1∆ alone (Figure 
2F), reminiscent of the H3H113Nctr1∆ phenotype (Figure 2A). These data are consistent with 
decreased availability of cuprous ions, as opposed to decreased abundance of elemental copper, 
as an explanation for the respiratory deficiency of the H3H113Nctr1∆ or ctr1∆p(GAL1)-GSH1 strains 
compared to ctr1∆ alone.
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The H3H113 residue is required for copper-dependent rescue of the ccs1∆ lysine 
auxotrophy. We next investigated whether the role of H3H113 residue in copper homeostasis is 
unique to mitochondrial function or if it more generally regulates copper utilization. Deletion of 
SOD1 or CCS1, the chaperone that delivers copper to Sod1, results in lysine auxotrophy in yeast 
when grown in the presence of oxygen (Lin and Culotta, 1996) (Figure 3A). We found that while 
the lysine auxotrophy of ccs1∆ is rescued by addition of excess exogenous copper, the 
H3H113Nccs1∆ growth in media lacking lysine is not fully restored even in presence of 500 µM 
copper (Figure 3A). Deletion of ASF1 has no effect on copper-dependent rescue of ccs1∆ (Figure 
3A).  In stark contrast to the H3H113N mutation, reducing intracellular levels of copper by deletion 
of CTR1 does not increase the requirement of ccs1∆ for exogenous copper (Figure 3B). This 
indicates that Ccs1-mediated function(s) are more dependent on an intact H3-H3’ interface than 
on total levels of intracellular copper.
Addition of manganese, zinc or iron did not rescue ccs1∆ growth, confirming the specific 
disruption of copper utilization (Figure S2A). The rescue of ccs1∆ strains by exogenous copper is 
likely through recovering Sod1 function since similar amounts of copper did not rescue the lysine 
auxotrophy of sod1∆ with or without H3H113N mutation (Figure S2B). Similar to growth on agar 
plates, H3H113Nccs1∆ showed little improvement in growth in lysine-deficient liquid media 
supplemented with copper compared to ccs1∆ alone (Figure 3C). The increased copper 
requirement of H3H113Nccs1∆ is not due to increased Cup1 buffering capacity (Figure S2C), or 
decreases in intracellular copper or iron levels (Figures 3D and S2D). There were also no 
significant differences in global gene expression profiles of ccs1∆ versus H3H113Nccs1∆ (Figure 
S2E) including genes involved in lysine biosynthesis, which were induced in lysine deficient 
media, copper homeostasis or antioxidant defense (Figures 3E and S2F). Hypoxic conditions 
restored the growth of ccs1∆ and sod1∆ in media lacking lysine, confirming the oxygen-dependent 
toxicity underlying the lysine auxotrophy. The H3H113N mutation had no effect on the rescue of 
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ccs1∆ and sod1∆ lysine auxotrophy by hypoxic conditions (Figure S2G), indicating that the 
H3H113N defect in lysine synthesis only manifests when copper-dependent Sod1 function is 
required. Altogether, these results indicate that extra copper can rescue ccs1∆ lysine auxotrophy, 
and that introduction of H3H113N mutation decreases the ability of ccs1∆ strain to use copper 
efficiently.
Consistent with these results, we also found that the growth of H3H113Nctr1∆ (note that this 
is the copper transporter deletion) on lysine deficient media is adversely affected relative to ctr1∆ 
(Figures 3F). Addition of the copper chelator bathocuproinedisulfonic acid (BCS) to decrease 
copper uptake exacerbates the growth defect of H3H113Nctr1∆ on lysine-deficient media much 
more so than that of ctr1∆ (Figures 3F and S2H). This indicates that in limiting copper conditions 
the H3H113N mutation makes cells auxotrophic for lysine. Since as little as 2% of functional Sod1 
is required for adequate lysine biosynthesis (Corson et al., 1998), our findings altogether suggest 
H3H113N significantly impairs efficiency of copper utilization.
Recombinant histone H3-H4 tetramer is a copper reductase.  Since the phenotypes of strains 
with the H3H113N mutation were consistent with loss of cuprous ion species, we hypothesized 
that histone H3 may be an enzyme that maintains cuprous ions for the cell by catalyzing reduction 
of Cu2+ to Cu1+. To test this hypothesis, we assembled and purified a histone H3-H4 tetramer from 
recombinant Xenopus laevis histones H3 and H4, which are identical to human H3.2 and H4 
histones respectively, using the standard salt dialysis method (Figure S3A) (Luger et al., 1999). 
We also empirically developed a colorimetric assay to measure production of Cu1+ based on the 
ability of the copper chelator neocuproine (NC) to chelate Cu1+ quantitatively. The NC•Cu1+ 
complex has a yellow color that absorbs light at 448 nm (Figure S3B). We used tris(2-
carboxyethyl)phosphine (TCEP) as a source of electrons (i.e., reducing co-factor) because of its 
low rate of spontaneous copper reduction. Most other commonly used reducing agents directly 
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reduced copper in our assay condition (see Methods). We performed the assay by first mixing the 
tetramer, TCEP and NC in 100 mM NaCl and then adding cupric chloride (CuCl2) in a sodium 
tricine buffer (pH=7.4). Upon addition of copper, we observed a time-dependent increase in 
production of Cu1+ as indicated by increasing yellow coloration of the reaction mixture containing 
the H3-H4 tetramer but not the control buffer (Figure 4A). Figure 4B shows a typical reaction 
profile for a tetramer versus buffer alone. The earliest measurement is 2.2 seconds (s) after 
addition of copper by which time a significant fraction of copper is already reduced (Figure 4B). 
The reaction plateaus at later time points due to near full consumption of TCEP. Because ~75% 
of total Cu1+ produced occurs within the first 30 seconds (Figure 4B inset), we focused on this 
time interval in subsequent experiments. The line and shadings represent the mean and standard 
deviations of at least three assays, respectively. We detected no significant activity in the absence 
of TCEP and increasing activity with increasing amounts of TCEP, indicating that TCEP provides 
the electrons for reduction of copper (Figure 4C). The enzymatic activity is specific to the tetramer 
since unassembled histone H3 and another histone protein such as the S. cerevisiae H2A do not 
show activity (Figure 4D). The tetramer’s enzymatic activity is heat labile as boiling the tetramer 
prior to the assay abolished copper reduction (Figure 4E). We did not detect iron reductase activity 
when using FeCl3 and a ferrous ion chelator, indicating that the reaction is specific to copper under 
these conditions (data not shown).
Within the H3-H4 tetramer, the H3C110 residues may become oxidized to form a disulfide 
bond (Camerini-Otero and Felsenfeld, 1977), in the process causing the reduction of a second 
reaction component. This raises the possibility that any set of cysteine residues capable of 
forming a disulfide bond per se may facilitate reduction of copper in our reaction conditions. To 
address this possibility, we performed the copper reduction assay with RNase A, which contains 
four disulfide bonds (Klink et al., 2000), and detected no significant copper reductase activity 
above background (Figure 4F).
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Finally, we assembled mononucleosomes using recombinant core histones and the 601 
nucleosome positioning DNA fragment using standard salt gradient dialysis (Figure S4) (Peterson, 
2008). The nucleosome was also able to reduce copper using TCEP as the reducing co-factor 
(Figure 4G). Altogether, these data indicate that the Xenopus histone H3-H4 tetramer, in free or 
nucleosome form, is an enzyme with copper reductase activity.
The kinetic properties of H3-H4 tetramer is comparable to eukaryotic enzymes. To establish 
the kinetic properties of the H3-H4 tetramer enzymatic activity, we determined the initial velocity 
of copper reduction at increasing concentrations of substrate (Figure 5A). Plotting the initial 
velocities against substrate concentrations, and curve-fitting with a Henri-Michaelis-Menten 
enzyme kinetics model, yielded a Km value of 28.8±4.0 µM (Figures 5B and C), which is 
approximately 4.5-fold lower than median Km values for typical eukaryotic enzymes (Bar-Even et 
al., 2011). Other kinetic parameters are indicated in Figure 5C. These data indicate that in our 
assay condition the kinetic parameters of the H3-H4 tetramer enzymatic activity are well within 
the range of eukaryotic enzymes (Bar-Even et al., 2011).
Mutations of the residues in the H3-H3’ interface affect enzyme activity. We next examined 
the effects of the histone H3C110A or H3H113N mutation on the in vitro enzyme activity of the 
Xenopus H3-H4 tetramer. The tetramer with histone H3C110A mutation assembled similarly to 
WT tetramer as indicated by their elution profiles from the size exclusion column (Figure 6A). 
However, the H3C110A tetramer had little to no copper reductase activity in our assay condition 
compared to buffer alone (Figure 6B), indicating that either H3C110 is required for or the presence 
of alanine disrupts the in vitro enzymatic activity of the tetramer. The histone H3H113N mutation 
also did not affect the assembly of the tetramer (Figure 6C) but, surprisingly, had little effect on 
the in vitro copper reductase activity when TCEP was used as the reducing co-factor (Figure 6D). 
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Enzyme kinetic analysis indicated that the H3H113N tetramer has a comparable Km value 
(29.4±6.3 µM) to the WT tetramer but a somewhat higher Vmax (Figure S5). In vitro assembled 
mononucleosomes with H3H113N histones also showed comparable copper reduction activity to 
WT mononucleosomes (Figure 6E). These data indicate that the H3H113 residue is not required 
for the enzymatic activity of the Xenopus tetramer in our assay conditions. However, when we 
used dihydrolipoic acid (LA) instead of TCEP as the reducing co-factor, the H113N tetramer 
generated somewhat less Cu1+ than the WT tetramer (p value=0.023 for area under the curve, t-
test) (Figure 6F). Although the H113N mutation does not abolish the enzymatic activity of the 
Xenopus tetramer, it may impair it under certain conditions. Altogether, the data indicate that 
H3C110 and H3H113 are important for the enzyme activity of the tetramer, and since substitutions 
with certain other amino acid residues did not significantly affect tetramer assembly in vitro, their 
roles in copper reduction and tetramer formation can be separated.
Decreasing histone H3 dosage impairs copper homeostasis. The finding that the H3-H4 
tetramer within the nucleosome generates cuprous ions for the cell suggests that decreasing the 
dosage of histones, and therefore nucleosomes, should decrease availability of cuprous ions and 
thus the efficiency of copper usage. To test this, we deleted one of the two copies of the histone 
H3 and H4 genes (hht1-hhf1∆) in WT cells or in the context of ctr1∆. We confirmed that the hht1-
hhf1∆ strain had less H3 and H4 proteins (Figure 7A) and increased susceptibility to chromatin 
digestion by MNase (Figure 7B), consistent with decreased average number of nucleosomes. 
Deletion of HHT1 and HHF1 did not significantly affect growth in YPD (Figure 7C). However, as 
predicted, combination of hht1-hhf1∆ with ctr1∆ required more copper for growth on YPEG (Figure 
7D) and was more sensitive to depletion of copper in lysine deficient medium (Figure 7E) 
compared to ctr1∆ alone. These data indicate that the number of nucleosomes, and therefore the 
number of copper reductase enzymes, affects intracellular copper dependent activities.
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Discussion 
Histones were considered initially to only be structural constituents of the eukaryotic 
genome, serving to package the large amount of DNA into the confines of the nucleus. Pioneering 
experiments in 1980s and 90s revealed that histones also function in regulating gene expression 
and essentially all other processes that contend with DNA through controlling access to certain 
DNA sequences and post-translational modifications (Felsenfeld, 1992; Grunstein, 1997; 
Jenuwein and Allis, 2001). We now show that the histone H3-H4 tetramer within a nucleosome 
also catalyzes reduction of Cu2+ to Cu1+, revealing eukaryotic chromatin as a major 
nucleocytoplasmic oxidoreductase enzyme that provides cuprous ions for cellular and 
mitochondrial biology. Considering the importance of copper to processes as diverse as tissue 
integrity, methylation cycle, iron homeostasis and melanin and neurotransmitter syntheses in 
mammals (Finney et al., 2014; Nevitt et al., 2012; Winston and Jaiser, 2008), the enzymatic 
activity of histones could have wide-ranging effects at molecular, cellular, and tissue levels with 
consequences for organismal physiology and disease.
The enzymatic activity of the H3-H4 tetramer suggests the protein complex has novel 
features that were previously unsuspected but must be fully discerned through future studies. An 
important feature is the location of the enzyme active site, which we favor to be at the interface of 
the two H3 proteins for multiple reasons. First, the H3-H3’ interface appears to be under an 
evolutionary selective pressure beyond what is required for thermodynamic stability of the 
tetramer (Ramachandran et al., 2011). The active site of an enzyme could constitute such a 
selective pressure. Second, the positioning of H3H113 at the end of an α-helix is an arrangement 
that is found commonly in oxidoreductases such as thioredoxin (Hol, 1985). H3H113 may stabilize 
the α2 helix dipole near the H3-H3’ interface, which may enhance transfer of electrons (Galoppini 
and Fox, 1996). Third, the potential requirement of H3C110 for the enzymatic activity of histones 
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that contain it, further supports the location of the active site at the H3-H3’ interface. The C110 
residues from apposing H3s within the tetramer are 6.2Å apart in the crystal structure but in vivo 
can form a disulfide bond, the length of which is 2.05Å (Camerini-Otero and Felsenfeld, 1977). 
Interestingly, the mechanism of electron transfer by other oxidoreductase enzymes such as 
thioredoxin reductase (Holmgren, 1995) or ribonucleotide reductase (Kolberg et al., 2004) 
involves cyclical oxidation and reduction of internal cysteine residues through disulfide bond 
formation. Yet in others, such as Sod1, the redox reactive cysteine residues play a regulatory role 
rather than participating in the electron transfer reaction (Furukawa et al., 2004). Whether 
oxidation/reduction of H3C110 residues is directly involved in electron transfer by the H3-H4 
tetramer remains to be determined. Nonetheless, formation of a disulfide linkage requires 
significant distortion of the conformation of the tetramer, suggesting that the structure of the 
tetramer, especially around the 4-helix bundle within the nucleosome, is dynamic (Luger et al., 
1997). H3C110 is in the center of the bundle and buried within the nucleosome structure but is 
also readily accessible as evidenced by reactivity with small molecular probes (Garcia-Gimenez 
et al., 2013). Thus, the potential flexibility of the 4-helix bundle, redox reactivity of H3C110 and 
accessibility of the H3-H3’ interface residues could be important for enzyme activity and/or its 
regulation. Fourth, the H3-H3’ interface coordinates metals such as zinc, cobalt, nickel (Adamczyk 
et al., 2007) or mercury (Lambert et al., 1999) when incubated with these metals in vitro. Finally, 
the H3-H3’ interface assembles in vivo only when histones are incorporated into a nucleosome. 
Therefore, the commencement of enzymatic activity would be inextricably coupled to the 
protection of DNA as it wraps on the outer surface of the nucleosome. Such a coupling may be a 
beneficial adaptation in species that require reduced intracellular copper as a failsafe mechanism 
to avoid potentially damaging effects of copper.
As a reductase, the H3-H4 tetramer must extract electrons from reducing co-factors, pass 
them through the protein and transfer them to copper ions at the active site. How the tetramer 
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achieves this is unclear but the position at which electrons are extracted from the reducing co-
factor need not be near the active site. In addition, since cellular copper ions are mostly bound by 
proteins (Rae et al., 1999), copper is likely delivered to and taken away from histones through as-
yet-to-be-identified chaperones. Furthermore, we have assessed the activity of one canonical 
histone H3, namely, H3.2. However, H3 has several variants with intriguing sequence differences 
that are functionally characterized based on their modes of incorporation into chromatin, position 
along the chromosome or expression pattern. Whether the histone H3 variants and/or their 
location across the genome (e.g., euchromatin vs. heterochromatin) influence the kinetic 
properties or co-factor requirements of the H3-H4 tetramer enzyme activity remain interesting but 
open questions. Like copper, iron is also used commonly in its ferrous form and is an important 
bioessential element for numerous processes including epigenetic gene regulation (Cartularo and 
Costa, 2014). Although we did not detect any iron reductase activity in our assay condition with 
H3.2-containing tetramers, we cannot rule out the ability of the tetramer with canonical or variant 
histones to catalyze reduction of iron in certain conditions or organisms.
We obtained our in vivo data from analysis of the budding yeast, arguing that the yeast 
nucleosome has copper reductase activity. Despite repeated efforts, we were unable to 
satisfactorily assemble the recombinant yeast H3-H4 tetramer, consistent with the known 
difficulties of using yeast histones for in vitro studies (Leung et al., 2016). Interestingly, S. 
cerevisiae and a number of other fungi possess histone H3 proteins that lack the cysteine residue 
equivalent to H3C110 in other eukaryotes (data not shown). Other than missing H3C110, the C-
terminal region of yeast H3 has additional sequence differences compared to the Xenopus/human 
H3 (Figure 1B, gray highlights). It is conceivable that enzymatic activity of tetramers with histone 
H3 proteins that lack C110 require additional co-factors or proceed through a different reaction 
mechanism. This may also explain why the H3H113N mutation has a minor effect on the Xenopus 
tetramer in vitro activity, but displays robust genetic phenotypes in S. cerevisiae that are 
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consistent with having a significant impact on the yeast tetramer copper reductase activity in vivo. 
We cannot determine whether the yeast H3H113N is a hypomorphic or a null allele vis-à-vis the 
enzymatic activity of the yeast tetramer. But it is possible that a complete loss of enzyme function 
would be lethal in yeast as several residues in the vicinity of H3-H3’ interface are required for 
viability (Dai et al., 2008).
Eukaryotes evolved from an archaeon that had a small genome but possessed ancestral 
histones without extended, positively-charged N-terminal tails or abundant posttranslational 
modifications. This evolutionary timeline questions whether the present-day functions of histones 
were also the reasons histones evolved to bind DNA and form chromatin in the first place; and if 
these functions contributed to the successful emergence of early eukaryotes. The appearance of 
the first eukaryotes coincided with extensive alterations in redox geochemistry with increasing 
levels of oxygen and decreased biousable forms of transition metals such as iron and copper 
(Anbar, 2008). This geochemical change presented a daunting challenge to cells for acquisition 
and intracellular maintenance of bioessential metals, which became rare and toxic in aerobic 
conditions. The oxidoreductase function of the H3-H4 tetramer, the ancient structural form of 
histones, could now provide a reasonable explanation for why the archaeal ancestor of the 
eukaryotes possessed histone tetramers. This enzymatic activity together with an associated 
intracellular transit capability for Cu1+ could have facilitated provision of cuprous ions to the 
nascent mitochondria to maintain a functioning ETC, intimately linking histones to the successful 
evolution of our common eukaryotic ancestor.
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Figure Legends 
Figure 1. Mutation of histone H3 histidine 113 to asparagine has little effect on global 
chromatin accessibility or gene expression in S. cerevisiae. (A) Left: X. laevis nucleosome 
core particle structure (PDB:1KX5) (Davey et al., 2002) viewed down the DNA superhelix axis. 
Histone H3, H4, H2A and H2B are shown in metallic orange, blue, green and red, respectively. 
The square box delineates the H3-H3’ interface. Right: Interface residues H113 and C110, one 
from each of the histone H3 molecules, are highlighted. (B) Alignment of the c-terminal region of 
S. cerevisiae histone H3, human non-centromeric histone H3 variants, and M. fervidus HMf-1 and
HMf-2. (C) Spot test growth assay and (D) average doubling times from steady-state growth in 
liquid SC media. Bar graphs show mean ± standard deviation (SD) from 3-6 replicate cultures. 
(E) Quantitative representation of the signal intensity profiles from chromatin digested with the
indicated amounts of MNase. A.U.: arbitrary units. (F) Scatterplots of average global gene 
expression values from exponentially growing cells in SC and YPD, with Spearman’s rank 
correlation coefficient (rs) as indicated. *P<0.05, **P≤0.01, ***P≤0.001.
Figure 2. H3H113N diminishes copper utilization for respiratory growth. See also Figure S1. 
(A and B) Spot test assays in respiratory media (YPEG) with the indicated amounts of CuSO4. 
Baseline copper concentration in YP media is ~ 1 µM. (C) Growth and oxygen consumption 
assays in liquid YPEG with increasing amounts of CuSO4. Bar and line graphs show mean 
population doublings ± SD and oxygen consumption rates after 24 hrs, respectively, from three 
independent experiments. P value representations are shown in black and red for growth and 
oxygen consumption measurements, respectively. (D) Intracellular copper and iron content of 
cells grown in the indicated media for 3-4 doublings for WT and H3H113N and 12 hrs for ctr1Δ 
strains. Bar graphs represent mean ± SD from 3-6 replicate cultures. #The ctr1∆ strains, which do 
not grow in non-fermentable media, were incubated in YPEG and assessed for metal content for 
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reference. (E) Average mRNA expression levels for three gene sets (Table S3) comparing 
fermentative (YPD) and respiratory (YPEG) growth conditions from two independent experiments. 
(F) Same as (A). *P<0.05, **P≤0.01, ***P≤0.001.
Figure 3. H3H113N is deficient in utilizing copper to rescue ccs1Δ lysine auxotrophy. See also 
Figure S2. (A and B) Spot test assays in the indicated media. Baseline copper concentration in 
SC media is ~ 0.16 µM (C) Growth assay in the indicated liquid media shown as average 
population doublings (± SD) after 24 hrs from three independent experiments. (D) Intracellular 
copper and iron content of cells grown in the indicated media for 3-4 doublings for WT and H3H113N 
and 24 hrs for ccs1Δ strains. Bar graphs represent mean ± SD from 3-6 replicate cultures. #The 
ccs1∆ strains, which grow minimally in SC-lys media, were assessed for metal content for 
reference. (E) Average mRNA expression levels for three gene sets (Table S3) in cells growing 
exponentially in the indicated media after 24 hrs from two independent experiments. (F) Spot test 
assays on SC or SC-lys plates containing 1 mM and 10 µM copper chelator (BCS), respectively. 
*P<0.05, **P≤0.01, ***P≤0.001.
Figure 4. The human H3.2/H4 tetramer is a copper reductase. See also Figures S3 and S4 
(A) Photographic representation of in vitro copper reductase assay at indicated times. Control
buffer or H3.2/H4 tetramer were reacted with 100 µM TCEP and 1 mM CuCl2. Note that reduction 
of copper occurs as soon as it is added to the tetramer reaction mix. (B) Reaction profiles of 1 μM 
H3.2/H4 tetramer or buffer reacted with 1 mM CuCl2 and 20 μM TCEP. Lines and shading 
represent the mean ± SD of 3-5 assays. Inset shows data from the initial 30 seconds of the same 
reaction. (C) Same as in (B) but with the indicated TCEP concentrations. (D) Same as in (B) 
including the reaction profiles of 1 μM monomeric histone H3.2 and S.cerevisiae histone H2A. (E) 
Same as in (B) except that the H3.2/H4 tetramer and control buffer were incubated at 100°C for 
15 minutes. (F) Same as in (B) but with FPLC purified RNase A and its control buffer. (G) Same 
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as in (B) but with 0.4 μM assembled nucleosome (instead of H3.2/H4 tetramer) and its control 
buffer.
Figure 5. Enzymatic parameters of the H3.2/H4 tetramer. (A) Reaction profiles of 1 μM the WT 
tetramer with 20 μM TCEP and the indicated CuCl2 concentrations. Lines and shading represent 
the mean ± SD of 4-5 assays. (B) Henri-Michaelis-Menten curve of initial velocities of reactions 
shown in A. (C) Calculated enzymatic parameters of the tetramer from the curve in (B).
Figure 6. Targeted mutations in the H3-H3’ interface alter the enzyme activity of the 
tetramer but not its assembly. See also Figures S4 and S5. (A and C) FPLC elution profiles of 
the indicated H3.2/H4 tetramers and a protein standard. (B and D) Reaction profiles of 1 μM of 
the indicated H3.2/H4 tetramers or control buffers, combined with 1 mM CuCl2 in the presence of 
20 μM TCEP. Lines and shading represent the mean ± SD of 3-5 assays. (F) Same as in (C) but 
with 0.4 μM assembled H3H113N nucleosome or its control buffer. (G) Same as in (C), but 
showing the reaction profile with 20 μM dihydrolipoic acid. 
Figure 7. Deletion of one copy of histone H3 and H4 genes renders cells defective in 
utilizing copper for respiratory growth. (A) Western blots of histone H3 and H4 and coomassie-
stained 15% SDS-PAGE (showing gel segment for 25-75 kDa) including the relative signal 
intensity for the indicated strains. (B) Quantitative representation of the signal intensity profiles 
from chromatin digested with the indicated amounts of MNase. A.U.: arbitrary units. (C) Average 
doubling times (± SD) from steady-state growth in liquid YPD from three replicate cultures. (D) 
Average population doublings (± SD) for growth in liquid YPEG with increasing amounts of CuSO4 
after 36 hrs from three replicate cultures. (E) Average population doublings (±SD) for growth in 
liquid SC-lys with increasing amounts of BCS after 24 hrs from three replicate cultures. *P<0.05, 
**P≤0.01, ***P≤0.001.
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Supplemental Figure Legends 
Figure S1, related to Figure 2. The H3H113N mutation does not affect CUP1 buffering 
capacity, cellular metal content, or gene expression in fermentative or non-fermentative 
media. (A-C) Spot test assays of the indicated strains in media as specified. Note that the ctr1∆ 
strain is respiratory deficient and cannot be rescued by exogenous manganese, zinc or iron. (D) 
Intracellular copper and iron content measured by ICP-MS for exponentially growing strains in 
YPD. Data are presented as mean ± SD from 3-6 replicate cultures. (E) Scatterplot of average 
global gene expression values from exponentially growing cells in YPEG from two independent 
experiments, with Spearman’s rank correlation coefficient (rs) as indicated. (F) Heat map of 
average mRNA expression levels for copper homeostasis genes (data summarized in Fig 2E) 
from two independent experiments. *P<0.05, **P≤0.01, ***P≤0.001. 
Figure S2, related to Figure 3. The H3H113N mutation does not affect CUP1 buffering 
capacity, cellular metal content, gene expression or oxygen sensitivity in lysine deficient 
media. (A-C) Spot test assays of the indicated strains in media as specified. Note that ccs1∆ and 
sod1∆ renders cells auxotrophic for lysine and cannot be rescued by exogenous manganese, zinc 
or iron. (D) Intracellular copper and iron content measured by ICP-MS for exponentially growing 
strains in YPD. Data are presented as mean ± SD from 3-6 replicate cultures. (E) Scatterplot of 
average global gene expression values from exponentially growing cells in complete (SC) or 
lysine deficient (SC-lys) media from two independent experiments, with Spearman’s rank 
correlation coefficient (rs) as indicated.  (F) Heat map of average mRNA expression levels for 
copper homeostasis genes (data summarized in Fig 3E) from two independent experiments.  (G) 
Spot test assays of the indicated strains in SC or SC-lys grown in normoxic or hypoxic conditions. 
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(H) Average population doublings (±SD) for growth in the indicated media after 36 hrs from three
independent experiments. *P<0.05, **P≤0.01, ***P≤0.001. 
Figure S3, related to Figure 4. Experimental outline of H3.2/H4 tetramer formation and in 
vitro copper reductase assay. (A) The procedure for preparation of histones and assembly of 
tetramer is outlined. (B) Graphical representation of the copper reductase assay. 
Figure S4, related to Figures 4 and 6. Electrophoretic quality control of octamers, 
nucleosomes, and tetramers. (A and B) Coomassie-stained 18% denaturing PAGE of the 
indicated tetramers. The molecular weight is indicated for reference. (C) Same as (A and B) but 
for the indicated octamers. (D) Ethidium bromide-stained 5% native PAGE of the un-assembled 
146-bp DNA fragment (DNA) or assembled nucleosomes containing H3.2 or H3H113N. A 100-bp
DNA ladder (M) is included for molecular weight reference. 
Figure S5, related to Figure 6. Enzymatic parameters of the H113N tetramer. (A) Reaction 
profiles of 1 μM the H113N tetramer with 20 μM TCEP and the indicated CuCl2 concentrations. 
Lines and shading represent the mean ± SD of 4-5 assays. (B) Henri-Michaelis-Menten curve of 
initial velocities of reactions shown in A. (C) Calculated enzymatic parameters of the H113N 
tetramer from the curve in (B). 
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Table S1: Yeast strains used in this study 
Strain 
name 
Mutant short name Description Reference 
BY4741 parental MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 
Brachmann et 
al., 1998 
OCY1131 WT MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0, (hht2Δ:: ura3)Δ::HHT2 This study 
OCY1136 H3H113N 
MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0, (hht2Δ:: ura3)Δ::HHT2-H113N 
HHT1-H113N 
This study 
NAY536 asf1Δ 
MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0, (hht2::ura3)::HHT2, 
asf1Δ::hphMX4 
This study 
OCY1861 ctr1Δ 
MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0, (hht2Δ:: ura3)Δ::HHT2, ctr1Δ:: 
hphMX4 
This study 
OCY1862 H3H113N ctr1Δ 
MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0, (hht2Δ:: ura3)Δ::HHT2-H113N 
HHT1-H113N, ctr1Δ:: hphMX4 
This study 
OCY2141 asf1Δ ctr1Δ 
MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0, (hht2Δ:: ura3)Δ::HHT2, asf1Δ:: 
hphMX4, ctr1Δ::His3MX6 
This study 
OCY2251 mac1Δ 
MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0, (hht2Δ:: ura3)Δ::HHT2, 
mac1Δ::His3MX6 
This study 
OCY2252 H3H113N mac1Δ 
MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0, (hht2Δ:: ura3)Δ::HHT2-H113N 
HHT1-H113N, mac1Δ::His3MX6 
This study 
OCY2381 p(GAL1)-GSH1 
MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0, (hht2Δ:: ura3)Δ::HHT2, kanMX6-
PGAL1-GSH1 
This study 
OCY2391 ctr1Δ p(GAL1)-GSH1 
MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0, (hht2Δ:: ura3)Δ::HHT2, ctr1Δ:: 
hphMX4, kanMX6-PGAL1-GSH1 
This study 
OCY2131 cox17Δ 
MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0, (hht2Δ:: ura3)Δ::HHT2, cox17Δ:: 
kanMX6 
This study 
OCY2132 H3H113Ncox17Δ 
MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0, (hht2Δ:: ura3)Δ::HHT2-H113N 
HHT1-H113N, cox17Δ:: kanMX6 
This study 
OCY1981 cup1F8stop 
MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0, (hht2Δ:: ura3)Δ::HHT2, cup1-
F8stop 
This study 
OCY1983 cup1F8stopH3H113N 
MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0, (hht2Δ:: ura3)Δ::HHT2, cup1-
F8stop, HHT1-H113N HHT2-H113N 
This study 
OCY2181 cup1F8stopctr1Δ 
MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0, (hht2Δ:: ura3)Δ::HHT2, cup1-
F8stop, ctr1Δ::His3MX6 
This study 
OCY2182 cup1F8stopH3H113Nctr1Δ 
MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0, (hht2Δ:: ura3)Δ::HHT2, cup1-
F8stop, HHT1-H113N HHT2-H113N, ctr1Δ::His3MX6 
This study 
NAY553 ccs1Δ 
MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0, (hht2:: ura3)::HHT2, ccs1Δ:: 
kanMX6 
This study 
NAY554 H3H113N ccs1Δ 
MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0, (hht2:: ura3)::HHT2-H113N 
HHT1-H113N, ccs1Δ:: kanMX6 
This study 
NAY597 asf1Δ ccs1Δ 
MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0, (hht2Δ:: ura3)Δ::HHT2, asf1Δ:: 
hphMX4, ccs1Δ::His3MX6 
This study 
NAY551 sod1Δ 
MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0, (hht2:: ura3)::HHT2, sod1Δ:: 
hphMX4 
This study 
NAY552 H3H113N sod1Δ 
MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0, (hht2:: ura3):: HHT2-H113N 
HHT1-H113N, sod1Δ:: hphMX4 
This study 
OCY2211 cup1F8stopccs1Δ 
MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0, (hht2Δ:: ura3)Δ::HHT2, cup1-
F8stop, ccs1Δ:: kanMX6 
This study 
OCY2212 cup1F8stopH3H113Nccs1Δ 
MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0, (hht2Δ:: ura3)Δ::HHT2, cup1-
F8stop, HHT1-H113N HHT2-H113N, ccs1Δ:: kanMX6 
This study 
OCY1135 hht1-hhf1Δ 
MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0, (hht2Δ::URA3)Δ::HHT2, hht1-
hhf1Δ::hphMX4 
This study 
OCY2421 ctr1Δ 
MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0, (hht2Δ::URA3)Δ::HHT2, 
ctr1Δ::His3MX6 
This study 
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NAY564 hht1-hhf1Δctr1Δ 
MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0, (hht2Δ::URA3)Δ::HHT2, hht1-
hhf1Δ::hphMX4, ctr1Δ::His3MX6 
This study 
110
Table S2: Oligonucleotide primers used in this study 
Name Sequence Description 
Δhht2-
CORE-F 
TTCCAACTGTTCTTCCCCTTTTACTAAAGGATCCAAGCAAACACTCCACAGAG
CTCGTTTTCGACACTGG 
Targeted HHT2 
deletion using 
pCORE Δhht2-
CORE-R 
ATGTCCCCCCAGTCTAAATGCATAGAAAAAAAAAAATTCCCGCTTTATATTCC
TTACCATTAAGTTGATC 
pRM-
HHT2-F 
TGTTTTGTGACTTCCACTTTGG 
Targeted HHT2 
reintroduction 
using pRM200 or 
pYX55 
pRM-
HHT2-R 
AAAAGGAGATGTTTGTATGATGTCC 
pCAS-
amp-uni-R 
AAAGTCCCATTCGCCACCCG 
Universal primer 
for pCAS sgRNA 
change 
pCAS- 
HHT1-
H113-
gRNA-F 
AGTGACACGCTTGGCGTGAAGTTTTAGAGCTAGAAATAGC 
HHT1-H113 
target sgRNA 
change on pCAS 
pCAS- 
HHT2-
H113-
gRNA-F 
TTTGTTTGAAGACACTAATCGTTTTAGAGCTAGAAATAGC 
HHT2-H113 
target sgRNA 
change on pCAS 
pCAS- 
CUP1-F8-
gRNA-F 
TTAATTAACTTCCAAAATGAGTTTTAGAGCTAGAAATAGC 
CUP1-F8 target 
sgRNA change 
on pCAS 
HHT1-
H113N-
mutrep-F 
CGAAGCCTACTTAGTCTCTTTATTTGAAGATACCAACTTGGCTGCCATTAATG
CCAAGCG 
Template for 
HDR to introduce 
HHT1-H113N 
HHT1-
H113N-
mutrep-R 
TCTTCTAGCCAACTTGATATCCTTCTTTTGGATAGTGACACGCTTGGCATTAA
TGGCAGC 
HHT2-
H113N-
mutrep-F 
CTTCTGCTATCGGTGCTTTGCAAGAATCCGTCGAAGCATACTTAGTCTCTTTG
TTTGAAGACACTAATCTTGCTGCTATT 
Template for 
HDR to introduce 
HHT2-H113N 
HHT2-
H113N-
mutrep-R 
ACCTCTTAGTCTTCTGGCCAATTTGATATCCTTCTTTTGGATAGTAACACGCT
TAGCGTTAATAGCAGCAAGATTAGTGT 
CUP1-
F8stop-
mutrep-F 
ACAATCAATCAATCAATCATCACATAAAATGTTCAGCGAATTAATTAACTGAC
AAAATGA 
Template for 
HDR to introduce 
CUP1-F8stop 
CUP1-
F8stop-
mutrep-R 
ATTTTTGCAGCTACCACATTGGCATTGGCACTCATGACCTTCATTTTGTCAGT
TAATTAA 
Δasf1-
Hph-U2 
TAACAGCGTACTCTCCCTACCATCCAATTGAAACATAAGATATAGAAAAGCCA
GCTGAAGCTTCGTACGC 
Targeted ASF1 
deletion using 
pAG32 Δasf1-
Hph-D2 
TAAAGTGTACCTCTCTTGCAGGTACCATTAATCTTATAACCCATAAATTCATA
GGCCACTAGTGGATCTG 
Δctr1-
Hph-U2 
ATAGAAAATAAAAAAAAGTGTATTATATTTGACATTCAAACCAGCTGAAGCTT
CGTACGC 
Targeted CTR1 
deletion using 
pAG32 Δctr1-
Hph-D2 
TGGAAGAAGAAGATATAGGTGGACGAACCTTGTCTAGTTAATAGGCCACTAGT
GGATCTG 
Δctr1-His-
F1 
ATAGAAAATAAAAAAAAGTGTATTATATTTGACATTCAAACGGATCCCCGGGT
TAATTAA 
Targeted CTR1 
deletion using 
pFA6a-His3MX6 Δctr1-His-
R1 
TGGAAGAAGAAGATATAGGTGGACGAACCTTGTCTAGTTAGAATTCGAGCTCG
TTTAAAC 
Δmac1-
His-F1 
CTTGTTTTAAACTTGAAACAGTCTGGTAAGTTCTTCAAGCTCTATCAGAGCGG
ATCCCCGGGTTAATTAA 
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Δmac1-
His-R1 
ATTTTCATTCCTGTTGCCTCAATGTGTTTTCTATCTGTATTTACGTGATTGAA
TTCGAGCTCGTTTAAAC 
Targeted MAC1 
deletion using 
pFA6a-His3MX6 
Kan-
PGAL-
GSH1-F4 
CTTGTAGAAGCTGAAAATTGAGCAGATTTAGTATAGGGCTGAATTCGAGCTCG
TTTAAAC 
Targeted p(GAL1)-
GSH1 insertion 
using pFA6a-
kanMX6-PGAL1 Kan-
PGAL-
GSH1-R2 
ACTCAAACCACTGCAAAGGCGTGCCCAAAGCTAAGAGTCCCATTTTGAGATCC
GGGTTTT 
Δcox17-
Kan-F1 
AGTGTACACAATCAGATAACTACACAATCAATTATACCCACGGATCCCCGGGT
TAATTAA 
Targeted COX17 
deletion using 
pFA6a-kanMX6 Δcox17-
Kan-R1 
ATATATACAAGAAATGGTTGTCGGCAGACTGTCAGTAAGAGAATTCGAGCTCG
TTTAAAC 
Δccs1-
Kan-F1 
ATATCTTTGCAAGGCAGAAACCCATTCGATCAGCACAAAACGGATCCCCGGGT
TAATTAA 
Targeted CCS1 
deletion using 
either pFA6a-
kanMX6 or 
pFA6a-His3MX6 
Δccs1-
Kan-R1 
TTATATCTGTATTACGCTACGTTGTGCTATCTTGGATGTTGAATTCGAGCTCG
TTTAAAC 
Δsod1-
Hph-U2 
AACAGGCAAGAAAGCAATCGCGCAAACAAATAAAACATAATTAATTTATACCA
GCTGAAGCTTCGTACGC 
Targeted SOD1 
deletion using 
pAG32 Δsod1-
Hph-D2 
CTTACTACTTACTTACATACGGTTTTTATTCAAGTATATTATCATTAACAATA
GGCCACTAGTGGATCTG 
Δhht1-
hhf1-Hph-
U2 
ATATTTGCTTGTTGTTACCGTTTTCTTAGAATTAGCTAAAAGAATACCCTCCT
TGACAGTCTT 
Targeted HHT1-
HHF1 locus 
deletion using 
pAG32 Δhht1-
hhf1-Hph-
D2 
TTTTGTTCGTTTTTTACTAAAACTGATGACAATCAACAAAATACGACTCACTA
TAGGGAGACCG 
xlH3-
A102G-F 
GAGGCTTATCTGGTCGGACTCTTTGAGGACACCA 
Mutagenesis 
primers to 
generate H3.2 
(A102G) 
xlH3-
A102G-R 
TGGTGTCCTCAAAGAGTCCGACCAGATAAGCCTC 
xlH3-
H113N-F2 
AACCTGTGCGCCATCAACGCCAAGAGGGTCACCA 
Mutagenesis 
primers to 
generate H3.2-
H113N 
xlH3-
H113N-R2 
TGGTGACCCTCTTGGCGTTGATGGCGCACAGGTT 
xlH3-
C110A-F 
GAGGACACCAACCTGGCCGCCATCCACGCCAAG 
Mutagenesis 
primers to 
generate H3.2-
C110A 
xlH3-
C110A-R 
CTTGGCGTGGATGGCGGCCAGGTTGGTGTCCTC 
601_146bp
_F 
CTGGAGAATCCCGGTGC 
Primers to 
amplify “601” 
sequence 601_146bp
_R 
CAGGATGTATATATCTGACACGTGC 
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Table S3: Gene sets for gene expression analysis 
Gene set Genes 
Copper 
homeostasis 
ATX1, CCC2, CCS1, COX11, COX17, COX19, CTR1, CTR2, CTR3, CUP2, FET4, FRE1, 
FRE2, FRE3, FRE4, FRE5, FRE6, FRE7, MAC1, MRS3, PIC2, SCO1, SCO2, SMF1 
Iron 
homeostasis 
AFT1, AFT2, ARN1, ARN2, ATX1, CCC2, CTH1, FET3, FET4, FET5, FIT1, FIT2, FIT3, 
FRE1, FRE2, FRE3, FRE4, FRE5, FRE6, FRE7, FRE8, FTH1, FTR1, HMX1, SIT1, SMF1, 
SMF3, TIS11 
Electron 
transport chain 
and TCA cycle 
ACO1, ACO2, AIF1, CIR2, CIT1, CIT2, CIT3, COR1, COX13, COX4, COX5A, COX5B, 
COX6, COX7, COX8, COX9, CYC1, CYC7, CYT1, DAL7, DLD2, DLD3, FUM1, ICL1, IDH1, 
IDH2, IDP1, IDP2, IDP3, KGD1, KGD2, LSC1, LSC2, MAS1, MDH1, MDH2, MDH3, 
MLS1, MTC3, NDI1, QCR10, QCR2, QCR6, QCR7, QCR8, QCR9, RIP1, SDH1, SDH2, 
SDH3, SDH4, SDH5, SHH3, SHH4, TAZ1, YJL045W, YJL045W, YMR31 
Lysine 
biosynthesis 
ACO2, ARO8, HOM2, HOM3, HOM6, KGD2, LYS1, LYS12, LYS14, LYS2, LYS20, LYS21, 
LYS4, LYS5, LYS9 
Antioxidant AHP1, CCP1, CCS1, CTA1, CTT1, CUP1-1, CUP1-2, DOT5, ECM4, GLR1, GPX1, GPX2, 
GRX1, GRX2, GRX6, GRX7, GRX8, GTO1, GTT1, HYR1, MRP1, PRX1, RSM26, SCO1, 
SCO2, SOD1, SOD2, SRX1, TRR1, TRR2, TRX1, TRX2, TRX3, TSA1, TSA2, URE2 
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STAR METHODS 
CONTACT FOR REAGENT AND RESOURCE SHARING 
Please direct request for resources to Siavash Kurdistani (skurdistani@mednet.ucla.edu). 
EXPERIMENTAL MODEL AND SUBJECT DETAILS 
Strains and general growth conditions 
Haploid Saccharomyces cerevisiae strains used in this study are based on the BY4741 
(S288C background, MATa) (Brachmann et al., 1998) strain, and are listed in Table S1. All strains 
were maintained on standard YPD (1% Yeast extract, 2% Peptone, 2% Glucose) plates and were 
grown at 30°C for varying amounts of time in all experiments as described below. Unless 
otherwise noted, all yeast experiments were initiated by growing cells overnight to dense cultures 
in various media conditions. The cells were subsequently diluted in fresh media as described 
below. Bacteria for histone expression were BL21(DE3)pLysS cells and BL21(DE3) (Agilent). 
Transformed bacteria were grown on 2xTY media (1.6% Bacto Tryptone, 1% Yeast Extract, 0.5% 
NaCl) supplemented with 100 μg/mL ampicillin. 
Oligonucleotides, plasmids, and strain generation for yeast experiments 
 All yeast strains were generated by the standard lithium acetate-based yeast 
transformation procedures. DNA fragments used for gene replacement deletions or promoter 
integrations were generated by PCR from plasmid templates listed in the Key Resources table. 
DNA fragments used as homology-directed repair templates for CRISPR-Cas9 mutagenesis were 
generated by primer extension to generate 100 bp-long oligonucleotides. Primers used to 
generate CRISPR repair templates and to amplify selectable markers containing 40 bp-long gene-
flanking homology regions for gene-specific targeting are listed in Table S2.  
The histone H3 His113Asn (H3H113N) mutation was generated in both chromosomal loci 
(HHT1 and HHT2) in a stepwise and marker-less manner. First, using the delitto perfetto approach 
(Storici and Resnick, 2006), H113N was introduced into the HHT2 locus. The entire HHT2 coding 
region was first replaced with a KanMX4-KlURA3 cassette, with selection on Geneticin. 
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Subsequently, the KanMX4-KlURA3 was precisely replaced with either the WT HHT2 as a control 
(essentially restoring the BY4741 strain, but distinguished as OCY1131 here to account for its 
history of temporarily lacking HHT2), or with an HHT2 variant harboring the H113N mutation (340-
CAC-342 becomes 340-AAC-342), with counter-selection on 5-fluroorotic acid. DNA fragments 
used for the reintroduction of WT HHT2 or hht2-H113N were generated by PCR using plasmids 
containing the WT HHT2 (pRM200) (Mann and Grunstein, 1992) or hht2-H113N (pYX55) as 
templates. The pYX55 plasmid was generated by site-directed mutagenesis of the WT HHT2 on 
pRM200 using the Agilent Lightning quick change mutagenesis kit, as directed by the 
manufacturer, and using primers listed in Table S2.  
Second, the H113N mutation was introduced in HHT1 using the CRISPR-Cas9 system 
optimized for S. cerevisiae (Ryan et al., 2014). The pCAS plasmid, containing both the Cas9 gene 
from Streptococcus pyogenes and a single guide RNA, was a gift from Jamie Cate (Ryan et al., 
2014). To target Cas9 to the HHT1 region containing H113, the 20 bp targeting sequence at the 
5’ end of the sgRNA was changed by PCR. First, pCAS was PCR-amplified with Phusion High-
Fidelity DNA Polymerase (NEB) using a 5’-phosphorylated reverse primer immediately upstream 
of the target sequence, and a forward primer containing the 20 nucleotide HHT1 region 
surrounding H113 on its 5’ end. The PCR product was treated with DpnI endonuclease (NEB) and 
re-circularized with T4 DNA ligase (NEB) according to manufacturers’ protocols. The H113N 
mutation (340-CAC-342 becomes 340-AAT-342) was then introduced in yeast by co-
transformation with the HHT1-H113-targeting pCAS plasmid, and a 100-nt double stranded 
homology-directed repair template containing the mutation. Successful mutagenesis at both 
HHT1 and HHT2 was confirmed by sequencing of the entire gene coding locus. 
Subsequent deletions of ASF1, CTR1, MAC1, COX17, CCS1, SOD1, and HHT1-HHF1 
genes, as well as insertion of the GAL1 promoter upstream of GSH1 were generated by standard 
yeast gene replacement and targeted insertion methodology using selectable marker integration 
(Goldstein and McCusker, 1999; Longtine et al., 1998). Successful integrations and deletions 
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were confirmed by PCR. Importantly, combinations of H113N with these gene deletions were 
generated in the strain already containing the H113N mutation in both histone H3 copies 
(OCY1136).  
The only exception is the generation of strains in which Cup1 is disrupted, alone or in 
combination with H113N. Because of the multi-copy CUP1 gene, and the complexity of the locus 
with respect to the flanking RSC30 gene, we disrupted the gene by introduction of a stop codon 
at Phe8 at all CUP1 copies. Introduction of the stop codon was performed using the CRISPR-
Cas9 system as described above for generating hht1-H113N, and correct mutagenesis was 
confirmed by sequencing. Lastly, H113N was introduced in both HHT1 and HHT2 using the same 
CRISPR-Cas9 approach for both loci in the strain already containing the cup1-F8stop mutation. 
Primers used to generate the targeting sgRNAs and the repair templates introducing mutations 
are listed in Table S2. 
Oligonucleotides, plasmids for histone expression and nucleosome assembly 
Plasmids for expression of Xenopus laevis histones are from (Luger et al., 1997). The 
histone H3 plasmid from this reference contains an H3-G102A mutation, which was corrected to 
the WT G102 by site directed mutagenesis (QuikChange, Agilent) using primers xlH3-A102G-F 
and xlH3-A102G-R, resulting in plasmid pH3.2. C110 of histone H3.2 was mutated to alanine 
using primers xlH3-C110A_F and xlH3-C110A-R to produce pH3.2-C110A. H3H113 was mutated 
to asparagine using primers xlH3-H113N-F2 and xlH3-H113N-R2, resulting in pH3.2-H113N. A 
plasmid containing 12 tandem 177 bp repeats of the 601 sequence for nucleosome positioning 
was kindly provided by Craig L. Peterson (Dorigo et al., 2003). Plasmids used are listed in the 
Key Resources table, and primers for mutagenesis are listed in Table S2. 
METHOD DETAILS 
 Steps were taken to reduce trace metal contamination in glassware. We found these 
steps to be critical for reliability and reproducibility of all data involving transition metals, especially 
for the H3-H4 tetramer enzyme activity. Failure to properly remove trace metal contaminants may 
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result in tetramers with no in vitro enzyme activity. In some cases, as described below, Bioultra 
grade reagents were used to ensure lowest possible trace metal contaminants. 
Preparation of solutions and glassware 
Buffers and solutions for the in vitro enzyme assays were treated with 10% hydrochloric 
acid for at least 12 hrs (acid-washed glassware) followed by further acid washing for 1 hr in 10% 
nitric acid. Acid-washed glassware was rinsed thoroughly before solution preparation. Buffers and 
solutions were prepared from BioUltra quality products and also treated with Chelex 100 (Sigma) 
to further reduce contaminating transition metals. Powder components were added without the 
use of metal spatulas to further avoid metal contamination. After components were dissolved, 
solutions were filtered through 0.2 µm membranes and stored in acid-washed glass containers or 
single-use polypropylene containers. Standard RC dialysis tubing for dialysis (Spectrumlabs.com) 
was washed in 1L of 10 mM EDTA (99.99% trace metal basis – Sigma) for 1h at 80oC, transferred 
to fresh 1L of 10 mM EDTA at 80oC and let cool slowly at room temperature for 16 hours. Clean 
membranes were dehydrated for 30 min in 95% EtOH and stored at 4oC in 47% EtOH, 5 mM 
EDTA. Before usage, the tubing strips were rehydrated in H2O for several hours at room 
temperature. 
All liquid media for yeast experiments were prepared in glassware that was treated with 
10% hydrochloric acid for at least 12 hrs (acid-washed glassware). For yeast media, addition of 
all components was done without the use of metal spatulas. Media was filtered through 0.2 µm 
membranes and additional components, BCS and CuSO4, were added from separately filtered 
stock solutions. Fermentative media was either YPD (1% Yeast Extract, 2% Peptone, 2% 
glucose), SC (synthetic complete media with 2% glucose) or SC lacking lysine. Non-fermentative 
media was YPEG (1% Yeast Extract, 2% Peptone, 3% ethanol, 3% glycerol).  
Agar media was prepared similarly using acid-washed glassware. Additional media 
components listed in figures were added after autoclaving and dissolving of agar, and just before 
pouring of plates. Agar media for hypoxic growth were supplemented with ergosterol and Tween-
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80. A stock solution of ergosterol at 2 mg/ml was prepared in a solution of 50% ethanol and 50%
Tween-80 and added to the media after autoclaving to achieve a final concertation of 20 µg/ml 
ergosterol, 0.5% Tween-80 and 0.5% ethanol. 
Liquid culture growth curves 
To determine doubling times shown in Fig 1 and Fig 7, following an overnight growth in 
SC or YPD media, cells were diluted to OD600 = 0.2 in fresh media, and grown at 30°C for up to 
10 hrs. Cell density of the culture was measured every 2 hrs and doubling times were calculated 
from 2-8 hrs of growth, when cells were growing exponentially.  
In growth experiments shown in Fig 2 and Fig 7D, following an overnight growth in YPD 
media, cells were diluted to OD600 = 0.4 in YPEG containing various concentrations of CuSO4, 
and incubated at 30°C. Growth experiments shown in Fig 3 and Fig S2 were done similarly in SC-
lys media containing various concentrations of CuSO4. For growth shown in Fig 7E, following an 
overnight growth in SC-lys containing various concentrations of BCS, cells were diluted to OD600 
= 0.2 in the respective media and incubated at 30°C. At 24 or 36 hrs, culture densities were 
measured and the total numbers of doublings in that period were calculated. 
Spot tests 
Following an overnight growth, cells were diluted to OD600 = 0.3-0.4 in YPD and grown at 
30°C for 4-5 hrs to log phase (OD600 = 1-2). Cells were subsequently pelleted by centrifugation, 
washed and resuspended in water to OD600 = 5. Cells were then 10-fold serially diluted and 5 µL 
of cells were spotted on agar plates containing media and additives as indicated in the figures. 
Cells were incubated at 30°C for up to 7 days and imaged daily using an Epson document 
scanner. Because of differing growth rates in the various media conditions, images shown in the 
figures were captured when sufficient growth had occurred and growth differences could be 
assessed, and this ranged between 2-7 days. The exception is for media conditions that 
prevented growth (e.g. ctr1Δ strains in YPEG), in which images shown were captured at 3 days 
of incubation. Experiments in hypoxic conditions (Fig S2) were done using a 2.5 L sealable jar 
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and anaerobic gas generating sachets (AnaeroGen) designed to rapidly (i.e. within 30 minutes) 
generate an anaerobic environment achieving atmospheric oxygen of <1%. Following growth in 
liquid media as described above, cells were pelleted by centrifugation, washed and resuspended 
in water to OD600 = 10. Cells were then 5-fold serially diluted and 5 µL of cells were spotted on 
agar plates with the media indicated in the figure. Media for normoxic and hypoxic conditions (Fig 
S2G) was supplemented with 20 µg/ml ergosterol and 0.5% Tween-80 to support growth in low-
oxygen conditions. The plates were then placed in the sealed hypoxic jar for 7 days at 30°C before 
capturing images, while normoxic control plates were incubated as usual.  
Images shown are representative examples of at least two replicates performed on 
different days with the same clones. 
Micrococcal nuclease digestion 
Micrococcal nuclease (MNase) digestion assays were performed to assess chromatin 
accessibility as an indicator of nucleosome assembly and abundance. MNase digestion was 
performed similarly to as described previously (Rando, 2010). Following an overnight growth in 
SC media, strains indicated in Fig 1 and Fig 7 were diluted to OD600 = 0.25 in 100 mL of fresh SC. 
Cells were grown at 30°C for ~2 doublings, at which point 37% formaldehyde (Sigma) was added 
to each culture to a final concentration of 2%. Cells were fixed for 30 min at 30°C. Cells were then 
transferred to centrifuge bottles and 2.5 M glycine was added to quench formaldehyde reactivity 
to a final concentration of 125 mM. Cells were pelleted by centrifugation at 3700 rpm, for 10 min, 
at 4°C and subsequently resuspended in water. A volume corresponding to 2x109 cells was 
transferred to new 15 mL conical tubes, pelleted and washed with water, and resuspended to 
OD600 = 12.5 in Zymolyase buffer (1 M Sorbitol, 50 mM Tris pH 7.5) on ice. β-mercaptoethanol 
was added to a concentration of 10 mM. To initiate cell wall digestion, 2 mg of Zymolyase 100-T 
was added and cells were incubated at 30°C for 35 min. Spheroplasts were pelleted by 
centrifuging at 3700 rpm for 10 min at 4°C, and resuspended in 2 mL of MNase digestion buffer 
(1 M sorbitol, 50 mM NaCl, 10 mM Tris pH 7.5, 5 mM MgCl2, 1 mM CaCl2, 500 µM spermidine, 
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0.075% Igepal CA-630, 10 mM BME). Resuspended spheroplasts were then equally distributed 
to 4 tubes, and varying amounts of MNase were added as indicated in the figures. Samples were 
incubated at 37°C for 20 min, at which point MNase was inactivated by the addition of 5X stop 
solution (5% SDS, 50 mM EDTA). Proteins were then digested by addition of 160 ug of proteinase 
K (Sigma), and formaldehyde crosslinks reversed, by incubation at 65°C for ~12 hrs. 
DNA was purified by standard phenol-chloroform extraction methods. One volume of 
phenol:chloroform:isoamyl alcohol (25:24:1) was added to each sample, and the samples were 
centrifuged at 16,000xg for 5 min to separate the aqueous and phenol phases. The upper 
aqueous phase was transferred to a new tube, 3 M sodium acetate pH 5.5 was added to 300 mM 
final concentration, and nucleic acids were precipitated with isopropanol. Nucleic acid pellets were 
then resuspended in 60 µL Qiagen buffer EB (10 mM Tris, pH 8.5). MNase-digested DNA samples 
were treated with 10 ug of RNase A (Roche) for 1 hr at 37°C. Lastly, DNA samples were purified 
using the Wizard SV PCR purification kit (Promega) according to the manufacturer’s protocol, and 
eluted in 30 µL of Qiagen buffer EB. Final DNA concentrations were determined using the Qubit 
DNA broad range assay (ThermoFisher) according to the manufacturer’s protocol. ScreenTape 
images shown and quantified are representative examples of three replicate MNase digestions 
from separately grown cultures of the same cell clones. 
MNase accessibility analysis 
MNase-digested DNA samples were normalized by concentration, and visualized using 
the DNA ScreenTape assay on the TapeStation 2200 instrument (Agilent), according to the 
manufacturer’s protocol. Using TapeStation Analysis software (Agilent) gel images were exported, 
without contrast adjustment, and saved in TIFF format. Pixel intensities along a line perpendicular 
to DNA bands and through the center of each lane were then quantified using FIJI (ImageJ 1.48k). 
SDS-PAGE and Western Blotting 
Whole cell protein extracts were prepared from 500 million cells growing exponentially in YPD 
medium. Cell pellets were resuspended in 2 mL of 0.2 M NaOH and incubated at room 
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temperature for 15 minutes. The samples were then centrifuged at 12,000 rpm for 5 minutes; 
pellets were resuspended in 200 µL of SDS-PAGE loading buffer (50 mM Tris-HCl pH 6.8, 2% 
SDS, 10% glycerol, 1% β-mercaptoethanol) and boiled for 5 minutes. Lysates were cleared by 
centrifugation at 13,000 rpm for 5 minutes to remove debris. For SDS-PAGE and western blots 
shown in Fig 7, 4 µg of lysate was used. Western blots were performed using the LI-COR Odyssey 
system. Primary antibodies to histone H3 and H4 were diluted in the recommended Odyssey 
buffer at 1:5000 and 1:800, respectively, and blots were incubated in diluted antibody at 4°C 
overnight. Signal quantifications were obtained using Image Studio Lite software.  
Sample preparation for inductively-coupled plasma mass spectrometry (ICP-MS) 
Cells from dense overnight cultures in SC or YPD media were diluted to OD600 = 0.2-0.4 
and grown at 30°C for ~3 doublings in SC or YPD, or for 18 and 24 hrs in YPEG and SC-lys, 
respectively. Three replicate cultures were prepared for each sample. Cells (4-12 x 108) were 
collected by centrifugation, and cell pellets were washed twice in 1 mM EDTA to remove cell 
surface-associated metals. This was followed by one wash in Nanopure Diamond filtered water 
to remove residual EDTA. Cell pellets were then stored at -20°C for 1-3 weeks prior to preparation 
for ICP-MS. 
Plastic bottles and cylinders used for preparation of solutions for sample digestion were 
treated with 7-10% ACS grade nitric acid for 5 days at 50°C. Acid-washed materials were rinsed 
thoroughly with Nanopure water before use. Frozen cell pellets were thawed at room temperature 
and packed by centrifugation at 3000xg. Pellets were overlaid slowly (not to disrupt the pellet) 
with 70% Optima Grade nitric acid and digested at 65°C for 12-16 hrs. Prior to mass spectrometry, 
the digested samples were diluted with Nanopure water to a final concentration of 2% nitric acid 
and a final volume of 3-5 mL.  
Inductively-coupled plasma mass spectrometry 
Total Fe and Cu content was measured by inductively coupled plasma mass spectrometry 
on the Agilent 8800 ICP-QQQ in MS/MS mode. The most abundant isotopes of iron and copper 
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(i.e. Fe56 and Cu63) were used to determine the total cellular iron and copper levels. Iron was 
measured both directly, with hydrogen present in the collision/reaction cell, and indirectly, after 
mass-shift to FeO with oxygen present in the cell. While both methods produced similar results, 
the data presented here for iron are from oxygen mass-shift mode. Copper was measured directly 
in oxygen-mode. The metal content was determined in comparison to an environmental 
calibration standard (Agilent 5183-4688), which contains 100x higher concentration of Fe 
compared to Cu, more accurately reflecting biological samples. Every run was calibrated 
individually, 45Sc or 89Y were used as internal standards to compare the calibration with the 
analyzed samples. Average counts of 5 technical replicates were used for each calibration 
standard and each individual biological sample. The deviation in between technical replicates 
never exceeded 5%. Standard deviation in figures reflects the standard deviation between 
biological replicates (n = 3 - 6). Prepared calibration standards ranged from 10 ppt to 500 ppb for 
63Cu and 1 ppb - 50 ppm for 56Fe. All Cu and Fe measurements in our study were within the 
calibrated linear ranges for Cu and Fe and well above the lower limits of detection, which were 
determined from multiple blank samples. We used ICP MassHunter software for ICP-MS data 
analysis. 
RNA extraction 
Following an overnight growth, cells were diluted in the various media conditions indicated 
in the figures. Cells grown in SC were diluted to OD600 = 0.05 and grown for 5 doublings at 30°C, 
at which point they were growing exponentially. Cells grown in YPD and YPEG were diluted to 
OD600 = 0.2 and grown for 3-4 doublings at 30°C, at which point they were growing exponentially. 
Cells in SC-lys media, with or without extra CuSO4, were diluted to OD600 = 0.4 and incubated at 
30°C for 24 hrs, at which point they had reached OD600 = 0.6–1.6. Approximately 1.5x108 cells 
were collected by centrifugation and frozen at -20°C until further processing. RNA was extracted 
using previously published methods (Schmitt et al., 1990) with some modifications. Frozen cell 
pellets, without significant thawing, were resuspended in 440 µL of AE buffer (50 mM Na acetate 
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pH 5.2, 10 mM EDTA, 1% SDS), and RNA was extracted by addition of 440 µL of 5:1 
phenol:chloroform pH 4.5 (ThermoFisher) and incubation at 65°C for 4 min. Samples were then 
rapidly frozen in dry ice-ethanol, and centrifuged at 16,000xg to separate the aqueous and phenol 
phases. The aqueous supernatant (350 µL) was transferred to a new tube, and re-extracted by 
addition of 300 µL of 25:24:1 phenol:chloroform:isoamyl alcohol, and centrifuged as above to 
separate phases. 250 µL was transferred to a new tube, 25 µL of 3 M Na acetate pH 5.2 was 
added, and nucleic acids were ethanol-precipitated. Nucleic acid pellets were then resuspended 
in 100 µL of nuclease-free water and stored at -20°C until further processing. RNA concentration 
was measured by Nanodrop 2000 microvolume spectrophotometer. Typical yield from this 
extraction method was about 30 µg of total RNA. RNA extracted for subsequent RNA-seq analysis 
are from two replicates of cells grown on different days with different media batches. The 
exceptions are cells grown in SC (Fig 1) which are from three replicates, and cells grown in SC-
lys+75 µM CuSO4 (Fig 3 and S2) which is from one experiment. 
Sample preparation for poly-A RNA sequencing 
Prior to preparing RNA-seq libraries for Illumina HiSeq sequencing, contaminating DNA 
was digested, and RNA quality was assessed. Total RNA (10 µg) was treated with Turbo DNase 
according to the manufacturer’s “Routine DNase treatment” procedures, in 50 µL reaction 
volumes. Samples were incubated at 37°C for 30 min. Following DNAse treatment and reagent 
inactivation, total RNA concentration was determined using the Qubit RNA broad range assay 
(ThermoFisher) according to the manufacturer’s protocol. RNA quality was then assessed using 
the RNA ScreenTape assay on the TapeStation 2200 instrument (Agilent), according to the 
manufacturer’s protocol with undiluted RNA samples. Using TapeStation Analysis software 
(Agilent), RNA Integrity Number equivalent (RINe) scores, which reflects the ratio of abundances 
of 28S, 18S, and sub-18S RNAs, were calculated. Only samples with RINe scores greater than 9 
(out of 10) were used for sequencing library preparation. 
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RNA-sequencing libraries were then prepared either manually with the KAPA Stranded 
mRNA-seq library prep kit (KAPA Biosystems), or with automation, using the Illumina TruSeq 
Stranded mRNA Library Kit for NeoPrep (Illumina). Both library preparation procedures first isolate 
polyA+ mRNAs using oligo-dT beads. Isolated polyA+ RNAs are then chemically fragmented, and 
random primers are used in the first cDNA reverse transcription step. For both approaches, 
libraries were prepared according to the manufacturer’s protocols, with the following important 
parameters. For libraries constructed using the KAPA kit, 250 ng of DNase-treated total RNA was 
used as input. Following the mRNA capture step, RNA was fragmented for 8 min at 94°C, which 
was designed to generate average library insert sizes of 100-200 bp. Illumina HiSeq-compatible 
adapters were ligated at reaction concentrations of 25 nM and ligation was performed for 15 min 
at 20°C. Following adapter ligation and post-ligation purification, library fragments were amplified 
with 15 PCR cycles, using the manufacturer’s provided thermal cycling times and temperatures. 
For libraries constructed using Illumina’s Neoprep automated library preparation system, 70 ng of 
DNase-treated total RNA was used as input. To maximize library product, we disabled the default 
library normalization step that occurs at the end of the automated library construction and 
quantification. The number of library amplification cycles was set to 15. 
RNA-seq libraries were assessed for correct fragment size and the presence of adapter 
dimers, using the DNA ScreenTape assay on the TapeStation 2200 instrument (Agilent), 
according to the manufacturer’s protocol. Average library sizes of ~270 bp were observed and 
deemed correct. Using TapeStation Analysis software (Agilent), library DNA concentrations were 
estimated. Libraries were then pooled for multiplexed sequencing at equimolar ratios. Because 
some libraries contained more than 1% adapter dimers, by concentration, the library pools were 
further purified using Agencourt RNAClean XP beads. One volume of beads, thoroughly 
resuspended, was added to the library pool, and allowed to incubate for 15 min at room 
temperature without perturbation. Beads were then magnetically isolated, and washed twice with 
70% ethanol. Beads were air-dried for 5 min, and resuspended, off the magnet, in 30 µL of 
125
resuspension buffer provided in TruSeq library preparation kits (Illumina, RSB, part # 15026770). 
Eluted DNA was transferred to a fresh 1.5 mL microcentrifuge tube. Bead-purified library pool 
DNA concentration was then measured using the Qubit DNA broad range assay (ThermoFisher) 
according to the manufacturer’s protocol, and total DNA concentration was adjusted to 10 nM for 
Illumina sequencing.  
mRNA-sequencing and data processing 
High throughput sequencing was performed on Illumina’s HiSeq 4000 system, with single-
end 50 bp insert reads, and dedicated index reads. Total read count per library ranged from ~1.5-
9 million. De-multiplexed reads, in FASTQ file format, were aligned to the R64-1-1 S288C 
reference genome assembly (sacCer3), downloaded from the UCSC database, using Tophat 
2.0.9 (Kim et al., 2013). The “-g 1” parameter was used to limit the number of alignments for each 
read to one, the top-scoring alignment. In the case of a tie, the read was randomly distributed to 
one of the tied top-scoring alignments. Percentage of reads aligned once was greater than 90% 
in all cases. 
Gene expression analysis 
Gene expression values, in reads per kilobase per million mapped reads (RPKMs), for 
6692 annotated open reading frames were calculated using SAMMate 2.7.4 (Xu et al., 2011). In 
calculating RPKM values, only reads that align to annotated exons were considered. Reads 
aligning to introns or intergenic regions were not counted in normalizing the read counts to the 
total number of mapped reads. Many of the 6692 annotated ORFs have no attributed function, 
localization, mutant phenotypes or interactions and are often labeled as “dubious” or “putative” in 
the Saccharomyces Genome Database (SGD). Furthermore, these putative ORFs typically have 
low expression values. We removed 1648 such ORFs from further analysis, and used the 
remaining 5044 ORFs for comparisons between groups. 
RNA-sequencing gene sets 
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Genes that were analyzed as part of functional groups in Figure 2 and 3 are listed in table 
S3. Each gene set was constructed by downloading and merging gene ontology term gene lists 
from AmiGO 2 in March 2017. For the “copper homeostasis” and “iron homeostasis” gene sets, 
we further modified the lists by adding or removing genes based on literature review. The “copper 
homeostasis” set was generated starting with the following list: GO 0006878 – Cellular copper ion 
homeostasis. The “iron homeostasis” set was generated by starting with the following list: GO 
0055072 – Iron ion homeostasis. The “electron transport and TCA cycle” set was generated by 
merging the following lists: GO 0022904 – Respiratory electron transport chain, and GO 0006099 
– Tricarboxylic acid cycle. The “lysine biosynthesis” set was based on the following list: GO
0006553 – Lysine metabolic process. The “antioxidant” set was based on the following list: GO 
0016209 – Antioxidant activity. 
Oxygen consumption assay 
Oxygen consumption rates were measured in whole cells using the Fiber Optic Oxygen 
Monitor, Model 110 (Instech laboratories Inc., Plymouth Meeting, PA). Cells from dense overnight 
cultures in YPD media were diluted in YPEG to OD600 = 0.4 and grown at 30°C for 24 hrs. Cells 
were then collected by centrifugation, and pellets concentrated in fresh YPEG media to achieve 
OD600 = 1.5 in a final volume of 500 µL. The cell suspension was placed in an airtight chamber 
for oxygen consumption measurement. Oxygen level is sensed by the quenching of fluorescence 
of an indicator dye. The increase in fluorescence represents a decrease in oxygen levels in the 
sealed chamber and is a measure of cellular oxygen consumption. Cells were recorded for 5 
minutes and the rate of oxygen consumption was determined for a one-minute steady state period 
during which fluorescence signal increased linearly. 
Histone purification 
Histone purification was performed essentially as described in (Luger et al., 1999) with 
some modifications. Histone H2A, H2B or H3 expression plasmids were transformed into 
BL21(DE3)pLysS cells (Agilent) and histone H4 expression plasmids into BL21(DE3). The entire 
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transformation reaction was plated onto 2xTY plates containing 100 μg/mL ampicillin. After 16 hrs 
of growth, the resistant cells were added to 1 L of 2xTY containing 100 μg/mL ampicillin and grown 
to OD600 = 0.6. A 100 μL aliquot was taken and analyzed by PAGE as a negative control sample. 
Expression was then induced with 0.4 μg/mL isopropyl β-D-1-thiogalactopyranoside for 3 hrs. A 
50 μL aliquot was analyzed by PAGE to control expression levels. The remaining culture was 
centrifuged at 5000 rpm for 15 min and the pellet resuspended in 14 mL of Wash Buffer (50 mM 
Tris pH7.5, 100 mM NaCl, 1 mM EDTA, 1 mM Benzamidine and 5 mM β-mercaptoethanol), flash 
frozen and stored at -80°C. Frozen cells were thawed at 37°C and sonicated for 3 seconds on, 5 
seconds off cycles for a total of 4-6 minutes at intensity setting 6 with a 550 Sonic Dismembrator 
(Fisher Scientific). All the following steps were conducted on ice. The lysate was centrifuged in a 
Sorvall SS-34 rotor at 4°C at 17000 rpm for 15 min and the supernatant was discarded. The pellet, 
which contains inclusion bodies, was resuspended in 20 mL Wash Buffer containing 1% Triton X-
100 using a pre-chilled Dounce homogenizer and collected by centrifugation at 17000 rpm. This 
wash step was repeated once followed by two washes without Triton X-100. The clean inclusion 
bodies were solubilized in 100 μL of DMSO and further resuspended in 15 mL Unfolding Buffer 
(7 M Guanidinium-HCl, 20 mM Tris-HCl pH 7.5, 10 mM DTT). Histones were extracted for 2 hrs. 
Debris was removed by centrifugation at 17000 rpm for 20 minutes and the supernatant, 
containing extracted histones, was dialyzed at 4°C two times into 1 L of SAU200 Buffer (7 M Urea, 
20 mM NaOAc pH 5.2, 200 mM NaCl, 1 mM EDTA, 5 mM β-Mercaptoethanol) for 1 hr, followed 
by one overnight dialysis. Histones in SAU200 Buffer were centrifuged in a Sorvall SS-34 at 10000 
rpm for 10 min at 4oC to eliminate possible debris. The histones were then pre-cleared by running 
the preparation over a Hi-Trap Q-Sepharose column (GE healthcare), after which they were 
loaded onto a Hi-Trap SP-Sepharose column (GE healthcare) and eluted by a salt gradient from 
SAU200 Buffer (buffer A) to SAU600 Buffer (same as SAU200, but 600 mM NaCl) (buffer B). 
Aliquots of 1 mL were collected and 3 μL of each was analyzed by PAGE on a 15% gel. Fractions 
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containing pure histones were pooled and dialyzed 3 times against 4 L of 2 mM β-
mercaptoethanol in water. Histones were then divided into aliquots, flash frozen and lyophilized.  
Tetramer and nucleosome assembly 
Please see above for critical notes on preparation of acid-washed glassware and buffers 
with low trace metal contaminants. 
H3/H4 tetramer and H2A/H2B/H3/H4 octamer assembly was performed as described in 
(Luger et al., 1999) with some adjustments. Equimolar amounts of H3 and H4 (tetramer) or H2A, 
H2B, H3 and H4 (octamer) were dissolved in Unfolding Buffer (see above) at a concentration of 
2 mg/mL total protein content and incubated for 1 hr with rotation at room temperature. Refolding 
was achieved by 2X 1 hr dialysis at 4°C against 1 L of Low Salt Refolding Buffer (500 mM NaCl, 
10 mM Tris-HCl pH 7.5, 1 mM EDTA, 5 mM β-mercaptoethanol) (Tetramer) or High Salt Refolding 
Buffer (2 M NaCl, 10 mM Tris-HCl pH 7.5, 1 mM EDTA, 5 mM β-mercaptoethanol) (Octamer), 
followed by one dialysis >16 h. The refolded tetramer/octamer was centrifuged for 1 min at full 
speed at 4°C to eliminate any insoluble particles and purified by size exclusion chromatography 
on a HiLoad 16/600 Superdex 200 column (GE healthcare) at 1 ml/min in Low Salt SE-Buffer 
(500mM NaCl, 10 mM Tris-HCl pH7.5) (tetramer) or High Salt SE-Buffer (2 M NaCl, 10 mM Tris-
HCl pH7.5) (octamer). Fractions containing the tetramer/octamer were concentrated using 
Amicon Ultra–15/Ultracel-10K centrifugal filters (Millipore). The flow-through buffer was used as 
negative control (“buffer”) in the copper reductase assay, described below (see also 
supplementary figure 3).  
Nucleosome assembly was performed using a 0.95:1 molar ratio of octamer to DNA and 
following the protocol described in (Peterson, 2008). The 146 bp fragment of the 601 nucleosomal 
positioning sequence (Lowary and Widom, 1998) was PCR amplified using primers 601_146bp_F 
and 601_146_R. The amplified fragment was ethanol precipitated and the recovered DNA was 
purified by a 4 hr incubation in 500 mM NaCl/12% PEG6000 followed by a 20 min centrifugation 
at 16000xg at 4°C . The resulting pellet was resuspended in 100 μL of 0.3 M NaOAc and 
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precipitated by addition of 250 μl of 100% EtOH. The purified 146 bp DNA fragment (150 μg/ml) 
was incubated with histone octamer (160.4 μg/ml) in 2 M NaCl and dialyzed at 4°C for at least 6 
hrs ( and up to 16 hrs) consecutively into 1 L of the following buffers: Buffer 1 (1 M NaCl, 10 mM 
Tris-HCl pH7.5, 1 mM EDTA, 5 mM β-mercaptoethanol), Buffer 2 (0.8 M NaCl, 10 mM Tris-HCl 
pH7.5, 1 mM EDTA, 5 mM β-mercaptoethanol), Buffer 3 (0.6 M NaCl, 10 mM Tris-HCl pH7.5, 1 
mM EDTA, 5 mM β-mercaptoethanol), Buffer 4 (0.0025 M NaCl, 10 mM Tris-HCl pH7.5, 1 mM 
EDTA, 5 mM β-mercaptoethanol). The assembled nucleosomes were further dialyzed 3 times for 
1 hr each in 1 L of Buffer 5 (0.0025 M NaCl, 1 mM Tris-HCl pH7.5) at 4°C. Proper nucleosome 
assembly was confirmed by native PAGE and nucleosomes were used for copper reductase 
assay within a few hrs. 
In vitro copper reductase assay 
The H3/H4 tetramer, or the same volume of control buffer, was resuspended to a final 
concentration of 1 μM in 100 mM NaCl, 1 mM Neocuproine (Sigma) and 20 μM BioUltra tris(2-
carboxyethyl)phosphine (TCEP, Sigma), unless otherwise stated. The reaction was started by 
adding a mix of CuCl2 and Tricine-HCl, pH 7.5, at final concentrations of 1 mM and 5 mM, 
respectively. The reaction was monitored by measuring absorbance at 448 nm every 0.5 seconds 
using a Hewlett-Packard HP8453 diode-array UV/Visible spectrophotometer. Nicotinamide 
Adenine Dinucleotide (NADH), Nicotinamide Adenine Dinucleotide Phosphate (NADPH), 
Dithiobutylamine (DTBA), Tris(hydroxypropyl)phosphine (THP) and glutathione (GSH) were also 
used as reducing co-factors, but showed high spontaneous reduction of copper (data not shown). 
Hence, TCEP was the reducing co-factor of choice during these studies, unless otherwise stated. 
Nucleosomes (0.4 μM) were assayed under identical reaction conditions except for that the 
reaction was started with a mix of CuCl2 and Tricine-HCl, pH 7.5, at final concentrations of 1 mM 
and 10 mM, respectively, and that the NaCl concentration was 300 mM. 
QUANTIFICATION AND STATISTICAL ANALYSIS 
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The number of experimental replicates (n), and the observed significance levels are 
indicated in figure legends. All statistical analyses were performed using Graphpad Prism 5 or 7, 
unless otherwise stated. Significance values for pair-wise comparisons of doubling times (Fig 1C 
and 7C) were calculated using the Mann-Whitney test. Significance values for comparisons of the 
number of population doublings in Fig 2C, 7D and 7E and oxygen consumption rates in Fig 2C 
were calculated using the Holm-Sidak method for multiple t-tests, with alpha = 0.05. Significance 
values for comparisons of the number of population doublings in Fig 3C and S2H were calculated 
using a mixed model Two-Way ANOVA with Bonferroni post-hoc test for pair-wise comparisons. 
For inductively coupled mass spectrometry, 3-9 replicates were measured for each sample (n) 
from 1-3 separate experiments. Statistical testing for iron and copper measurements was done 
using unpaired Student’s t- tests. For gene expression data, we averaged RPKM values from 
replicates and used mean values for calculation of global gene expression correlations (e.g. Fig 
1D) and for analyzing gene sets (e.g. Fig 2E). For global correlations, Spearman’s rank correlation 
coefficients were calculated. Significance values for pair-wise comparisons of gene expression 
levels of gene sets (e.g. Fig 2E) were calculated using the Mann-Whitney test. We also assessed 
differential gene expression, using the SAMMate RPKM values, for each gene and between WT 
and H3H113N strains grown in SC media. Student’s t-test was used to calculate p values with the 
Benjamini-Hochberg procedure to control the false discovery rate at 0.1. This analysis was 
performed using Microsoft Excel 2016. No genes were found to be significantly differentially 
expressed by this procedure. For MNase digestion profiles (Fig 1E), signal intensities measured 
using FIJI were scaled to DNA length using a gel migration distance-to-DNA fragment size 
calibration curve. Signal intensities were also normalized by dividing by the total lane intensity 
and multiplying by 1000. Curve fitting for enzymatic kinetic analysis was performed online using 
“mycurvefit” tool (https://mycurvefit.com), taking zero as starting value. Predicted values for 0.3 
seconds were within 20% of the maximum values detected and used to calculate the initial 
velocities. These initial velocities were then transferred to Graphpad Prism version 5.01 and fitted 
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with the Michaelis-Menten non-linear regression function to determine enzymatic parameters. The 
“area under curve” non-linear regression function of the same software was used to determine 
the value of the area under progress curves for p value measurement by the t-test. 
132
KEY RESOURCES TABLE 
REAGENT or RESOURCE SOURCE IDENTIFIER 
Antibodies 
Rabbit polyclonal anti histone H3 (C-terminal) Active motif Cat# 39163 
Rabbit polyclonal anti histone H4 Abcam Cat# 10158 
IRDye® 800CW Goat anti-Rabbit IgG (H + L), 0.1 
mg 
LI-COR Cat# 925-32211 
Bacterial and Virus Strains 
BL(DE3) Agilent 
Technologies 
Cat# 200131 
BL(DE3)pLysS Agilent 
Technologies 
Cat# 200132 
Chemicals, Peptides, and Recombinant Proteins 
BD Bacto™ Dehydrated Culture Media Additive: 
Tryptone 
Fisher Scientific Cat# 211705 
BD Bacto™ Dehydrated Culture Media Additive: 
Yeast Extract 
Fisher Scientific Cat# 212750 
BD BBL™/Difco™ Bacto™ Media 
Additives/Ingredients/Reagents: Peptone 
Fisher Scientific Cat# 211677 
BD™ Difco™ Yeast Nitrogen Base without Amino 
Acids and Ammonium Sulfate 
Fisher Scientific Cat# 233520 
BD Bacto™ Dehydrated Agar Fisher Scientific Cat# 214010 
SC Powder, 30 grams Sunrise Science 
Products 
Cat# 1300-30 
SC-lys Powder, 30 grams Sunrise Science 
Products 
Cat# 13007-30 
Ampicillin Sodium Salt Sigma-Aldrich Cat# A9518 
Isopropyl β-D-thiogalactopyranoside Goldbio.com Cat# 12481C25 
Ergosterol ≥95.0% (HPLC) Sigma-Aldrich Cat# 45480 
Geneticin Gibco Cat# 11811-031 
Bathocuproinedisulfonic acid disodium salt hydrate Sigma-Aldrich Cat# 146625 
Copper(II) chloride Sigma-Aldrich Cat# C1654 
Copper(II) sulfate pentahydrate Sigma-Aldrich Cat# C6283 
Manganese Chloride Tetrahydrate 
(Crystalline/Certified ACS) 
Fisher Scientific Cat# M87-100 
Iron(III) chloride hexahydrate Sigma-Aldrich Cat# 236489 
Zinc sulfate heptahydrate Sigma-Aldrich Cat# 221376 
Nitric Acid 67-69%, Optima™, for Ultra Trace 
Elemental Analysis 
Fisher Scientific Cat# A467 
Nitric Acid (Certified ACS Plus) Fisher Scientific Cat# A200-212 
Hydrochloric acid Fisher Scientific Cat# A144SI-212 
Hydrochloric acid (ACS grade) Sigma-Aldrich Cat# 320331 
ICP-MS Multi-element calibration standard Agilent 
Technologies 
Cat# 5183-4688 
1000 ppm (µg/mL) Sulfur for ICP Inorganic Ventures Cat# CGS1 
1000 ppm (µg/mL) Phosphorus for ICP Inorganic Ventures Cat# CGP1 
1000 ppm (µg/mL) Scandium for ICP Inorganic Ventures Cat# CGSC1 
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100 ppm (µg/mL) Yttrium for ICP-MS Inorganic Ventures Cat# MSY-
100PPM 
Agencourt RNAClean XP beads Beckman Coulter Cat# A63987 
Zymolyase® 100-T Nacalai USA Cat# 07665-55 
Nuclease micrococcal from Staphylococcus aureus Sigma-Aldrich Cat# N5386 
RNase A from bovine pancreas (RNASEA-RO 
ROCHE) 
Sigma-Aldrich Cat# 10109142001 
Proteinase K from Tritirachium album Sigma-Aldrich Cat# P6556 
Trizma Base (BioUltra) Sigma-Aldrich Cat# 93362 
Sodium Chloride (BioUltra) Sigma-Aldrich Cat# 71376 
Tris(2-carboxyethyl)phosphine hydrochloride 
(BioUltra) 
Sigma-Aldrich Cat# 75259 
β-Mercaptoethanol (Pharmagrade) Sigma-Aldrich Cat# 07604 
Tris(hydroxymethyl)phosphine Sigma-Aldrich Cat# 177881 
Dihydrolipoic acid Sigma-Aldrich Cat# T8260 
DL-Dithiothreitol Goldbio.com Cat# DTT25 
(S)-2-Aminobutane-1,4-dithiol hydrochloride Sigma-Aldrich Cat# 774405 
β-Nicotinamide adenine dinucleotide 2-phosphate 
reduced sodium salt 
Sigma-Aldrich Cat# N9660-15VL 
β-Nicotinamide adenine dinucleotide reduced 
disodium salt hydrate 
Sigma-Aldrich Cat# N8129 
L-Glutathione reduced Sigma-Aldrich Cat# G4251 
Neocuproine Sigma-Aldrich Cat# N1501 
Chelex 100 (Mol. Biol. Grade Resin) Biorad Cat# 142-1253 
Ethylenediaminetetraacetic acid (99.99% trace 
metal basis) 
Sigma-Aldrich Cat# 431788 
Poly(ethyleneglycol) 3500 Sigma-Aldrich Cat# 202444 
Poly(ethyleneglycol) 6000 (BioUltra) Sigma-Aldrich Cat# 81255 
Sodium hydroxide (semiconductor grade) Sigma-Aldrich Cat# 306575 
Sodium Acetate Trihydrate Fisher Scientific Cat# S209-500 
Urea Affimetrix/USB Cat# 23036 
Guanidine hydrochloride Sigma-Aldrich Cat# G3272 
Critical Commercial Assays 
Stranded mRNA-Seq Kit, with KAPA mRNA 
Capture Beads 
KAPA Biosystems Cat# KK8420 
TruSeq Stranded mRNA Library Prep Kit for 
NeoPrep 
Illumina Cat# NP-202-1001 
D1000 ScreenTape Agilent 
Technologies 
Cat# 5067-5582
D1000 Sample Buffer Agilent 
Technologies 
Cat# 5067-5602 
RNA ScreenTape Agilent 
Technologies 
Cat# 5067-5576
RNA ScreenTape Sample Buffer Agilent 
Technologies 
Cat# 5067-5577 
Qubit dsDNA BR Assay Kit ThermoFisher 
Scientific 
Cat# Q32850 
TURBO DNA-free Kit ThermoFisher 
Scientific 
Cat# AM1907 
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Quickchange II sitedirected mutagenesis kit Agilent 
Technologies 
Cat# 200523 
Deposited Data 
Raw and analyzed data This study GEO: GSE100034 
Experimental Models: Organisms/Strains 
See Table S1 
Oligonucleotides 
See Table S2 
Recombinant DNA 
pCORE (KanMX4-KlURA3) 
(Storici and Resnick, 
2006) 
Addgene plasmid 
#72231 
pRM200 (HHT2-HHF2, TRP1) (Mann and 
Grunstein, 1992) 
N/A 
pYX55 (HHT2-H113N-HHF2, TRP1) This study N/A 
pCAS (LYP1 sgRNA, kanMX) 
(Ryan et al., 2014) Addgene plasmid 
#60847 
pCASk-HHT1-H113 (HHT1-H113 sgRNA, kanMX) This study N/A 
pCASk-HHT2-H113 (HHT2-H113 sgRNA, kanMX) This study N/A 
pCASk-CUP1-F8 (CUP1-F8 sgRNA, kanMX) This study N/A 
pET3a-H3 (Luger et al., 1997) N/A 
pET3a-H4 (Luger et al., 1997) N/A 
pET3a-H2A (Luger et al., 1997) N/A 
pET3a-H2B (Luger et al., 1997) N/A 
pH3.2 This study N/A 
pH3.2-C110A This study N/A 
pH3.2-H113N This study N/A 
p601-12-177 (Dorigo et al., 2003) N/A 
Software and Algorithms 
SAMMate 2.7.4 (Xu et al., 2011) http://sammate.sou
rceforge.net/ 
Tophat 2.0.9 (Kim et al., 2013) https://ccb.jhu.edu/
software/tophat/ind
ex.shtml 
Agilent 2200 Tapestation Software A.02.01 Agilent 
Technologies 
http://www.genomi
cs.agilent.com/arti
cle.jsp?pageId=91
00002 
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MassHunter Agilent 
Technologies 
http://www.agilent.
com/en-
us/products/softwa
re-
informatics/massh
unter-
suite/masshunter/
masshunter-
software 
Prism GraphPad Software https://www.graph
pad.com/scientific-
software/prism/ 
Image Studio Lite LI-COR https://www.licor.c
om/bio/products/so
ftware/image_studi
o_lite/index.html 
My Curve Fit (beta) My Assays Ltd. https://mycurvefit.c
om/ 
FIJI (Schindelin et al., 
2012Schindelin et 
al., 2012) 
https://imagej.net/F
iji/Downloads 
Other 
AnaeroGen sachet Thermo Scientific Cat# AN0025 
Falcon™ 15mL Conical Centrifuge Tubes Corning Inc. Cat# 352097 
Spectra/Por standard RC dialysis tubing (50mm 
Nominal Flat Width) 
Spectumlabs.com Cat# 132665 
Spectra/Por standard RC dialysis tubing (23mm 
Nominal Flat Width) 
Spectumlabs.com Cat# 132650 
Hi-Trap Q-HP column GE Healthcare Cat# 17-1154-01 
Hi-Trap SP-HP column GE Healthcare Cat# 17-1152-01 
HiLoad 16/600 Superdex 200 column GE Healthcare Cat# 28989335 
Amicon Ultra–15/Ultracel-10K centrifugal filters Millipore Cat# UFC901024 
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Chapter VI 
Nucleosome Copper Reductase Activity is Required for SOD1 Function in 
Supporting Iron Metabolism 
This chapter was written for inclusion in this dissertation. More investigations pertaining to this 
chapter is currently underway. Briefly, this chapter describes the role of the nucleosome copper 
reductase activity in iron metabolism. The novel function of the copper-dependent superoxide 
dismutase in mediating this connection is revealed. The significance of this role of copper in iron 
metabolism and the potential mechanistic links are discussed. This work also highlights the 
potentially far-reaching affects of the enzymatic activity of the nucleosome in cellular physiology and 
disease through its impact on iron-dependent essential processes.  
I authored this chapter for inclusion in my dissertation. I am responsible for the literature review, 
drafting the article and the conception and design of the experiments. I conducted the experiments 
in collaboration with Oscar Campos.
137
The Nucleosome Copper Reductase Activity is Required for Sod1 Function to Support Iron 
Metabolism 
Summary 
The link between copper and iron metabolism has been described in many organisms, 
mainly through the role of copper in uptake and acquisition of iron. Here we describe the impact of 
nucleosome copper reductase activity on cellular iron requirement. We provide genetic and 
molecular evidence that impairment of the nucleosome copper reductase activity makes cells 
sensitive to iron deficiency. This is not due to disruption of the copper-dependent iron uptake 
machinery in Saccharomyces Cerevisiae. Instead, we have discovered a novel function of the Cu-Zn 
superoxide dismutase (SOD1) in supporting growth under iron-deficient conditions. This function 
of SOD1 is dependent on provision of cuprous ions by the nucleosome.   
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Introduction 
Iron, one of the most abundant elements on Earth and a catalyst for the formation of life on 
this planet, is an essential metal for all biological systems. The use of iron as a co-factor in cellular 
functions is ubiquitous. It is required for wide-ranging processes including DNA replication and 
repair, ribosome biogenesis, metabolic catalysis, and oxygen transport1,2. Iron may exist in several 
oxidation states, -2 to +6, with +2 (ferrous) and +3 (ferric) being the most common and biologically 
relevant. The redox property of iron makes it suitable for a variety of cellular chemistry involving 
electron loss or gain3.  
Biological systems utilize iron either as diiron clusters (2 Fe2+ ions) or in prosthetic groups 
such as iron-sulfur clusters and heme. The speciation of iron and its redox state in the cell is an 
important determinant of its biousability. The bioavailability of iron is also affected by its oxidation 
state4. Oxidized iron (Fe3+) is the prominent form found in the aerobic environment established on 
Earth since the Great Oxygenation Event. The ferric form of iron is poorly soluble and forms 
precipitates with inorganic molecules such as phosphate5. Organisms have devised mechanisms for 
enhancing the bioavailability and acquisition of Fe3+. These include cell-surface reduction of iron to 
soluble Fe2+, acidification of the extracellular environment to solubilize ferric iron, and the use of 
ferric-binding siderophores4,6.  
Assimilatory iron reduction—the process of enzymatic iron reduction for uptake and 
intracellular incorporation—has been found in nearly all organisms. Most ferric reductases in 
eukaryotes are associated with cellular membranes that make Fe2+ available for a variety of iron 
transport systems6. However, a major iron uptake pathway requires its conversion back to Fe3+ once 
ferric reductases have reduced it to soluble Fe2+. This system involves a multicopper ferroxidase that 
oxidizes Fe2+ to Fe3+ for transport by specific ferric transporters7. The copper-dependent mechanism 
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of iron acquisition partly accounts for the interdependency observed between the homeostasis of 
these two metals in eukaryotes as well as a number of bacteria. This system has been well-defined in 
Saccharomyces Cerevisiae and includes the multicopper ferroxidase, Fet3, coupled to the ferric 
transporter Ftr1. Fet3 contains four copper ions and depends on the redox property of copper for 
its iron oxidase activity7,8. Fet3-Ftr1 system serves as the high affinity iron uptake machinery in yeast 
and is induced under iron-limiting conditions. A second homologous ferroxidase, Fet5, is involved 
in mobilization of iron from the vacuole, a major organelle for metal storage9. The analogous 
multicopper ferroxidases in mammals, hephaestin and ceruloplasmin, are also involved in iron 
uptake and iron mobilization between organs10.  
Given the requirement of copper for iron uptake, disruption of copper homeostasis may 
impact iron metabolism. The significance of the molecular link between copper and iron 
homeostasis is highlighted by iron disorders resulting from copper deficiency or genetic lesions in 
ceruloplasmin11. Copper is an essential transition metal and its homeostasis is tightly regulated to 
ensure efficient utilization while preventing toxicity. In addition to abundance, biousability of copper 
is a critical consideration for all copper-dependent processes. Copper, much like iron, is a redox 
active transition metal and is utilized as a co-factor either in its cupric (Cu2+) or in cuprous (Cu1+) 
form for redox chemistry. The oxidation state of copper is also important for proper intracellular 
trafficking, which is mediated by chaperons that carry the cuprous form of copper12. Thus reduced 
copper is the biousable form of copper.  
It is presumed that the reducing environment of the eukaryotic cell is responsible for 
maintaining the pool of cuprous ions. This presumption is based on the unproven idea that the 
reducing state of the cytoplasm non-specifically affects oxidation state of all things within it. In the 
case of copper, the recently described function of the yeast and human nucleosome as a cupric 
reductase provides evidence for an active mechanism for ensuring copper is reduced for use by the 
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cell and mitochondria (Attar 2017, submitted). The enzymatic function of the eukaryotic 
nucleosome was shown to be important for two copper-dependent pathways, mitochondrial 
respiration and superoxide dismutase activity. Here, we asked whether the nucleosome copper 
reductase activity provides biousable copper for iron homeostasis. 
We provide genetic and molecular evidence that mutation of H3H113 to asparagine in the 
H3-H3’ dimerization interface of the nucleosome, the likely active site for the cupric reductase 
activity, leads to poor survival in iron-limiting conditions in S. Cerevisiae. This phenotypic defect 
cannot be accounted for by diminished intracellular iron levels or iron uptake capacity, suggesting 
that the copper-dependent iron transport systems is unaffected by the H3H113N mutation. 
Interestingly, we found that Cu-Zn superoxide dismutase 1 (Sod1) contributes to the ability of cells 
to survive iron limitation. The previously unrecognized role of Sod1 in iron deficiency is dependent 
on the provision of reduced copper ions by the nucleosome. Our data reveal a novel pathway 
through which the eukaryotic nucleosome copper reductase activity contributes to iron metabolism 
via maintaining Sod1 function without affecting iron uptake and acquisition.  
The link between Sod1 function and the integrity of iron metabolism described here has 
important implications for understanding the pathogenic mechanisms underlying many diseases with 
alterations in these two cellular activities. Sod1 is implicated in certain human pathologies, most 
notably amyotrophic lateral sclerosis, as well as Parkinson’s disease and cancer13,14. The occurrence 
of iron deficiency is widespread and has implication for diseases ranging from anemias to 
neurodegeneration and numerous chronic diseases15. The role of histones in providing copper for 
Sod1 functions, including its role in iron metabolism, can provide new insights into such diseases 
and a novel perspective for understanding the role of copper in iron homeostasis.  
Results 
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Histone H3 H113 residue is required for growth in iron limiting conditions. Histidine residue 
113 in histone H3 lies at the interface between the two H3 molecules at the core of the nucleosome. 
We previously showed that the mutation of this histidine to asparagine (H113N) disrupts copper-
dependent processes in S. Cerevisiae through potential defects in the copper reductase activity of the 
nucleosome. Given the copper dependency of the high affinity iron uptake system through the 
function of Fet3 in S. Cerevisiae, we asked whether the H113N mutation results in diminished iron 
uptake abilities and survival in iron-limiting conditions. 
We examined the ability of H3H113N mutant to grow in iron-deplete media using the iron 
chelator, bathophenanthrolinedisulfonic acid (BPS), which limits iron availability for cellular uptake. 
Although H3H113N has a slower growth rate than the wild type counterpart (WT) in rich media, it 
does not show enhanced sensitivity to iron depletion, even at BPS concentrations that significantly 
reduce growth (Figure 1A).  
Upon iron depletion, a comprehensive cellular response is mediated by the iron-responsive 
transcription factor Aft1, that induces the expression of multiple iron uptake systems and 
downregulates non-essential iron consuming processes16,17. We reasoned the function of the 
multicopper ferroxidase, Fet3, may still be dependent on nucleosome copper reduction but a defect 
may be difficult to detect given the robust presence of other iron uptake systems and the 
hypomorphic nature of the H113N allele. To test the functionality of Fet3 more directly, we deleted 
the copper-transporting P-type ATPase, Ccc2, that is needed to provide copper into the 
endomembrane system for constitution of enzymatically active Fet318. As expected ccc2 strains are 
more sensitive to iron depletion when compared with the wildtype counterpart. The combination of 
H3H113N with ccc2 exacerbates the growth defect in iron-limiting conditions (Figure 1B). This 
defect is rescued by addition of excess copper to the media suggesting a copper-related deficiency in 
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H3H113Nccc2 compare to ccc2 alone in iron-limiting conditions. Deletion of AFT1 to disable the 
overall transcriptional response to iron depletion significantly reduces growth in iron-limited media. 
The defect of aft1 strain in iron limitation is recovered by addition of exogenous copper; however, 
more copper is needed to achieve a similar rescue in H3H113Naft1 (Figure 1B). This further 
highlights the copper-dependent defect in strains harboring H3H113N.  
Deletion of CTR1, a primary copper transporter renders cells sensitive to iron depletion, 
confirming the known requirement of copper for Fet3 activity and iron uptake18 (Figure 1C). Similar 
to ccc2 and aft1 backgrounds, the H3H113N mutation significantly reduces growth in iron 
depletion when combined with ctr1. The greater defect of H3H113Nctr1 compared with ctr1 is 
recovered by addition of excess exogenous copper (Figure 1C).  
The reduced survival upon iron limitation in the context of H113N histone H3 is not due to 
differences in gene expression, since strains harboring H3H113N mutation have similar global gene 
expression patterns as the WT counterpart (Figure 1D). Importantly, the expression of genes 
involved in iron homeostasis and the induction of the iron-deficiency response mediated by Aft1 is 
similar between strains with WT and H113N histone H3 (Figure 1E). Altogether our data suggest 
that H3H113 is required to contend with iron-limiting conditions, likely through the nucleosome 
copper reductase activity and provision of biousable copper.  
Diminished survival of H3H113N-harboring strains in iron limitation is not due to 
differences in total cellular iron content or iron uptake capacity. We hypothesized that 
defective iron uptake due to decreased copper provision for Fet3 may be the reason H3H113N 
mutant sensitizes cells to iron limitation. To determine the mechanism by which nucleosome copper 
reductase activity may be contributing to iron homeostasis, we first measured intracellular iron 
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content using inductively-coupled mass spectrometry (ICP-MS). Deletion of AFT1 or CTR1 results 
in an expected reduction in steady-state levels of intracellular iron in rich media (Figure 2A). When 
grown in BPS-containing media, a further reduction in iron levels is detected (Figure 2A). However, 
strains harboring H3H113N have similar levels of intracellular iron as the WT counterpart both in 
iron-replete and iron-deplete conditions. Surprisingly, addition of exogenous copper to low iron 
media, which we show to enhance growth, does not lead to a detectable increase in intracellular iron 
levels (Figure 2A). These findings challenge the idea of a defect in iron uptake or accumulation as 
the underlying problem in H3H113Nctr1  and H3H113Naft1.  
Steady-state iron measurements in aft1 and ctr1 backgrounds, especially in low iron 
conditions, are significantly lower than the wildtype counterparts. These measurements in some 
cases fall close to or below the lower limit of the linear range in our ICP-MS experiments. This 
poses a technical problem for accurate detection of differences between strains. But even if 
H3H113N-harboring strains have lower levels of iron than their WT counterparts, it is unclear how 
such small differences would be biologically meaningful. 
We therefore decided to assess the high affinity iron uptake machinery by testing the ability 
of strains with WT or H113N histone H3 to functionally induce this system in response to a period 
of iron limitation. To do so, strains were grown in BPS-containing media to deplete iron, leading to 
induction of the iron deficiency response and upregulation of iron uptake mechanisms, most notably 
the Fet3-mediated high affinity uptake system. After a period of growth in low iron, cells were 
transferred to iron-replete media and intracellular iron was measured. Total cellular iron content 
during the depletion phase is reduced equally in both WT and H3H113N (Figure 2B). Upon iron 
addback, an increase in intracellular iron is observed as a result of the activation of the iron 
deficiency response during the depletion phase. However, WT and H3H113N increase intracellular iron 
to the same level (Figure 2B). Similarly, iron uptake after a period of depletion in the background of 
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ctr1 or ccc2 is identical between strains harboring WT and H113N histone H3 (Figure 2C). To 
further limit copper availability for Fet3 activation, copper chelator Bathocuproinedisulfonic acid 
(BCS) was used during iron addback for experiments done with ccc2 strains. However, even in such 
copper-limiting media no iron uptake defect was observed in H3H113Nccc2 compared with ccc2 
(Figure 2C). These findings are in agreement with steady-state measurements also revealing wildtype 
levels of iron in the context of H3H113N. Despite diminished survival conferred by H3H113N 
mutation in iron-limiting conditions, we failed to reveal a defect in iron uptake capacity and iron 
accumulation in this context. This suggests that the copper-related defect of H3H113N strains in 
coping with iron depletion cannot be accounted for by limited Fet3 activity for iron uptake.  
Sod1, not the multicopper ferroxidase Fet3, is dependent on H3H113 for supporting iron 
metabolism. Since the functionality of the high affinity iron uptake system and hence Fet3 is intact 
in H3H113N, we wondered whether other components of iron metabolism are dependent on 
utilization of copper. The Fet3-related multicopper ferroxidase, Fet5, and the ferric transporter Fth1 
form a complex analogous to Fet3-Ftr1 on the vacuolar membrane. Fet5 uses the same copper-
dependent redox mechanism as Fet3 for transport of iron across the vacuolar membrane into the 
cytoplasm19. This intracellular iron transport system is induced by iron limitation in an Aft1-
dependent manner and can contribute to iron metabolism by allowing the utilization of stored 
vacuolar iron9. We deleted FET3 alone and in combination with FET5 in the context of WT or 
H113N histone H3. Deletion of FET3 renders cells defective in low iron conditions, while deletion 
of FET5 has a minor effect alone and does not enhance the growth defect of fet3 strains (Figure 
3A). Interestingly, the growth defect in low iron associated with H3H113N is observed in absence 
of FET3 (Figure 3A). In addition, exogenous copper can rescue the growth defect of fet3 strains 
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(Figure 3A). These genetic data further support the iron uptake results and suggest the contribution 
of histones to a Fet3-independent, copper-dependent pathway for iron metabolism.  
Iron metabolism and utilization depends not only on the intracellular concentration but also 
proper trafficking, storage and speciation of iron4. An essential species of iron used ubiquitously as a 
co-factor in all forms of life is the iron-sulfur (Fe-S) cluster prosthetic group20. The properties of Fe-
S clusters such as oxidation states and the local protein environment are important for the function 
of these co-factors in diverse biological reactions21. The activity of these co-factors is therefore 
sensitive to oxidants. Superoxide dismutase 1, as one of the major cytosolic antioxidant defense 
systems, is important for protecting Fe-S clusters21–23. For instance, Sod1 is required for maintaining 
the activity of Fe-S cluster containing enzymes in certain amino acid biosynthetic pathways, 
explaining the auxotrophy of sod1 for those amino acids22.  
The integrity of Fe-S clusters and the potential protective role of Sod1 may be even more 
imperative when iron is limiting. Since the nucleosome copper reductase activity has been shown to 
be required for optimal Sod1 function, we questioned whether in iron limitation suboptimal Sod1 
function underlies the poor survival of strains harboring H3H113N. Deletion of SOD1 in the 
context of WT or H113N histone H3 results in a growth defect in iron limitation suggesting a 
requirement of this enzyme for iron metabolism (Figure 3B). In contrast to what we observed in 
strain backgrounds null for components of the iron regulon, H3H113Nsod1 does not show any 
additional defect in iron-deplete conditions compared to sod1 alone (Figure 3B). This suggests that 
the enhanced defect in coping with iron depletion conferred by H3H113N may be attributed to 
Sod1.  
Addition of exogenous copper rescues the growth defect of sod1 and H3H113Nsod1 
similarly, through the activation of an intact Fet3-Ftr1 uptake system in both strains (Figure 3B). 
Combination of FET3 and SOD1 deletion leads to an even greater growth defect in low iron than 
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the deletion of either gene alone (Figure 3C). Interestingly, the double deletion abrogates the 
copper-mediated rescue in low iron media regardless of the histone allele (Figure 3C). This finding 
strongly indicates that the added exogenous copper is utilized by these two independent pathways to 
support growth in iron limitation. While both high-affinity iron uptake system and Sod1-mediated 
antioxidant defense are required for supporting growth under iron limitation, the enzymatic activity 
of the nucleosome only impacts the latter. These data indicate that the enzymatic activity of the 
nucleosome can have far-reaching effects on numerous biological processes through supporting 
Sod1 activity and the iron metabolome. 
Discussion 
The link between iron and copper metabolism has been appreciated for decades. The notion 
that copper can interfere with iron metabolism through competition for uptake or displacement of 
protein-bound iron is certainly a consideration when copper is in excess or improperly handled24,25. 
The more intricate dependence of iron homeostasis on copper is an intriguing topic of study. The 
discovery of multicopper ferroxidases involved in iron acquisition and homeostasis in numerous 
organisms have provided a molecular explanation for this connection26,27.  
More recently, sparse evidence suggesting a connection between iron homeostasis and 
oxidative stress that goes beyond iron-mediated oxidative stress have been put forth. Deficiencies in 
iron homeostasis achieved by limiting iron abundance, either via deletion of components of the iron 
regulon in yeast (e.g. Fet3) or use of iron chelators, have been shown to render cells sensitive to 
oxidants28. Although other interpretations can be offered, these findings can suggest a vulnerability 
to oxidative damage in iron deprivation or a requirement of iron for antioxidant defense. 
Conversely, oxidative stress partially induces the iron deficiency response and plays a role in 
activating Aft1 in yeast28,29. Although more work is required to understand the underlying 
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mechanisms, these findings suggest a regulatory link between iron metabolism and cellular redox 
states. 
Superoxide dismutase 1, a major contributor to redox homeostasis, has been shown to affect 
iron homeostasis as its deletion results in upregulation of genes involved in iron uptake30. 
Vulnerability of iron-sulfur clusters to oxidation in the absence of Sod1 anti-oxidant activity is 
suggested to account for these observations. It is well established that disruptions in Fe-S cluster 
biogenesis or abundance, as may be the case in absence of Sod1, lead to the activation of the iron 
regulon31,32. Reactive oxygen species can oxidize Fe-S clusters and bring about remarkable 
conformational changes leading to disassembly, inactivation or interconversion between different 
Fe-S cluster forms21. In all cases, the activity of these essential iron co-factors can be diminished or 
altered by oxidative stress and may be dependent on the function of Sod1. We now provide 
evidence for the requirement of the highly conserved eukaryotic Cu-Zn Sod1 for surviving iron 
limitation in the model organism S. Cerevisiae. This requirement may reflect the importance of Sod1 
function in protecting Fe-S clusters when iron is limiting. We further reveal a novel role of the 
copper reductase enzymatic activity of the nucleosome in iron metabolism through supporting Sod1 
function, rather than supporting the high affinity iron uptake system.  
The role of copper in ensuring proper iron metabolism has so far been mainly appreciated 
by its impact on the function of multicopper ferroxidases. The involvement of superoxide dismutase 
in supporting the iron metabolome reveals another layer of connection between these two metals. 
This finding expands the interdependency between the functions and homeostasis of iron and 
copper in eukaryotes. 
The newly discovered function of histones in copper homeostasis may open a window into 
other possible links between biousability of copper and iron metabolism. A potential crosstalk 
between the nucleosome and the iron metabolome can be hypothesized which could regulate the 
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copper reductase activity in response to cellular iron status. In such crosstalk regulation, lower levels 
of iron may increase the nucleosome copper reductase activity to meet the demand for cuprous ions 
by Sod1 to protect the remaining Fe-S clusters from oxidative damage. Whether the nucleosome can 
more directly affect iron metabolism is also an intriguing notion. Although the reductase activity of 
the nucleosome seems to be specific to copper, the possibility of iron reduction cannot be fully ruled 
out. Nucleosome-catalyzed ferric reduction can theoretically result in significant changes in the 
overall iron redox of the cell and thus its utilization in prosthetic groups such and heme and Fe-S 
clusters.  
Our data indicate that provision of Cu1+ by nucleosomes for intracellular copper-dependent 
processes may be specific; however, it is unclear what determines this specificity. We postulate the 
idea of functional separation between potentially distinct intracellular pools of copper. It is intriguing 
to investigate whether such putative functional separation stems from compartmentalization of 
copper or of copper-dependent cellular components. Copper-dependent processes in the 
mitochondrial and cytoplasmic compartments, respiration and Sod1 function, respectively, but not 
the endomembrane compartment (i.e. Fet3 activation) seem to be dependent on the copper 
reductase activity of the nucleosome. However, it is important to note that the lack of defect in iron 
uptake in our system may not completely rule out the dependency of this copper-mediated pathway 
on the nucleosome copper reductase activity. The H113N mutation investigated in this study may 
represent a mild disruption of the copper reductase activity, whereby still maintaining sufficient 
cuprous ion generation for utilization by Fet3. Further investigation of the nucleosome enzymatic 
activity is required to address this possibility. 
Viewing this through an evolutionary lens, one might also hypothesize that the specificity is 
driven by a potential advantage bestowed on the bacterial symbiont and/or the host during 
eukaryogenesis by histone copper reductase activity. The archaeal host for endosymbiosis possessed 
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ancestral nucleosomes33 which may have harbored copper reductase capacity. Histones, by supplying 
copper specifically for respiration and Sod1 function, can more directly support and tolerate 
mitochondrion-related processes such as the electron transport chain. Respiration by the 
mitochondria can be a source of oxidants which may impose an additional pressure for protection of 
Fe-S clusters34. Iron-sulfur clusters are not only synthesized in the mitochondria but are also 
required for mitochondrial respiration20. The integrity of Fe-S clusters is therefore a critical 
parameter for mitochondrial function and even more so for cellular fitness in the face of 
mitochondrial respiration. Histones may have been important for mediating this fitness while 
supporting the symbiont by providing copper for electron transport chain and Sod1. Whether or not 
this function served as an evolutionary force for the presence of histones in early eukaryotes, it is 
clear that our knowledge of the nucleosome copper reductase activity in modern eukaryotes is 
limited. More investigation is warranted to better understand the impact of this novel function of 
histones on metal homeostasis. Nonetheless, given the essential nature of iron for diverse cellular 
processes, the enzymatic activity of the nucleosome in supporting iron metabolism can have far-
reaching effects for eukaryotic biology, human physiology and disease.  
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FIGUR LEGENDS 
Figure 1. H3H113N mutation reduces fitness in iron limiting conditions. A) Spot growth 
assays in iron-replete SC (synthetic complete media) and iron-deplete SC achieved using the iron 
chelator bathophenanthrolinedisulfonic acid (BPS). B) and C) Spot growth assays in iron-deplete 
media with and without additional exogenous CuSO4. Iron and copper concentrations in SC are ~ 
1.2 and 0.25 M, respectively. D) Scatterplots of average global gene expression values from 
exponentially growing cells in SC and SC containing BPS, with Spearman’s rank correlation 
coefficient (rs) as indicated. E) Average mRNA expression levels for genes involved in iron 
homeostasis in iron replete and deplete growth conditions from two independent experiments.  
Figure 2. Histone H3 H113 residue is not required for iron accumulation or iron uptake in 
response to iron deprivation. A) Intracellular iron content of cells grown in the indicated media 
for 3-4 doublings. Bar graphs represent mean ± SD from 3-6 replicate cultures. B) and C) Assay for 
iron uptake capacity showing intracellular iron content from exponentially growing cells in SC and 
cells grown in SC containing BPS for 2-3 doublings followed by incubation in SC for 1 population 
doubling (B) or 1 hour (C). Note: the copper chelator Bathocuproinedisulfonic acid (BCS) is used to 
deplete copper during iron addback for experiments done with ccc2 strains to further limit copper 
availability for Fet3 activation.  
Figure 3. Sod1 is protective in iron deficient conditions and is dependent on the copper 
reductase activity of the nucleosome in contrast to Fet3. A) Spot growth assays in SC and SC 
containing BPS with and without additional CuSO4. B) and C) same as (A) for the indicated strains.  
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Methods 
Spot tests 
Following an overnight growth, cells were diluted to OD600 = 0.3-0.4 in YPD and grown at 30°C 
for 4-5 hrs to log phase (OD600 = 1-2). Cells were subsequently pelleted by centrifugation, washed 
and resuspended in water to OD600 = 5. Cells were then 10-fold serially diluted and 5 μL of cells 
were spotted on agar plates containing media and additives as indicated in the figures. Cells were 
incubated at 30°C for up to 7 days and imaged daily using an Epson documentscanner. Because of 
differing growth rates in the various media conditions, images shown in the figures were captured 
when sufficient growth had occurred and growth differences could be assessed, and this ranged 
between 2-7 days. 
RNA extraction 
Following an overnight growth, cells were diluted in the various media conditions indicated in the 
figures. Cells grown in SC were diluted to OD600 = 0.05 and grown for 5 doublings at 30°C, at 
which point they were growing exponentially. Approximately 1.5x108 cells were collected by 
centrifugation and frozen at -20°C until further processing. RNA was extracted using previously 
published methods (Schmitt et al., 1990) with some modifications. Frozen cell pellets, without 
significant thawing, were resuspended in 440 μL of AE buffer (50 mM Na acetate pH 5.2, 10 mM 
EDTA, 1% SDS), and RNA was extracted by addition of 440 μL of 5:1 phenol:chloroform pH 4.5 
(ThermoFisher) and incubation at 65°C for 4 min. Samples were then rapidly frozen in dry ice-
ethanol, and centrifuged at 16,000xg to separate the aqueous and phenol phases. The aqueous 
supernatant (350 μL) was transferred to a new tube, and re extracted by addition of 300 μL of 
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25:24:1 phenol:chloroform:isoamyl alcohol, and centrifuged as above to separate phases. 250 μL was 
transferred to a new tube, 25 μL of 3 M Na acetate pH 5.2 was added, and nucleic acids were 
ethanol-precipitated. Nucleic acid pellets were then resuspended in 100 μL of nuclease-free water 
and stored at -20°C until further processing. RNA concentration was measured by Nanodrop 2000 
microvolume spectrophotometer. Typical yield from this extraction method was about 30  μg of 
total RNA. RNA extracted for subsequent RNA-seq analysis are from two replicates of cells grown 
on different days with different media batches.  
Sample preparation for poly-A RNA sequencing 
Prior to preparing RNA-seq libraries for Illumina HiSeq sequencing, contaminating DNA was 
digested, and RNA quality was assessed. Total RNA (10 μg) was treated with Turbo DNase 
according to the manufacturer’s “Routine DNase treatment” procedures. RNA-sequencing libraries 
were then prepared either manually with the KAPA Stranded mRNA-seq library prep kit (KAPA 
Biosystems), or with automation, using the Illumina TruSeq Stranded mRNA Library Kit for 
NeoPrep (Illumina). Both library preparation procedures first isolate polyA+ mRNAs using oligo-
dT beads. Isolated polyA+ RNAs are then chemically fragmented, and random primers are used in 
the first cDNA reverse transcription step. For both approaches, libraries were prepared according to 
the manufacturer’s protocols. 
mRNA-sequencing and data processing 
High throughput sequencing was performed on Illumina’s HiSeq 4000 system, with singleend 50 bp 
insert reads, and dedicated index reads. Total read count per library ranged from ~1.5-9 million. De-
multiplexed reads, in FASTQ file format, were aligned to the R64-1-1 S288C reference genome 
assembly (sacCer3), downloaded from the UCSC database, using Tophat 2.0.9 (Kim et al., 2013). 
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The “-g 1” parameter was used to limit the number of alignments for each read to one, the top-
scoring alignment. In the case of a tie, the read was randomly distributed to one of the tied top-
scoring alignments. Percentage of reads aligned once was greater than 90% in all cases. 
Gene expression analysis 
Gene expression values, in reads per kilobase per million mapped reads (RPKMs), for 
6692 annotated open reading frames were calculated using SAMMate 2.7.4 (Xu et al., 2011). In 
calculating RPKM values, only reads that align to annotated exons were considered. Reads aligning 
to introns or intergenic regions were not counted in normalizing the read counts to the total number 
of mapped reads. Many of the 6692 annotated ORFs have no attributed function, localization, 
mutant phenotypes or interactions and are often labeled as “dubious” or “putative” in the 
Saccharomyces Genome Database (SGD). Furthermore, these putative ORFs typically have low 
expression values. We removed 1648 such ORFs from further analysis, and used the remaining 5044 
ORFs for comparisons between groups. 
Sample preparation for inductively-coupled plasma mass spectrometry (ICP-MS) 
Cells from dense overnight cultures in SC media were diluted to OD600 = 0.2-0.4 and grown at 
30°C for ~3 doublings in SC or SC containing the iron chelator, bathophenanthrolinedisulfonic acid 
(BPS). Three replicate cultures were prepared for each sample. Cells (4-12 x 108) were collected by 
centrifugation, and cell pellets were washed twice in 1 mM EDTA to remove cell surface-associated 
metals. This was followed by one wash in Nanopure Diamond filtered water to remove residual 
EDTA. Cell pellets were then stored at -20°C for 1-3 weeks prior to preparation 
for ICP-MS. Plastic bottles and cylinders used for preparation of solutions for sample digestion were 
treated with 7-10% ACS grade nitric acid for 5 days at 50°C. Acid-washed materials were rinsed 
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thoroughly with Nanopure water before use. Frozen cell pellets were thawed at room temperature 
and packed by centrifugation at 3000xg. Pellets were overlaid slowly (not to disrupt the pellet) with 
70% Optima Grade nitric acid and digested at 65°C for 12-16 hrs. Prior to mass spectrometry, the 
digested samples were diluted with Nanopure water to a final concentration of 2% nitric acid and a 
final volume of 3-5 mL. 
Inductively-coupled plasma mass spectrometry 
Total Fe content was measured by inductively coupled plasma mass spectrometry 
on the Agilent 8800 ICP-QQQ in MS/MS mode. The most abundant isotopes of iron 
(i.e. Fe56) was used to determine the total cellular iron and copper levels. Iron was measured both 
directly, with hydrogen present in the collision/reaction cell, and indirectly, after mass-shift to FeO 
with oxygen present in the cell. While both methods produced similar results, the data presented 
here for iron are from oxygen mass-shift mode. The metal content was determined in comparison to 
an environmental calibration standard (Agilent 5183-4688) reflecting biological samples. Every run 
was calibrated individually, 45Sc or 89Y were used as internal standards to compare the calibration 
with the analyzed samples. Average counts of 5 technical replicates were used for each calibration 
standard and each individual biological sample. The deviation in between technical replicates never 
exceeded 5%. Standard deviation in figures reflects the standard deviation between biological 
replicates (n = 3 - 6). Prepared calibration standards ranged from 1 ppb - 50 ppm for 56Fe. All Fe 
measurements in our study were well above the lower limits of detection, which was determined 
from multiple blank samples. We used ICP MassHunter software for ICP-MS data analysis. 
Liquid cultures for iron uptake assays 
To assess iron uptake capacity, following an overnight growth in SC media, cells were diluted to 
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OD600 = 0.2 in fresh media with or without the iron chelator, bathophenanthrolinedisulfonic acid 
(BPS), and grown at 30°C for 2-3 doublings. Cell density of the culture was measured after this 
period and cells were collected from growth in SC media for preparation for ICP-MS. Cells grown in 
presence of BPS were washed with Nanopure Diamond filtered water and diluted to OD600 = 0.5 
in fresh SC media. Cells were grown at 30°C for 1 hour or 1 doubling after which point they were 
collected for ICP-MS. 
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